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Abstracts of the publications 
 
 
Paper 1:  
Early and presenting symptoms of dementia with Lewy bodies 
 
Background/Aims:  
To explore the presenting and early symptoms of dementia with Lewy bodies (DLB).  
 
Method: 
 Patients with mild dementia fulfilling diagnostic criteria for DLB (n = 61) and Alzheimer’s 
disease (AD) (n = 109) were recruited from outpatient dementia clinics in western Norway. At 
diagnosis, caregivers were asked which symptom had been the presenting symptom of 
dementia.  
 
Results: 
 Caregivers reported that memory impairment was the most common presenting symptom in 
DLB (57%), followed by visual hallucinations (44%), depression (34%), problem solving 
difficulties (33%), gait problems (28%), and tremor/stiffness (25%). In contrast, 99% of AD 
caregivers reported impaired memory as a presenting symptom, whereas visual hallucinations 
were a presenting symptom in 3% of the AD cases.  
 
Conclusion: 
DLB should be suspected in pre-dementia cases with visual hallucinations. 
 
 
Paper 2:  
White matter integrity and cognition in Parkinson’s disease:  
a cross-sectional study 
 
Objective:  
We used diffusion tensor imaging (DTI) to test the following hypotheses: (1) there is decreased 
white matter (WM) integrity in non-demented Parkinson’s disease (PD), (2) WM integrity is 
differentially reduced in PD and early Alzheimer’s disease (AD) and (3) DTI changes in non-
demented PD are specifically associated with cognitive performance. 
 
Methods:  
This study included 18 non-demented patients with PD, 18 patients with mild cognitive 
impairment due to incipient AD and 19 healthy elderly normal control (NC) participants in a 
cross-sectional design. The participants underwent DTI, and tract based 
spatial statistics was used to analyze and extract radial diffusivity and fractional anisotropy. 
Correlations between scores from a battery of neuropsychological tests and DTI were 
performed in the PD group. 
 
Results:  
11 
 
Patients with PD had significant differences in DTI in WM underlying the temporal, parietal 
and occipital cortex as compared with NC. There were no significant differences between the 
PD and AD groups in the primary region of interest analyses, but compared with NC there was 
a tendency for more anterior changes in AD in contrast to more posterior changes in PD. In a 
secondary whole-brain analysis there were frontoparietal areas with significant differences 
between AD and PD. In patients with PD, there were significant correlations between DTI 
parameters in WM underlying the prefrontal cortex and executive and visuospatial abilities. 
 
Conclusions:  
In early, non-demented PD we found reduced WM integrity underlying the temporal, parietal 
and occipital cortices. In addition, WM integrity changes in prefrontal areas were associated 
with executive and visuospatial ability. These findings support that DTI may be an important 
biomarker in early PD, and that WM changes are related to cognitive impairment in PD. 
 
 
Paper 3: 
Neurobiological correlates of depressive symptoms in people with subjective 
and mild cognitive impairment 
 
Objective 
To test the hypothesis that depressive symptoms correlate with Alzheimer's disease (AD) type 
changes in CSF and structural and functional imaging including hippocampus volume, cortical 
thickness, white matter lesions, Diffusion Tensor Imaging (DTI) and Fluoro-Deoxy-Glucose 
Positron Emission Tomography (FDG-PET) in patient with subjective (SCI) and mild (MCI) 
cognitive impairment.  
 
Methods 
In 60 patients depressive symptoms were assessed using the Geriatric Depression Scale. The 
subjects underwent MRI, 18F-FDG PET imaging and lumbar CSF extraction. 
 
Results 
Subjects with depressive symptoms (n=24) did not have more pathological AD biomarkers than 
non-depressed. Uncorrected there were trends towards larger hippocampal volumes (p=0.06), 
less orbital WM damage measured by DTI (p=0.10) and higher orbital glucose metabolism 
(p=0.02) in the depressed group. The findings were similar when SCI and MCI were analyzed 
separately.  
Similarly, in patients with pathological CSF biomarkers (i.e. pre-dementia AD, n=24), we 
found that correlations between scores on GDS and CSF Aß42 and P-tau indicated less severe 
AD-specific CSF changes with increasing depression. 
 
Conclusion 
Depressive symptoms are common in SCI/MCI, but are not associated with pathological 
imaging or CSF biomarkers of AD. Depression can explain cognitive impairment in SCI/MCI 
or add to cognitive impairment leading to an earlier clinical investigation in pre-dementia AD. 
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Abbreviations and definitions 
 
 
Aȕ                                Amyloid Beta 
 
ADL                             Activities of daily living  
 
AD                                Alzheimer’s disease 
 
CSF                               Cerebrospinal fluid 
 
DLB                               Dementia with Lewy bodies 
 
DR                                 Radial diffusivity 
 
DTI                                Diffusion tensor imaging 
 
GWAS                           Genome wide association study 
 
FA                                 Fractional anisotropy 
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ICD-10                           International classification of diseases 10th edition 
 
LB                                  Lewy bodies 
 
Lewy body dementia     Clinical diagnosis. Includes DLB and PDD 
 
Lewy body disease        Pathological diagnosis. Includes PD, DLB and PDD  
 
LDD                               Late life depression 
                                 
MDD                             Major depressive disorder 
 
MRI                               Magnetic resonance imaging 
 
PD                                  Parkinson’s disease 
 
PDD                               Parkinson’s disease dementia 
 
MCI                               Mild cognitive impairment, i.e. objectively measured cognitive  
 
                                       impairment, but only slight reduction in ADL (no dementia).            
 
MMSE                           Mini Mental State Examination 
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P-tau                               Phospho-tau 
 
ROI                                Region of interest  
 
RBD                               REM sleep behavior disorder 
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                                       cognition and ADL.   
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TBSS                              Tract-based spatial statistics 
 
T-tau                               Total-tau   
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1.0  Clinical definitions 
 
 
1.1 Cognitive impairment  
 
The word “cognition” comes from the Latin (and partly Greek) verb “cognosco” which can be 
translated to “with knowledge”. In a broader sense the concept of cognition involves higher 
mental processes including reasoning and problem-solving ability, memory, attention, 
orientation and language. Cognitive impairment refers to deficits in a person's ability to execute 
these mental processes by various reasons. 
 
1.2 Pre-dementia, pre-clinical, prodromal 
 
The pre-dementia stage is understood as the phase where the degenerative process has begun, 
but where cognitive impairment is too mild to meet established criteria for dementia (Textbox 
4). The pre-dementia phase can further be subdivided in a pre-clinical phase where no clinical 
signs of neurodegenerative disease are evident and a pre-dementia clinical phase where only 
slight symptoms have emerged. The latter term is equivalent to a prodrome, or prodromal 
symptoms, which originates from the Greek word prodromos (precursor) and means early, 
often non-specific symptoms of disease. 
 
The pre-dementia phase has long been unrecognized and seen as unimportant. Recent evidence 
strongly suggest that dementia subtypes, including Alzheimer- and Lewy body disease, may 
start decades before onset of obvious signs of cognitive impairment and that other symptoms, 
including depression and affection of the peripheral and autonomic nervous system, can be 
prodromal signs of disease.     
This new insight has urged a reclassification of the traditional concept of dementia (see section 
1.6). 
 
1.3 Mild cognitive impairment 
 
The term mild cognitive impairment (MCI) is now widely accepted as a state encompassing the 
earliest features of cognitive impairment before functional impairment is evident (only slightly 
impaired) with an increased risk of a later conversion to dementia (Petersen et al., 2009). The 
first MCI criteria (Petersen et al., 1999), focusing on AD, defined MCI as a state of memory 
complaints, objective measured memory impairment, essentially normal performance in other 
cognitive domains and with preserved Activities of Daily Living (ADL-) functions (not 
demented) (see section 1.5). A later revision and broader conceptualization by Winblad et al. 
(Winblad et al., 2004), emphasized that patients with MCI could also convert into other 
dementia subgroups, not only AD, and that other cognitive domains than memory could be 
affected. The Winblad criteria broadly divide MCI in amnestic (affection in the memory 
domain only) and non-amnestic (affection of other domains than memory, i.e. language, 
executive or visuospatial ability and attention) and further in single or multiple domains 
(textbox 1).   
 
The prevalence of MCI has recently been estimated to about 14-18 % in people 70 years or 
older (Petersen et al., 2009), and the annual dementia conversion rate is about 10-15 % from 
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referral sources including memory clinics. In epidemiological studies, the conversion rates are 
lower and in the 6-10 % range per year (Petersen et al., 2009). The different conversion rates in 
different clinical settings emphasize an important issue in trying to define at risk populations; 
although MCI is believed to be a prodrome of dementia, it is a heterogeneous concept 
constituting other conditions including normal aging, depression or other brain disorders and 
cognitive impairment may not progress and can even be reversible (text box 2).    
 
 
 
 
  Text box 1: 
 
General criteria for mild cognitive impairment (MCI) (Winblad et al. 2004) 
 
1. Not normal, not demented (Does not meet criteria (DSM IV, ICD 10) for a dementia   
syndrome) 
 
2. Cognitive decline 
 
- Self and/or informant report and impairment on objective 
  cognitive tasks and / or 
 
- Evidence of decline over time on objective cognitive tasks 
 
3. Preserved basic activities of daily living / minimal impairment in complex  
    instrumental functions 
 
 
 
 
 
 
  Text box 2: 
 
Heterogeneity of the clinical presentation of mild cognitive impairment (MCI) and 
potential multiple etiologies (Winblad et al. 2004) 
 
 
    Clinical presentations:                                                                 Possible etiologies : 
 
MCI amnestic, single domain                                                                Degenerative 
MCI amnestic, multiple domains                                                           Vascular 
                                                                                                                Metabolic   
MCI non-amnestic, single domain                                                         Traumatic 
MCI non-amnestic, multiple domains                                                    Psychiatric  
                                                                                                                Other ? 
 
 
Multiple causes 
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1.4 Subjective cognitive impairment 
 
In an effort to select patients even earlier in the disease process and before irreversible signs of 
disease are evident, the term subjective cognitive impairment (SCI) has recently been suggested 
as a pre-MCI stage, a condition with only subjective and subtle cognitive impairment on a SCI-
MCI-dementia continuum (Reisberg and Gauthier, 2008). This state is even more 
heterogeneous than the MCI stage, but still with higher dementia conversion rates than the base 
annual incidence rates of AD and other dementias of around 1-2 % (Mayeux and Stern, 
2012;Mitchell et al., 2014).   
Due to the lack of common standards in defining patients with SCI and an attempt to define 
consensus on terminology, a conceptual framework including research criteria for subjective 
cognitive decline (a proposed new term replacing SCI) in pre-MCI has recently been proposed 
(Jessen et al., 2014).   
This new way of defining at risk populations has opened up the field to substantial research 
efforts including implementation of various biomarkers for diagnostic purposes and  
monitoring of medical trials (see also sections 3.2.8,  3.3.6.6 and 4.6).     
 
1.5 Activities of daily living (ADL) 
 
In the context of neurodegenerative brain disorders, one has traditionally equated the term 
cognitive impairment and “dementia”, which indicates a rather advanced disease stage 
including impaired ADL (text box 3). ADL can be defined as routine activities that people do 
every day without the need for assistance. Basic ADLs include eating, dressing, bathing, 
toileting (continence) and walking (transferring). 
  
 
 
Text box 3: 
 
Definition of Activities of Daily Living (ADLs) (MedicineNet.com Medical Dictionary):  
 
- ADLs refer to daily self-care activities within an individual's place of residence, in 
outdoor environments or both. 
 
- ADLs include activities such as feeding ourselves, bathing, dressing, grooming, work, 
homemaking and leisure. The ability or inability to perform ADLs can be used as a very 
practical measure of ability/disability in many disorders. 
 
 
 
1.6 Dementia 
 
Dementia can be translated into being without “mind” or “sense” and has been known since 
antiquity. Before the beginning of modern dementia research around the 20th century, dementia 
encompassed all conditions causing severe mental disability, including psychiatric disorders 
and delirium caused by reversible somatic disease. Often it was equated with normal aging, 
hence the commonly used term “senile dementia”. Traditionally the term dementia refers to a 
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variety of conditions of different etiology and is as such a syndrome of cognitive decline where 
Alzheimer’s disease (AD), Lewy body disease (LBD) and cerebrovascular disease are the most 
common causes. According to the World Health Organization’s (WHO) international 
classification of diseases (ICD-10, 10th edition), dementia is characterized by memory loss, 
impairment of other cognitive functions including judgment, planning and reasoning, clear 
consciousness (as opposed to delirium), a decline in emotional control or motivation (including 
emotional lability, irritability, apathy and coarsening of social behavior) and impaired ADL-
functions (textbox 4). To ensure that the symptoms are of a chronic nature, the duration must 
be at least 6 months. Of note, a few conditions are potentially reversible including vitamin 
deficiencies (vitamin B1, B2, B12), normal pressure hydrocephalus, encephalitis (Borelia, 
Lues,) and even drug side effects, and are thus per definition not dementia. The ICD-10 criteria 
are primarily based upon typical symptoms seen in AD. The prevalence of the five most 
common causes of dementia account for about 95 % of all cases and are listed in table 1. 
 
 
 
   
  Textbox 4:  
 
Definition of the dementia syndrome according to the ICD-10 research criteria 
 
1. Impairment of memory and other cognitive functions (judgment, planning,   
    thinking, abstraction) 
 
Mild: Decline in cognitive abilities affects a person's capacity to cope with everyday  
          activities, but the individual is not dependent upon others. 
Moderate: Decline in cognitive abilities makes the individual dependent upon others in    
          daily living. 
Severe: Decline in cognitive abilities makes the individual dependent on continuous care 
 
2. Clear consciousness 
 
3. Impairment in emotional control or motivation or change in social behavior in at   
    least one of the following: 
    
   - Emotional stability 
   - Irritability 
   - Apathy 
   - Coarsening of social behavior 
 
4.  Duration of cognitive decline at least six months 
 
 
 
In light of the past decades recognition of a pre-dementia phase and subsequent redefinition of 
the clinical characterization of cognitive disorders, the newly published fifth edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has replaced the term 
“dementia” with “minor and major neurocognitive disorder”. DSM-5 now recognizes that 
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dementia is on a continuum from MCI, in DSM-5 labelled “minor cognitive impairment”, an 
initial stage without significant changes in a person’s ability to manage ADL-functions to more 
profound deficits that interfere with independence, i.e. “major cognitive impairment”. This is 
an important distinction because it promotes attention also to early clinical features of dementia 
and encourages a higher research focus on pre-dementia stages.  
DSM-5 also includes Dementia with Lewy bodies (DLB) and Parkinson's disease dementia 
(PDD) (see section 3.0) for the first time, referring to it as "major or mild neurocognitive 
disorder with Lewy Bodies" and “major or mild neurocognitive disorder due to Parkinson's 
disease” respectively.  
Accordingly, the new criteria focus less on memory and recognize that the different dementia 
subtypes have different presentations including deficits in other cognitive domains.     
 
 
 
Table 1: Prevalence of different dementia subtypes (Aarsland et al. 2008) 
 
Dementia subtype 
 
Percentages of subjects having subtypes of dementia 
 
Alzheimer's disease 
 
60-70 % 
 
Dementia with Lewy bodies 
 
15-20 % 
 
Vascular dementia 
 
5-30 % (depending on definition) 
 
Frontotemporal dementia 
 
5-15 % (> 65 years of age; until 50% < 65 years of age). 
 
Parkinson's disease dementia 
 
3-6 % 
 
Alcoholic dementia 
 
2-10 % 
 
 
 
 
1.7  Depression 
 
Depression can refer to a symptom of low mood, but is also a clinical diagnosis fulfilling a set 
of operationalized criteria. The latter is an umbrella term for different mood (affective) 
disorders including major depression ,dysthymia, cyclothymia, recurrent brief depression, 
bipolar disorder and seasonal affective disorder. Mood disorders often accompany medical 
conditions and can be secondary to a diversity of disorders including organic brain disease, 
cancer, vitamin deficiencies and drug effects. 
Diagnostic criteria for a major depressive episode (MDD) according to ICD- 10 (text box 5) 
consist of 3 key depressive symptoms and 7 associated symptoms. The three key symptoms are 
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1) persistent low mood or sadness, 2) loss of interest or pleasure and 3) fatigue, and at least two 
of them must be present most days, most of the time for at least two weeks. In addition the 
episode is not attributable to psychoactive substance use or an organic mental disorder. 
Associated symptoms are 1) sleep problems, 2) poor concentration or indecisiveness, 3 poor 
appetite, 4) suicidal thoughts, 5) agitation or retardation, 6) guilt or self-blame and 7) low self-
esteem.  
 
A major depressive episode is typically subdivided in mild, moderate and severe depression. A 
diagnosis of mild depression requires at least 4 symptoms (minimum 2 key symptoms), 
moderate depression at least 6 symptoms (minimum 2 key symptoms) and severe depression at 
least 8 symptoms (including all 3 key symptoms). Severe depression can be with or without 
psychotic symptoms. Minor depression is thus defined as a “sub-threshold” depressive state 
with clinical relevant symptoms not fulfilling diagnostic criteria for major depression.   
Thus, depression has a variety of clinical manifestations and, not surprisingly, also a multitude 
of possible explanations. Depression can run in families and impose an increased genetic risk, 
some people may be at higher risk due to personality traits, traumatic events including 
accidents may be precipitating causes and serious medical illness can trigger depression 
directly or be a consequence of associated stress.  
 
With regard to neurological disorders, a bidirectional relationship has been proposed between 
depression and (among others) cerebrovascular brain disease (e.g. stroke), epilepsy, AD and 
Parkinson's disease (PD) (Kanner, 2005;Thomas et al., 2004). That means that these patients 
are not only at increased risk of developing depression, but also that depression in itself 
increases the risk of certain neurological disorders. For possible mechanisms and associations 
between depression, neurodegenerative disease and cognition, see section 5.5.  
 
1.8   Biomarker  
 
A “biomarker” is the short form of “biological marker” and can be defined as a characteristic 
that is (ideally) “objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or a pharmacological response to a therapeutic intervention“. 
There is a variety of biomarkers in use in medicine today, for instance different blood test, 
ultrasound, imaging, and even by definition clinical symptoms such as hallucinations, 
depression, etc. Often several biomarkers in combination are needed for optimal diagnosis and 
treatment or in order to find underlying disease mechanisms of specific conditions. Typically 
each biological system (nervous system, gastro-intestinal system, etc.) has its own set of 
biomarkers that is adapted for optimal disease control or measurement of biological activity. 
Selection of an ideal biomarker or sets of biomarkers will thus depend on the nature of the 
desired study. An ideal biomarker should be reproducible, have high sensitivity and specificity 
(> 80%), provide a rapid response and be non-invasive and cost-effective (Mayeux, 2004). In 
science, where the goal often is exploratory research, biomarkers will not always meet all of 
these criteria. 
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  Textbox 5:  
Severity criteria of a major depressive episode according to the ICD-10 
 
 
A. General criteria:  
 
- The depressive episode must last at least two weeks 
- The episode is not attributable to use of psychoactive substances or an organic mental disorder 
- No former hypomanic or manic episode as part of a bipolar disorder 
 
B. Presence of at least two of the following three symptoms: 
- Clearly abnormal depressive mood for the subject, present during most of the day and almost every day,       
which is altered very little by environmental circumstances and which persists for at least two weeks 
- Marked loss of interest or of the ability to enjoy activities that were previously pleasurable 
- Lack of vitality or increased fatigability 
 
C. One or more symptoms from the list must be present so that the sum total is at        
     least four: 
 
- Loss of confidence and self-esteem and feelings of inferiority 
- Disproportionate self-blame and feelings of excessive guilt or inadequacy 
- Recurrent thoughts of death or suicide or any suicidal behavior 
- Complaints about or a decrease of the ability to concentrate and think, accompanied by a lack of  
decision and vacillation 
- Changes of psychomotor activity, with agitation or inhibition 
- Sleep alterations of any kind 
- Changes of appetite (decrease or increase), with corresponding weight change 
 
Mild depressive episode:  
Two or three of the symptoms of criteria B are present, in addition to symptoms of criteria C until there is a 
minimum of total 4 symptoms. A person with a mild episode is probably capable of continuing with the 
majority of their activities. 
 
Moderate depressive episode:  
At least two of the symptoms of criteria B are present; in addition to symptoms of criteria C until there is a 
minimum total of 6 symptoms. A person with a moderate episode will probably have difficulties continuing 
with their ordinary activities. 
 
Severe depressive episode:  
There must be 3 symptoms of criteria B, in addition to symptoms of criteria C until there is a minimum of 8 
symptoms. People with this type of depression present marked and distressing symptoms, mainly the loss of 
self-esteem and feelings of guilt or worthlessness. Suicidal thoughts and actions are common, and a number 
of somatic symptoms are present. Psychotic symptoms can appear, such as hallucinations, delusions, 
psychomotor retardation or severe stupor. In this case, it is called a severe depressive episode with psychotic 
symptoms. Psychotic phenomena such as hallucinations or delusions may or may not be mood-congruent. 
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2.0  Overarching themes 
 
Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common and 
debilitating dementia syndromes accompanied by parkinsonism and a range of other 
psychiatric, sleep and autonomic disturbances. The overall negative impact on the individual 
patient and caregiver, as well as the health-related costs of Lewy body dementia (i.e. DLB and 
PDD) are even higher than those of AD (Bostrom et al., 2007a;Bostrom et al., 2007b;Rongve 
et al., 2014;Vossius et al., 2011), and diagnosis and treatment of the diversity of 
neuropsychiatric symptoms related to the disease are particularly challenging. Disease 
mechanisms are unknown, but aggregated Lewy bodies (LB) containing alfa-synuclein are 
believed to play a central role in the pathogenesis (see also section 3.0). Giving individualized 
treatment as early as possible is a clinical priority, preferably in the pre-dementia phase before 
irreversible brain damage has occurred, but there are few available studies and validated 
guidelines are lacking. 
AD is the most common form of dementia, with core pathological hallmarks of amyloid 
deposits and neurofibrillary tangles, and clinical and pathological features overlap with DLB 
and PDD, especially in end-stage disease (see also sections 3.0 and 4.0). As for DLB and PDD, 
treatment options for AD are limited. The overall cost of dementia disease for society is high 
and expected to rise considerably the next decades. Development of disease-modifying 
therapies is thus urgently needed.  
 
In contrast to the situation in AD and PD, the pre-dementia phase of DLB is almost unexplored, 
and there exists no consensus criteria for DLB-mild cognitive impairment (DLB-MCI). Given 
the known diversity of clinical DLB features, the non-demented phase is probably 
heterogeneous and complex (see also section 3.2.6 and figures 1 and 3).  
It has become increasingly clear that PD has a long pre-motor period, the most prevalent and 
best documented symptoms being gastrointestinal (constipation) and olfactory dysfunction, 
REM sleep Behavior Disorder (RBD) and neuropsychiatric symptoms such as depression (see 
section 3.3.4.2). Despite the fact that MCI is prevalent in early (including untreated) PD (see 
section 3.3.6.2), it is unclear whether cognitive impairment is an antecedent of motor PD 
(Sanchez-Ferro et al., 2013). Further, it is not known whether depression is common in pre-
dementia DLB (Fritze et al., 2011). This is a relevant question since depression can precede 
AD and PD by several years and is also known to be a risk factor in development of cognitive 
impairment and dementia (see also sections 5.5 and 8.4). Similar studies have not been 
performed with DLB as an outcome. 
 
Since both DLB and PDD are synucleinopathies (see section 3.2.2), it is not surprising that they 
share common features (Lippa et al., 2007). Widely accepted is the Braak staging system for 
PD that proposes a pathologic progression from the enteric nervous system, olfactory bulb and 
the lower parts of the brain stem (i.e. medulla oblongata) with subsequent rostral distribution 
involving the substantia nigra and finally cortical areas (bottom-up pathological progression) 
(Braak et al., 2003) (see sections 3.2.3 and 3.3.3). In DLB, alfa-synuclein positive Lewy bodies 
(LBs) are typically more abundant in cortical areas, and parkinsonism develops later in the 
disease process. Although the mechanisms of disease development is unknown, a top-down 
pathological progression (i.e. cortical involvement first) rather than the bottom-up progression 
as suggested by Braak et al. for PD may be a more common pattern in DLB (Langston, 
2006;Parkkinen et al., 2008). In addition to the similarities between DLB and PDD, there are 
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also overlapping features between Lewy body dementia and AD that need to be disentangled. 
This thesis aims to further this understanding. Our main focus will be on Lewy body disease 
since less is known about the existing pathophysiology and early clinical features compared to 
AD. Important research questions asked in this thesis include (figure 1):  
 
- What are the earliest and most prevalent clinical symptoms in DLB ? Is depression an  
  early presentation in DLB (paper 1) ? 
 
- What role does depression have as an early marker of neurodegenerative disease  
  (papers 1 and 3) ?  
 
- Is depression in subjective cognitive impairment (SCI) and MCI associated with   
   neurobiological correlates of early AD pathology (paper 3) ? 
 
- What is the potential relevance of white matter disintegrity in pre-dementia Lewy body  
  disease ? Are these changes related to cognitive impairment (paper 2) ? 
 
                                                                                         
                                          ?                                            ?                        ? 
                                                                                            
                                                                                                                  
                                                                                                                ? 
                                                                                          
 
                                                                         
                                                                          ? 
 
 
                                                                                                  ?                             
 
 
 
                                                                     ?                
 
 
 
 
___________________________________________________________________________ 
Figure 1:  
Single arrow indicates increased probability for a certain condition to lead to another. Double 
arrows indicate a bidirectional relationship, i.e. increased probability that one condition will 
lead to another and vice versa. Question marks represent research hypothesis raised in this 
thesis. RBD=REM sleep behavior disorder. MCI=mild cognitive impairment. DLB=dementia 
with Lewy bodies. PD=Parkinson's disease. AD=Alzheimer's disease. SCI=Subjective 
cognitive impairment.  
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3.0  Lewy body disease 
 
 
3.1 Introduction 
 
James Parkinson's (1755 - 1824) “essay on the shaking palsy” written in 1817, was the first 
clinical description of a patient group characterized by motor symptoms such as slowing of 
movement, tremor and flexed posture. The essay was based on only six cases that James 
Parkinson had observed in his own practice in London or around his neighborhood. The essay 
was meant to encourage research, and about 60 years later the influential French neurologist 
Jean-Martin Charcot (1825 - 1893) working at the Salpetriere hospital in Paris saluted 
Parkinson for his observations and suggested the name Parkinson' disease (PD). Charcot 
recognized that cardinal symptoms of PD were tremor, rigidity, bradykinesia and postural 
instability and classified the disorder as a “neurosis”, meaning a neurologic disease of unknown 
origin. This established PD as a recognized medical disorder.   
 
In 1912, the German born American neurologist Friedrich Heinrich Lewy (1885-1950), who 
studied under Alois Alzheimer (1864 -1915) in Munich at that time, discovered that abnormal 
aggregates of intracytoplasmatic proteins could be found in the brainstem of PD patients 
(including the dorsal vagal nucleus, but also the nucleus basalis of Meynert in the basal 
forebrain), now better known under the eponym of Lewy bodies (LB). In 1919 the Russian 
neuropathologist Konstantin Tretiakoff (1892 – 1958) found LBs in the substantia nigra of PD 
patients, at present the hallmark of idiopathic PD.  
 
In his original description James Parkinson himself stated that the “intellect was preserved”. 
Although Friedrich Lewy described significant cognitive impairment in PD patients, it was 
merely seen as an incidental finding, and for decades PD was regarded as a disease with pure 
motor dysfunction. From 1960 and later more sensitive immunocytochemical methods could 
detect LBs also in cortical and limbic structures in patients with dementia both with and 
without typical motor symptoms. Typical symptoms such as visual hallucinations, 
disorientation, autonomic dysfunction and cognitive impairment in addition to parkinsonian 
motor symptoms were described and linked to autopsy confirmed presence of cortical LBs 
(Okazaki et al., 1961). Similar histopathological changes were also seen in the peripheral 
nervous system (Kosaka et al., 1976;Kosaka et al., 1984).  
 
Another key development was the detection of the neurotransmitter dopamine and its relevance 
for PD and the remarkable efficacy of dopaminergic drugs in the treatment of motor symptoms 
(Carlsson, 2002;Olanow and Schapira, 2013). In the absence of cortical senile plaques and 
neurofibrillary tangles typically seen in Alzheimer's disease (AD), a distinct and new dementia 
subtype was starting to emerge with a diversity of symptoms affecting several brain structures 
and transmitter systems. Thus, the first clinical criteria for dementia with Lewy bodies (DLB) 
(McKeith et al., 1996) and a decade later the clinical, diagnostic criteria for dementia 
associated with PD (PDD) were proposed (Emre et al., 2007). 
There has been much debate about whether these two disorders are different, but the common 
view now is that similarities dominate, and that the relative timing of dementia and motor 
symptoms is the major difference. Lewy body disease (LBD) has thus been proposed as an 
umbrella term for PD, PDD and DLB, the latter subsequently named Lewy Body dementias 
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(Lippa et al., 2007). A Movement Disorders Society commissioned task force has recently 
initiated a redefinition of the criteria for PD, PDD and DLB (Berg et al., 2014) (see also section 
8.3), proposing that DLB should be included as a subtype of PD. 
Increased knowledge of LBD progression will provide patients and caregivers with an 
explanation to the diversity of symptoms often seen years before onset of dementia. In addition, 
greater insight into disease mechanisms will help facilitate future administration of targeted 
disease-modifying medication before irreversible brain damage occurs. 
 
In this section I will attempt to address the important features of cognitive impairment in LBD. 
Despite similarities between DLB and PDD, I will describe the current known risk factors and 
epidemiology separately. I will review highlights from the current status of both established 
and potential future biomarkers, such as clinical features, genetics, cerebrospinal fluid (CSF) 
and imaging parameters. Finally, a brief outline of the treatment options in Lewy body 
dementia is presented together. This review is partly overlapping with a recent publication 
(Auning et al., 2012, Norsk epidemiologi), but has been expanded and updated. 
 
3.2   Dementia with Lewy bodies (DLB) 
 
3.2.1 Clinical criteria 
The original DLB criteria (McKeith et al., 1996) had low sensitivity (20-80 %), but high 
specificity (80-100 %) (McKeith et al., 2005), i.e. a lot of DLB cases were missed, but when a 
diagnosis was made it was most often correct. The revised criteria included a pathological 
dopamine transporter single photon emission computed tomography (SPECT) using ioflupane 
(123I) or other ligands (Dopamine transporter scan) and REM-sleep Behavior Disorder (RBD) 
as suggestive features to increase sensitivity (McKeith et al., 2005) (text box 6).  
According to the revised criteria DLB is defined by the presence of dementia together with two 
of three core symptoms:  
(1) Parkinsonism, (2) typically well-formed and persistent visual hallucinations and (3) 
fluctuating cognition and/or consciousness. A probable DLB diagnosis can also be made with 
only one core symptom together with one or more suggestive features like RBD, neuroleptic 
hypersensitivity or pathologic Dopamine transporter scan. A diagnosis of possible DLB can be 
made with only one core or suggestive feature. In addition, the consensus criteria list a number 
of supporting clinical features like frequent falls, psychotic and depressive symptoms and 
autonomic failure.  
 
The revised clinical criteria await further systematic validation, but seem to be more sensitive 
than the previous criteria. In a study by Aarsland et al., the number of cases diagnosed with 
probable DLB increased by 25 % using the new compared to the old criteria (Aarsland et al. 
2008b), and the sensitivity and specificity has been found to increase if RBD is added as a core 
feature (sensitivity 90%) and cognitive fluctuation excluded (specificity 85%) in advanced 
disease (Ferman et al., 2011). 
However, in a large multi-center study were 2861 patients with final clinical diagnoses (of 
neurodegenerative disease) were compared systematically with subsequent neuropathology 
diagnoses, the sensitivity for a clinical diagnosis of DLB was low (32,1 %), but sensitivity high 
(> 95 %) (Nelson et al., 2010). 
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  Textbox 6:  
 
Revised criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) 
(McKeith et al. 2005) 
 
1. Central features (essential for a diagnosis of possible or probable DLB): 
- Dementia defined as progressive cognitive decline of sufficient magnitude to interfere with normal social or   
  occupational function 
- Prominent or persistent memory impairment may not necessarily occur in the early stages but is usually  
  evident with progression 
- Deficits on tests of attention, executive function, and visuospatial ability may be especially prominent. 
 
2. Core features (two core features are sufficient for a diagnosis of probable DLB, one for possible DLB): 
- Fluctuating cognition with pronounced variations in attention and alertness 
- Recurrent visual hallucinations that are typically well formed and detailed 
- Spontaneous features of parkinsonism 
 
3. Suggestive features (If one or more of these is present in the presence of one or more core features, a 
diagnosis of probable DLB can be made. In the absence of any core features, one or more suggestive features 
are sufficient for possible DLB. Probable DLB should not be diagnosed on the basis of suggestive features 
alone.): 
- REM sleep behavior disorder 
- Severe neuroleptic sensitivity 
- Low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET imaging 
 
4. Supportive features (commonly present but not proven to have diagnostic specificity): 
- Repeated falls and syncope 
- Transient, unexplained loss of consciousness 
- Severe autonomic dysfunction, e.g., orthostatic hypotension, urinary incontinence 
- Hallucinations in other modalities 
- Systematized delusions 
- Depression 
- Relative preservation of medial temporal lobe structures on CT/MRI scan 
- Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity 
- Abnormal (low uptake) MIBG myocardial scintigraphy 
- Prominent slow wave activity on EEG with temporal lobe transient sharp waves 
 
5. A diagnosis of DLB is less likely 
- In the presence of cerebrovascular disease evident as focal neurologic signs or on brain imaging 
- In the presence of any other physical illness or brain disorder sufficient to account in part or in total for the   
clinical picture 
- If parkinsonism only appears for the first time at a stage of severe dementia 
 
6. Temporal sequence of symptoms 
DLB should be diagnosed when dementia occurs before or concurrently with parkinsonism (if it is present).  
The term Parkinson disease dementia should be used to describe dementia that occurs in the context of well-
established Parkinson disease. In a practice setting the term that is most appropriate to the clinical situation 
should be used and generic terms such as Lewy body disease are often helpful. In research studies in which 
distinction needs to be made between DLB and PDD, the existing 1-year rule between the onset of dementia 
and parkinsonism DLB continues to be recommended. Adoption of other time periods will simply confound 
data pooling or comparison between studies. In other research settings that may include clinicopathologic 
studies and clinical trials, both clinical phenotypes may be considered collectively under categories such as LB 
disease or alpha-synucleinopathy. 
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Furthermore, evidence suggested that the core symptoms of parkinsonism, visual hallucinations 
and fluctuating cognition added little to the diagnosis in severe dementia. DLB was most often 
misdiagnosed as AD, which is in accord with the mixed AD pathology in the majority of DLB 
cases (see section 3.2.3).  
 
3.2.2 Molecular pathology 
LBs are intraneural, cytoplasmic, eosinophilic inclusions and found in neuronal cell processes 
they are called Lewy neurites (or intraneuritic LBs). They are traditionally classified in a 
brainstem (classical) and a cortical type, each type with distinct histopathological features 
(Wakabayashi et al., 2013). LBs in the substantia nigra is regarded the hallmark of idiopathic 
PD. Furthermore, the association between the extent of LB pathology and clinical symptoms is 
well established (Ballard et al., 2013) although some individuals have severe alfa-synuclein 
pathology at autopsy but not the typical symptoms of Lewy body disease (LBD) (Parkkinen et 
al., 2008). LBs accompanied by neuronal loss are characteristic of all forms of LBD.  
LBs consist of more than 90 molecules, mainly proteins of the ubiquitin-proteasome system 
(involved in protein degradation) and alfa-synuclein, but their exact functions are poorly 
understood. Increased expression of alfa-synuclein has been shown to inhibit synaptic 
reclustering and subsequently inhibit neurotransmitter release in the synaptic cleft (Nemani et 
al., 2010). The biological function of alfa-synuclein is thus believed to be involved in neural 
plasticity. Recent evidence suggest that alfa-synuclein can spread directly from cell to cell 
leading to neurodegeneration (Luk et al., 2012), and a hypothetical model of alfa-synuclein 
toxicity includes increased oxidative stress, disruption of axonal transport and synaptic 
dysfunction, inhibition of the ubiquitin proteasome system and mitochondrial dysfunction 
(Irwin et al., 2013;Olanow and Brundin, 2013).  
Alfa-synuclein seems to play a key role in the pathogenesis of several conditions, and thus the 
term alfa-synucleinopathy is increasingly being used (table 2). 
  
 
Table 2: The alfa-synucleinopathies 
 
Condition 
 
Clinical features 
Parkinson's disease Tremor, rigidity, bradykinesia and gait 
disturbance 
Parkinson's disease dementia Development of dementia in established (at 
least one year) Parkinson's disease. 
Dementia with Lewy bodies Dementia prior to parkinsonism (at least one 
year); visual hallucinations, fluctuating 
cognition, REM sleep behavior disorder 
Multiple system atrophy Parkinsonism, autonomic dysfunction, ataxia, 
minimal effect of L-dopa 
Pure autonomic failure Orthostatic hypotension, visual disturbances, 
sexual dysfunction, sweating 
Idiopatic REM sleep behavior disorder 
 
Acting out dream content during REM sleep 
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3.2.3 Neuropathology 
The gold standard when diagnosing Lewy body dementias (and other dementias) is autopsy. A 
neuropathological diagnosis of DLB and PD is based on the widespread finding of LB both in 
the central and peripheral nervous system. In contrast to previous staining methods with 
hematoxylin/eosin and ubiquitin immunohistochemistry, LBs and Lewy neurites are now 
directly detected with immunehistochemical staining of alfa-synuclein (McKeith et al. 2005). 
This new method has increased sensitivity and specificity significantly.  
 
Historically, several staging systems in Lewy body disease have been proposed. One of the 
earlier classifications differentiated between three DLB subgroups based solely on the 
localization of LBs, namely brainstem, transitional (intermediate between brainstem and 
cortical) and (diffuse) cortical predominant (Kosaka et al., 1984). This broad classification has 
also been adopted in the current semi quantitative assessment of LB density and distribution in 
DLB (McKeith et al., 1996), However, the underlying pathology in DLB is often mixed with 
typical AD pathology (amyloid and neurofibrillary tangle deposits). With increasing LB 
pathology in the brain, the likelihood of a typical DLB phenotype increases. Concomitant AD-
type pathology, on the other hand, decreases the probability of the clinical syndrome of DLB 
and increases the likelihood of a mixed DLB and AD phenotype. In contrast, AD pathology 
seems to be less prominent in PDD, although the presence of cortical amyloid beta 42 ($ȕ) 
are associated with progression of dementia also in PDD (Siderowf et al., 2010). The new 
pathologic criteria propose to take into account not only LB pathology but also concomitant 
AD-related pathology to assess the probability that the neuropathologic findings can explain the 
clinical syndrome of DLB (McKeith et al., 2005). 
 
In 2003 Braak et al. proposed a pathological staging scheme for PD with ascending caudal-
rostral progression with increasing severity throughout the brain starting in the peripheral 
nervous system and lower medulla oblongata and ultimately involving the entire cortex (Braak 
et al., 2003). Stage 1-2 includes the dorsal vagal motor nucleus, anterior olfactory structures 
and eventually the entire enteric nervous system (olfactory and autonomic symptoms may 
present). Stage 3-4 involve the basal forebrain and mesocortex (where typical motor symptoms 
occur) and stage 5-6 the neocortex (frequently associated with cognitive symptoms). This 
staging system is currently widely accepted in PD, but is in contrast to the spread of LBs in 
DLB, which per definition has earlier cortical involvement. Despite a proposal by Beach et al. 
to unify the staging systems to allow for the classification of all subjects with LB disorders, the 
need for further refinement of  the neuropathological criteria (for DLB) is clear (Beach et al., 
2009) (see also table 3).    
 
It is at present unclear whether LB pathology is toxic or neuroprotective. Indeed, up to 30 % of 
elderly patients have LBs at autopsy, but not the clinical syndrome of LB dementia, so-called 
incidental LBD (Halliday et al., 2011a;Parkkinen et al., 2005). One explanation could be that 
these patients would eventually develop symptoms had they lived longer, and evidence in 
support of this hypothesis indicates that predilection sites for LBs in these cases are similar to 
those seen in early stage PD (Del et al., 2002).  
Of note, LBs and alfa-synuclein related pathology are found in up to 60 % of AD cases, and 3 
out of 4 DLB patients also have AD pathology (although usually with less neurofibrillary 
tangles) (Halliday et al., 2011a;Hamilton, 2000;Iseki, 2004), but how the different pathologies 
affect the other is not known. The Amygdala seems especially vulnerable in cases with AD and 
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mixed pathology (Hamilton, 2000). The comorbid role of cardiovascular factors is at present 
also poorly understood. 
Interestingly, in an autopsy study of 1720 subjects, 83% (of 248 cases with alfa-synuclein 
positive autopsy) showed a distribution pattern compatible with the current staging systems 
(Parkkinen et al., 2008). However, 55 % of the subjects with abundant alfa-synuclein pathology 
(Braak stage 5-6) remained cognitively intact which raises doubts whether the actual disease 
process is measured in all cases. In addition, 17% of cases deviated from the suggested caudo-
rostral progression suggesting that alternative routes are perhaps more relevant in DLB. 
 
 
 
Table 3: Staging of Lewy body pathology 
 
 
Reference 
 
 
Staging 
 
Kosaka et al., 1984 
Group A:  Diffuse type of LBD involves cerebral  
                  cortex, basal ganglia,diencephalon and  
                  brainstem. 
 
Group B:  Transitional type between group  
                  A and C. 
 
Group C:  Involves brainstem and diencephalon. 
 
 
Braak et al. 2003 
 
Stages 1-2:  Pathology confined to lower medulla   
                     oblongata, olfactory bulb and enteric   
                     nervous system. 
 
Stages 3-4:  Pathology in the substantia nigra,  
                    midbrain and basal forebrain. 
 
Stages 5-6:  Pathology in the cortex. 
 
 
Beach et al. 2009 
 
 
 
 
 
Stage 1:  Pathology in olfactory bulb only. 
 
Stage 2a:  Brainstem predominant involvement. 
 
Stage 2b:  Limbic predominant involvement.  
 
Stage 3:    Brainstem and limbic roughly equally  
                  involved. 
 
Stage 4:    Neocortical involvement.  
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3.2.4 Diagnosis  
A main challenge in diagnosing DLB is making an accurate and early diagnosis. There is 
evidence that DLB patients have a more rapid decline, need more resources, have poorer 
quality of life and higher mortality as compared to AD (Bostrom et al., 2007a;Bostrom et al., 
2007b;Williams et al., 2006). In addition, a diversity of symptoms can probably precede the 
clinical syndrome of DLB (see also section 3.2.6 and figure 3), making it essential for the 
physician in charge to be able to make informed decisions, educate the patient and caregiver 
and plan the best course of management as early as possible.   
 
At present, there is evidence that DLB is underdiagnosed (Toledo et al., 2013) and that the 
clinical DLB criteria has low sensitivity in a clinical setting, low to moderate sensitivity in 
research settings, but overall high specificity when a diagnosis of probable DLB can be made 
(see section 3.2.1).  
 
In order to increase sensitivity, a structured assessment of the core and suggestive features of 
DLB is recommended. Parkinsonism can be identified by a routine clinical examination or 
preferably by using the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale 
(Fahn S et al., 1987) or the validated short version (Ballard et al., 1997). Of note, parkinsonism 
is present in only about 75 % of DLB cases (Hanson and Lippa, 2009;McKeith, 2007), and 
subjects without motor symptoms are less likely to be considered for the diagnosis. Visual 
hallucinations affect around 60-80 % of patients with DLB (Ferman and Boeve, 2007) and can 
be evaluated with the Neuropsychiatric Inventory (NPI) (Cummings et al., 1994).  The most 
difficult symptom to reliably evaluate in clinical practice is fluctuating cognition which affects 
around half of the DLB patients. The 2005 consensus criteria for DLB recommends using at 
least one formal measure when searching for fluctuating cognition, and the Clinician 
Assessment of Fluctuation Scale or The Mayo Fluctuation Composite Scale can be used for this 
purpose (McKeith et al. 2005). Of note, these scales define different aspects of cognitive 
fluctuation and await further validation. 
The Mayo Sleep Questionnaire is a structured and validated instrument used to screen for a 
wide range of sleep disturbances including RBD (Boeve et al., 2011). RBD is characterized by 
vivid and often frightful dreams and a tendency to “acting out” dream content (e.g. moving 
limbs including hitting/kicking the bed partner, screaming, etc.) during REM sleep and is 
suggestive of a DLB disorder. A bed partner is asked to elaborate by use of a semi-structured 
interview. A tentative diagnosis of RBD can be confirmed by polysomnography. 
A pathologic [123I]FP-CIT SPECT (Dopamine transporter scan) can increase the sensitivity and 
specificity in separating DLB from AD, even in cases without clinical parkinsonism (see also 
section  3.2.8.6).  
 
Importantly, neuropsychological deficits in DLB are heterogeneous and (eventually) affect all 
domains, and memory problems do not preclude a diagnosis of DLB. However, there is 
evidence that early visuospatial dysfunction is more prominent in pure DLB and early memory 
problems more pronounced in pure AD, and that mixed DLB and AD pathology increases the 
probability of similar clinical phenotypes (Yoshizawa et al., 2013) (see also section 3.2.3). 
 
Clinical and biomarker changes in DLB and PDD are overall similar, but there are subtle 
differences, especially in early disease, including early features that per definition are slightly  
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Table 4: Studies reporting the prevalence of dementia with Lewy bodies   
 
 
Study 
 
 
Number 
in 
study 
 
Number with 
dementia 
 
Number with 
DLB 
 
DLB 3/all 
dementia % 
 
Criteria 
Yamada et al., 
2001 
 
3715 1 
 
142 
 
4 
 
2.8 
 
1996 
Herrera et al., 
2002 
 
1656 1 
 
118 
 
2 
 
1.7 
 
1996 
Harvey et al., 
2003 
  
185 2 
  
6.5 
 
1996 
Takada et al., 
2003 
  
275 2 
  
2.2 
 
1996 
Rahkonen et al., 
2003 
 
601 1 
 
137  
 
30 
 
21.9 
 
1996 
Sambrook et al., 
2004 
  
766 2 
  
3.0 
 
1996 
Yokota et al., 
2005 
  
464 2 
  
4.0 
 
1996 
 
Shinagawa et al., 
2007 
 
 
 
 
483 2 
  
11.0 
 
 
1996 
Molero et al., 
2007 
 
2438 1 
 
196 
 
4 
 
2.0 
 
1996 
Gascon-Baiarry 
et al., 2007 
 
1754 1 
 
165 
 
15 
 
9.1 
 
2005 
Fernandez 
Martinez et al., 
2008 
 
1931 1 
 
 
108 
 
10 
 
9.2 
 
1996 
Aarsland et al., 
2008 
  
196 2 
  
15.8 
 
2005 
Arslantas et al. 
2009 
 
3100 1 
 
262 
 
0 
 
0 
 
1996 
 
Kim et al., 2011 
 
1673 1 
 
351 
 
2 
 
0.6 
 
1996 
Yoshida et al. 
2011 
  
126 2 
  
8.7 
 
1996 
 
Alladi et al., 2011 
  
347 2 
  
8.9 
 
 
2005 
 
Dimitrov et al. 
2012 
 
540 
 
39 
 
2 
 
5.1 
 
2005 
 
1 Population-based prevalence    2 Clinic-based prevalence  3 Dementia with Lewy bodies 
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different (Aarsland et al., 2009b;Johansen et al., 2010;Lippa et al., 2007). In DLB there is less 
resting tremor and asymmetry, a more rapid progression of motor symptoms and a poorer 
response to levodopa as compared to PDD. DLB patients are usually reported to have more 
frequent visual hallucinations and fluctuating cognition and in mild dementia more severe 
executive impairment than in PDD. Finally, although considerable overlap, there seems to be 
more early and extensive AD plaque pathology in DLB compared to PD and PDD. 
Of note, at the stage of severe dementia a distinction between the different dementia subtypes is 
almost impossible due to extensive brain damage and the considerable overlap in symptoms. In 
addition most DLB cases have comorbid AD changes at autopsy with less likelihood of 
detecting the clinical syndrome of DLB with increasing AD pathology. Additionally, there is 
evidence that a synergistic relationship between LB and AD pathology exist (Galpern and 
Lang, 2006;Irwin et al., 2013). 
 
3.2.5  The prevalence and incidence of DLB 
Few community-based epidemiological studies have focused on DLB and few have applied the 
new 2005 clinical diagnostic criteria. 
In the first review of epidemiological studies in DLB, only 7 prevalence and incident studies 
were included (Zaccai et al., 2005). It was concluded that the prevalence of DLB ranged from 0 
to 5% with regard to the general population (> 65 years) and from 0 to 30.5% of all dementia 
cases. A large part of this variation was probably due to methodological differences.  
 
Since 2005, new diagnostic criteria for DLB have been published and the awareness of the 
clinical syndrome of DLB has been raised considerably. In a recent review 28 prevalence and 3 
incidence studies were identified (Vann Jones and O'Brien, 2014), but the majority (about 80 %) 
still used the original 1996 criteria. The largest prevalence studies are shown in table 4.  
The mean prevalence of DLB in the whole population over 65 was estimated to 0.36%, or one 
in 270 people, with a wide range from 0 - 21.9 %. 4.2 % of cases with dementia were estimated 
to be DLB, but prevalence rates varied considerably between studies. In studies implementing 
the 2005 criteria, the prevalence rates ranged from 0 - 1.2 % in the general population (> 65 
years) and 0-9.7 % in those with dementia. In two population-based studies, the probable and 
possible DLB cases were added resulting in an increase in prevalence numbers from 9.7 - 30.5 % 
and 9.1 - 12.7 % in all dementia cases respectively (Gascon-Bayarri et al., 2007;Stevens et al., 
2002). 
In clinical settings the prevalence rates for DLB were overall higher, with an average of 7.5 % 
of all dementia cases, ranging from 2.2 – 24.7 %. Using the 2005 criteria, both population and 
clinical based studies had higher prevalence rates than compared to the original 1996 criteria. 
Still, the mean prevalence numbers are probably an underestimation since four studies (three 
clinic-based, one population-based) specifically looking for DLB, including a neurological 
examination, had considerably higher rates (range 16-24 %). In one of these, the DemVest 
study in Western Norway, the revised 2005 criteria was applied on a referral cohort to old age 
psychiatry and geriatric medicine clinics, including all referrals with a first time diagnosis of 
mild dementia (defined as a Mini Mental State Examination (MMSE) score of 20 or more). In 
196 patients, 15.8% of cases with mild dementia were diagnosed with probable DLB and 20% 
with possible and probable DLB combined (Aarsland et al., 2008).  
 
33 
 
Population incidence studies report 0.57 - 1.4 % new DLB cases for every 1.000 persons per 
year and annual incidence rates in the 3.2-4.5 % range (Matsui et al. 2009, (de Lau et al., 
2004;Lopez-Pousa et al., 2004;Miech et al., 2002;Perez et al., 2010). 
 
3.2.6   Clinical features preceding DLB 
Very few studies have explored the early, pre-dementia stages of DLB, but evidence is 
emerging to suggest that several possible starting points and trajectories can lead to the 
pathological and clinical syndrome of DLB (figure 3). This is in accord with the more 
extensive evidence found to support a long pre-dementia period in AD and pre-motor phase in 
PD (see also sections 3.3.4.2 and 4.0). 
 
MCI has been shown to precede AD with an annual conversion rate of about 10-15% (Petersen 
et al., 2009), but the pre-dementia stage of DLB is at present undefined and essentially 
unexplored. A clinicopathological study of eight MCI patients with subsequent autopsy-proven 
LBD shoved that RBD preceded MCI in six cases with a median of 12 years (Molano et al., 
2010). The cognitive domains most frequently affected at the pre-dementia stage were 
attention, executive and visuospatial functioning. Memory was less frequently impaired.  
The same cognitive pattern was seen in another study with a similar design (Jicha et al., 2010). 
In a recent study including 337 MCI patients, patients with non-amnestic MCI were more likely 
to develop DLB and those with amnestic MCI more likely to develop probable AD (Ferman et 
al., 2013). Parkinsonism, visual hallucinations and delirium were also shown to be early 
features in contrast to the MCI-stage of AD, which is dominated by memory problems.  
In another autopsy proven study, visual hallucinations were seen as the best positive predictor 
and the absence of visuospatial impairment the best negative predictor of a later diagnosis of 
DLB versus AD (Tiraboschi et al., 2006). Similarly, in a recent study visual hallucinations 
were found to be highly specific for a pathological diagnosis of DLB (Toledo et al., 2013). 
 
In the DemVest study, higher frequencies of RBD and Excessive Daytime Sleepiness (EDS) in 
mild DLB were found compared to normal controls and mild AD patients. RBD started on 
average seven years (range 0.5-35 years) before dementia was diagnosed in 39 
patients, indicating a strong association (unpublished data from the DemVest study). This long-
duration preclinical phase was also demonstrated in another study (Claassen et al., 2010).  
In a recent study 80 % of males with an initial diagnosis of RBD eventually developed a 
parkinsonian disorder over a 16 year follow-up (Schenck et al., 2013). 
 
Pure Autonomic Failure (PAF) is restricted clinically to the peripheral nervous system and 
includes orthostatic hypotension, constipation, olfactory dysfunction and urinary incontinence. 
Autonomic symptoms has been shown to be the initial presentation in both DLB and PD 
(Postuma et al., 2013), and a positive [123I]FP-CIT SPECT in PAF supports the hypothesis of a 
common etiology (Tolosa et al., 2007).  
 
Chiba et al. found that non-motor symptoms such as olfactory dysfunction, constipation,  
increased salivation and RBD was increased in DLB compared to AD (Chiba et al., 2012).   
 
Finally, a recent retrospective study suggest that a history of suspected delirium is more often 
associated with a later diagnosis of DLB than AD (Vardy et al., 2014). 
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Figure 3: 
 
Potential presenting symptoms in dementia with Lewy bodies  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______________________________________________________ 
 
*   REM sleep behavior disorder 
** Mild cognitive impairment 
1  Claassen et al., 2010, Boot et al., 2012, Schenk et al., 2013 
2  Molano et al., 2010, Jicha et al., 2010  
3  Tiraboschi et al., 2006, Toledo et al., 2013 
4  Jicha et al., 2010 
5  Tolosa et al., 2007, Chiba et al., 2012 
6  Vardy et al., 2014 
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3.2.7  Genetic contributions in DLB 
Causal genes are rare in the common types of neurodegenerative diseases. More common are 
gene mutations or single nucleotide polymorphisms (SNPs) associated with an increased risk of 
disease. Established genetic causes for AD include rare autosomal dominant mutations in the 
genes coding for Presenilin1, Presenilin 2 and Amyloid Precursor Protein (APP) (Goate et al., 
1991;Levy-Lahad et al., 1995;Schellenberg et al., 1992). The genetics of DLB are largely 
unexplored, but two autosomal dominant genes (alfa-synuclein and LRRK2) and three 
recessive genes (PINK1, PARK2 and PARK7) are causal disease genes found in familial PD 
(Nuytemans et al., 2010). 
 
Most DLB cases occur sporadically, although families have been described as having several 
members diagnosed with DLB with gene alterations in different locations, some of which 
overlap with PD and others with AD (Kurz et al., 2006). Cousins of DLB patients have a 2.3 
fold increased risk of developing DLB compared to members of the general population (Nervi 
et al., 2011). Traditional genetic studies have identified multiplications (Chartier-Harlin et al., 
2004;Singleton et al., 2003) and mutations in the gene encoding alfa-synuclein 
(Polymeropoulos et al., 1997;Yamaguchi et al., 2005;Zarranz et al., 2004) and beta-synuclein 
(Ohtake et al., 2004). Genetic mutations known to be risk factors of early onset familial AD, 
like Presenilin 1 and 2, have also been identified in DLB (Meeus et al., 2012). As in PD, 
mutations in the gene coding for glucocerebrosidase (GBA, an enzyme involved in lysosome 
activity) is known to increase the risk for DLB (Nalls et al., 2013). 
 
The ApoE İ4 allele is the strongest genetic risk factor for developing AD, but in DLB there are 
conflicting results regarding APOE as a risk factor (Singleton et al., 2002;Tsuang et al., 2013). 
Conversely, the ApoE İ2 allele has recently been shown to be a possible protective factor also 
in DLB (Berge et al., 2014). A recent, large neuropathologically proven study involving 667 
DLB cases and 2624 controls shoved that the APOE, alfa-synuclein and SCARB2 (Scavenger 
Receptor class B, member 2) loci are strongly associated with DLB (Bras et al., 2014). The 
SCARB2 gene is a known PD-reported locus and encodes a lysosomal protein, and the 
affection of the GBA and SCARB2 loci suggest a dysfunction in lysosomal function in DLB. 
 
Genome-wide association studies (GWAS) have not yet been presented for DLB, but it is to be 
hoped that in the near future more of the underlying disease mechanism and risk factors will be 
revealed. 
 
3.2.8  Potential biomarkers in DLB 
Due to the relatively low sensitivity of the consensus criteria for DLB, the need for reliable 
biomarkers is evident. A complicating factor is the heterogeneous brain pathology in DLB and 
the considerable overlap between neuropathological changes and clinical presentation 
in DLB and AD.  
A standard computerized tomography (CT) or magnetic resonance imaging (MRI) is used in 
the routine clinical examination of cognitive impaired patients (i.e. to exclude secondary causes 
of dementia). The development of biomarkers is vastly growing, and in this section, present and 
some promising and potential future biomarkers are presented, see also table 5. 
Diffusion Tensor Imaging (DTI) is presented in section 3.3.6.6. 
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3.2.8.1 Structural MRI including computer-based analyzes 
MRI is a non-invasive technique that uses a magnetic field and pulses of radio wave energy to 
create detailed images of organs and structures inside the body. A powerful magnetic field 
temporarily realigns hydrogen atoms in the body and the radio waves cause these aligned atoms 
to produce faint signals, which are then used to create cross-sectional MRI images (slices). 
FreeSurfer is a freely available software package that can create computerized models of the 
brain based on MRI data (http://surfer.nmr.mgh.harvard.edu/) including measurements of 
cortical thickness and volumes and other morphological properties. 
 
There is generally more global (grey matter) atrophy in AD compared to DLB, and among 
established biomarkers for AD is atrophy of the medial temporal lobe (hippocampus) (Bloudek 
et al., 2011;Hansson et al., 2006). The same pattern can also be seen in DLB, but typically the 
hippocampus is less damaged.  Comparable patterns have been shown with Hippocampus 
subfield imaging (including subiculum, CA1 and entorhinal cortex), but it cannot be used to 
separate DLB from AD on an individual level (Mak et al., 2014). This is also in accord with the 
relative preservation of memory in DLB on neuropsychological testing compared to AD. 
Furthermore, the midbrain including the substantia innominata (and the nucleus basalis of 
Meynert where F. Lewy first documented LBs) has shown greater atrophy in DLB as compared 
to AD (Kantarci et al., 2012a;Whitwell et al., 2007). The latter is highly involved in cholinergic 
transmission and can explain the greater cholinergic deficits found in Lewy body disease. 
Comparisons of grey matter atrophy between DLB and PDD seems variable and often similar 
patterns can be seen (Mak et al., 2014). 
 
Advancements in imaging processing using automatic whole-brain segmentation techniques 
extracted from structural MRI (e.g.by use of  FreeSurfer), allows for a more none-biased 
approach (not regions of interest driven). Lebedev et al. recently conducted a multivariate MRI 
classification of cortical thickness demonstrating an 82 % sensitivity and 85 % specificity in 
separating DLB and AD patients (Lebedev et al., 2013). The finding that DLB patients have a 
more occipital and posterior affection compared to the more temporal affection in AD is 
consistent with several other structural imaging studies (Mak et al., 2014). 
 
White matter hyperintensities or lesions (WML) and a special variant of MRI, Diffusion Tensor 
Imaging (DTI), are discussed in section 3.3.6.6 (Biomarkers of cognitive impairment in PD). 
 
3.2.8.2  Cerebrospinal fluid (CSF) and plasma 
CSF is a colorless fluid surrounding the brain and spine functioning as a buffer or shock 
absorber, but also offering immunologic and nourishing properties. About 500 ml of CSF is 
produced in the choroid plexus (situated in the roof the third ventricle) each day and 
recirculated within the ventricular system. CSF is constantly being reabsorbed and only about 
100-160 ml is present at any given time in the subarachnoid space. Lumbar puncture (or spinal 
tap) and extraction of CSF gives the opportunity to analyze for abnormalities in a fluid standing 
in direct contact with the brain and the central nervous system. 
 
CSF amyloid beta 1-42 ($ȕ42) and phospho-tau are established biomarkers in AD and 
contributes to an early diagnosis with a sensitivity and specificity of around 85 % (Hansson et 
al., 2006). These markers cannot at present separate AD from DLB although lower levels of 
$ȕDQG$ȕ42 have been shown in DLB and PDD compared to controls (Bibl et al., 
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2006;Parnetti et al., 2008). In a recent study, the level of concomitant AD pathology in DLB 
FRUUHODWHGWR$ȕ42, but not tau (Brunnstrom et al., 2013). 
 
Reduced levels of alfa-synuclein in the CSF of DLB patients compared to that of those with 
AD have recently been demonstrated (Ballard et al., 2010), but most studies are small and 
routine measurement of alfa-synuclein has proven technically difficult. In a recent meta-
analysis comprising 13 studies and 2728 patients, CSF alfa-synuclein concentrations were 
lower in DLB compared to AD (Lim et al., 2013). These findings are promising, but more 
confirmatory studies are needed in order to incorporate alfa-synuclein as a good and valid 
biomarker for DLB. 
There are currently no blood markers in DLB. 
 
3.2.8.3  Electroencephalography (EEG) 
Slowing of the EEG rhythm is a frequent finding in AD and other dementias, and several 
studies have shown a more pronounced slowing in DLB patients. These early studies have, 
however, included few patients, and larger studies have not been able to reproduce the findings 
(Londos et al., 2003). More recently, a longitudinal study including 50 DLB, 50 AD and 40 
3''SDWLHQWVZLWKHDUO\GHPHQWLDRQWKH006(FRQFOXGHGWKDW((* could 
discriminate between AD and DLB (Bonanni et al., 2008). In a systematic review of the 
diagnostic utility of EEG in early onset dementia (< 65 years) involving 12 studies and 965 
patients with different dementia subtypes, it was concluded that slow wave activity was more 
prominent in DLB (Micanovic and Pal, 2014). At present more confirmatory studies are needed 
in the older age groups before EEG can serve as a reliable biomarker for DLB. 
 
3.2.8.4  Myocardial scintigraphy 
Autonomic dysfunction involving the cardiovascular system is common in DLB, and 
myocardial scintigraphy with (123)I-metaiodobenzylguanidine (MIBG) enables the 
quantification of post-ganglionic cardiac sympathetic innervation. Several studies have 
demonstrated reduced cardiac uptake in DLB compared to AD patients, and the 2005 
diagnostic criteria has included a pathologic (123) I-MIBG cardiac scintigraphy as a 
"supportive" diagnostic feature, based on limited evidence. A recent meta-analysis involving 46 
studies and 2680 patients concluded that AD and DLB (and PD) could be discriminated with a 
high level of accuracy (King et al., 2011).   
However, cardiac heart disease and diabetes can also cause an abnormal myocardial 
scintigraphy, and pathology must be interpreted with care, especially in the elderly with 
comorbid somatic disease. 
 
3.2.8.5  Perfusion SPECT  
Single-photon emission computed tomography (SPECT) is a nuclear medicine imaging 
technique that can measure among others cortical blood flow, tumor spread, infection and 
thyroid activity, providing 3D biological information. A radioisotope (radionuclide, an atom 
with an unstable nucleus, ultimately emitting gamma rays) is attached to a specific ligand 
(creating a radio ligand) and usually injected intravenously in the patient. The radioligand binds 
to biological tissue depending on the quality and properties of the ligand, and a gamma camera 
can thus detect the ligand concentration. Several ligands are used to measure blood flow, one 
commonly used ligand is 99mTc hexamethylpropyleneamineoxime. Dopamine transporter scan 
is a specific form of SPECT targeting dopamine producing neurons in the basal ganglia, the 
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ligand most frequently studied is 123I-ȕ-carbomethoxy-ȕ-(4-iodophenyl)-N-(3-fluoropropyl) 
nortropane (FP-CIT), (see section 3.2.8.6 below).  
 
Radiolabelled tracers used in SPECT to measure regional, cortical blood flow have shown a 
typical pattern of reduced perfusion in temporoparietal areas in AD. In DLB a pattern of 
occipital and parietal hypoperfusion is more common, often referred to as the “horse-shoe sign” 
(Lobotesis et al., 2001), at present a supportive feature in the diagnosis of DLB (McKeith et al., 
2005). Relatively few studies with small samples have assessed the precision of cerebral 
SPECT as a biomarker for DLB, and available results are conflicting, indicating the need for 
multicenter studies for better diagnostic accuracy. 
 
3.2.8.6  Dopamine transporter imaging 
The most convincing evidence exists for Dopamine transporter scan where a soluble 
radioactive isotope, most often containing ioflupane (123I) ([123I]FP-CIT SPECT), is injected 
intravenously in the patient. About 3 hours later a gamma camera is used to visualize the 
uptake in the brain (Booij et al., 1999). Ioflupane has a high binding affinity for presynaptic 
dopamine transporters which is especially enriched in the striatum (part of the basal ganglia). In 
cases of reduction of dopaminergic neurons in the substantia nigra, the visualization of 
dopamine transporters is greatly reduced.  
These findings were first demonstrated in PD, but can now also be seen in preclinical cases of 
nigro-striatal degeneration including multiple system atrophy, progressive supranuclear palsy 
and DLB. This means that DLB patients without clinically detectable parkinsonism can now be 
identified (Walker et al., 2007), whereas the scans of patients with AD are normal.  
In a large pivotal multicenter study, Dopamine transporter scan demonstrated a sensitivity of 
78% and a specificity of 90% in distinguishing probable DLB from AD (McKeith et al., 2007). 
Recent findings suggest that Dopamine transporter scan could be of even greater clinical 
relevance in identifying patients with possible DLB. In a 12-month longitudinal study no 
patients with possible DLB and a normal scan at baseline had developed probable DLB at the 
follow-up examination. In contrast, 63% (12 of 19) of subjects with an abnormal scan had 
probable DLB at follow-up, a significant difference (O'Brien et al., 2009). Thus, Dopamine 
transporter scan can help to identify DLB at an early stage, before the full clinical syndrome 
has developed. 
 
3.2.8.7  PET based imaging 
In Positron Emission Tomography (PET) a radioactive tracer (drug) is used to evaluate the 
biological activity in various tissues and organs. The tracer can be injected intravenously, 
swallowed or inhaled and different radioisotopes can be used depending on the preferred 
uptake in different tissues or organs. Fluorodeoxyglucose-positron emission tomography (FDG-
PET) uses glucose to measure metabolic activity, N-11C-methyl-4-piperidyl acetate can be 
used to investigate cholinergic pathways, 18-fluorodopa to assess the dopaminergic system and 
Pittsburgh compound B (PIB) and18 F-labelled compounds, such as18 F-Flutemetamol, to 
assess amyloid load. In contrast to SPECT, PET-based imaging is more expensive and not 
easily available. 
 
Consistent with perfusion SPECT findings, FDG-PET has also shown the typical pattern of 
occipital hypometabolism with relative preservation of the posterior cingulate (as opposed to 
AD, the so-called positive cingulate island sign) (Kemp and Holmes, 2007), and the same 
cortical pattern has been linked to visual hallucinations in DLB (Kantarci et al., 
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2012b;Perneczky et al., 2008).  The pattern of occipital hypometabolism is also typical for 
PDD, but the sensitivity and specificity is at present to low to recommend FDG-PET in the 
clinical routine. 
 
Most studies using amyloid imaging has focused on AD using 11C-Pittsburgh compound-B 
(PIB). Typical predilection sites for amyloid in AD are pre-frontal and temporoparietal cortices. 
Studies in DLB have been variable, but amyloid retention seems to be less than in AD, but 
overall higher than in PDD and NC (Donaghy et al., 2015). DLB has been shown to have 
increased amyloid retention in 80 % of cases while infrequent in PDD (Edison et al., 2008). At 
present the diagnostic use of amyloid PET in lewy body disease is not established, but amyloid 
deposits are associated with faster cognitive decline (DLB) and progression to dementia (PD) 
as compared to normal controls (Halliday et al., 2011b).  
 
Biomarkers in Lewy body dementia are summarized in table 5. 
 
3.3  Parkinson’s disease 
 
3.3.1 Introduction 
Parkinson' disease (PD) is a chronic, idiopathic, neurodegenerative disease that affects not only 
movement, but also includes a range of non-motor features such as autonomic dysfunction, 
sleep problems and neurobehavioral symptoms. PD is the second most common progressive 
neurodegenerative disorder after Alzheimer's disease (AD) and wordwide an estimated 7-10 
million people are believed to be affected (Parkinson’s Disease Foundation: Statistics on 
Parkinson’s. Retrieved from http://www.pdf.org/en/parkinson_statistics. (2013)). 
The age-adjusted incidence is estimated to about13.5 per 100.000 person-years and an age-
related prevalence of about 115 per 100.000 populations. The frequency of PD is about 1.3 
cases per 100 000 people younger than 45 years of age, 3100 per 100.000 in the 75–85 age 
group, and 4300 per 100.000 in those older than 85 years (de Lau and Breteler, 2006). The 
prevalence of PD is expected to rise dramatically over the next decades due to the aging of the 
population. 
 
3.3.2  Diagnostic criteria 
PD is a clinical diagnosis defined by the gradual occurrence of motor symptoms such as 
rigidity (stiffness), bradykinesia (slowness of movements), resting tremor, and postural and gait 
disturbances, usually with unilateral onset, progressing to bilateral symptoms overtime. Rest 
tremor is the presenting symptom in over 70 percent of cases and postural and gait disturbance 
usually develop later in the disease process. The “pill rolling” rest tremor of idiopathic PD is 
most noticeable when the body part is not engaged in purposeful movement.  
The most widely accepted clinical criteria for the diagnosis of PD are those introduced by the 
UK PDS Brain Bank Diagnostic Criteria (Hughes et al., 1992) and National Institute of 
Neurological Disorders and Stroke (NINDS) diagnostic criteria for Parkinson’s disease (Gelb et 
al., 1999) (text box 7). Typically, the clinical diagnosis is based on the presence of cardinal 
motor symptoms, associated and exclusionary symptoms and response to levodopa. 
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Text box 7: 
 
Criteria for the diagnosis of Parkinson's disease (Gelb et al. 1999) 
 
Group A features: Characteristic of Parkinson disease: 
Resting tremor 
Bradykinesia 
Rigidity 
Asymmetric onset 
 
Group B features: suggestive of alternative diagnoses (features unusual early in the    
    clinical course): 
Prominent postural instability in the first 3 years after symptom onset 
Freezing phenomena in the first 3 years 
Hallucinations unrelated to medications in the first 3 years 
Dementia preceding motor symptoms or in the first year after diagnosis 
Supranuclear gaze palsy (other than restriction of upward gaze) or slowing of vertical 
    saccades 
Severe symptomatic dysautonomia unrelated to medications 
Documentation of a condition known to produce parkinsonism and plausibly connected 
    to the patient’s symptoms (such as suitably located focal brain lesions or neuroleptic use 
    within the past 6 months) 
Criteria for possible diagnosis of Parkinson disease: 
At least 2 of the 4 features in Group A are present; at least 1 of these is tremor or 
bradykinesia and 
either none of the features in group B is present or 
symptoms have been present for less than 3 years and none of the features in group B is 
present and 
either substantial and sustained response to levodopa or a dopamine agonist has been 
documented or  
patient has not had an adequate trial of levodopa or dopamine agonist 
 
Criteria for probable diagnosis of Parkinson disease: 
At least 3 or the 4 features in Group A are present and 
none of the features in Group B is present (note: symptom duration of at least 3 years is 
necessary to meet this requirement) and 
substantial and sustained response to levodopa or a dopamine agonist has been documented 
 
Criteria for definite diagnosis of Parkinson disease: 
All criteria for possible Parkinson disease are met and 
histopathological confirmation of the diagnosis is obtained at autopsy 
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3.3.3 Pathogenesis 
The defining hallmark of PD is the finding of Lewy bodies (LBs) in the substantia nigra (see 
sections 3.2.2 and 3.2.3 for details) including loss or degeneration of dopamine-producing 
neurons. The preferential loss of dopaminergic neurons eventually leads to the typical motor 
syndrome, and pathological and neuroimaging studies suggest that between 50-70% of 
substantia nigra neurons have degenerated at that point (Cheng et al., 2010). This means that 
the neurodegenerative process in PD is at a rather advanced stage when clinical motor 
symptoms are evident. 
 
There are five genes associated with familial PD (causal genes) including alfa-synuclein, 
PARK2, PINK1, DJ-1 (PARK7) and LRRK2. These familial cases are found in only 1-2 % of 
PD cases. In addition, there are associated genes that do not directly cause, but contribute to 
disease susceptibility (Spatola and Wider, 2014). Although causal mechanisms in PD are rare, 
evidence suggest that environmental factors including exposures to pesticides, drug abuse and 
chronic low-level inflammation of the brain due to aging are contributing. Smoking and 
caffeine intake can possibly offer protective properties (de Lau and Breteler, 2006).  
 
Braak et al. developed a staging scheme of LB pathology in PD suggesting that the disease 
spreads from the medulla, enteric nervous system and the olfactory bulb and ascends in a 
predictable manner eventually involving the entire neocortex (Braak et al., 2003) (se section  
3.2.3). It is well established that clinical symptoms, both motor and non-motor, are associated 
with the regional distribution and extent of LB pathology (Braak et al., 2005;McKeith et al., 
2005) 
  
3.3.4  Clinical features 
 
3.3.4.1  Motor symptoms 
The typical motor symptoms are described in section 3.3.2. 
 
3.3.4.2  Non-motor symptoms 
There is a broad spectrum of non-motor symptoms (NMS) in PD (Aarsland et al., 2009c), and 
although they can be present in all stages of disease, they are especially problematic as the 
disease progresses. Most patients with PD also describe NMS symptoms at the time of 
diagnosis.  
There are typically four domains affected including neuropsychiatric symptoms (depression, 
anxiety, psychosis and apathy), autonomic dysfunction (orthostatic hypotension, urinary 
urge/incontinence, constipation/fecal incontinence, sexual dysfunction, etc.), sensory disorders 
(olfactory dysfunction, pain syndromes, abnormal sensation) and sleep problems (insomnia, 
REM sleep Behaviour Disorder (RBD), restless legs syndrome, day time 
sleepiness). Neuropsychiatric and behavioral symptoms are especially common in PD and were 
found in 89% of patients in one study, with depression (58%), apathy (54%), anxiety (49%), 
and visual -hallucinations (44%) emerging as the most common symptoms (Aarsland et al., 
2007a). 
It has also become increasingly recognized that a number of NMS can precede the traditional 
motor symptoms and clinical diagnosis of PD, including constipation, RBD, olfactory 
dysfunction and depression (Postuma et al., 2012), and that PD may start even decades before 
evident motor features. Although the underlying mechanisms of NMS, including pathological 
and biochemical substrates, are poorly understood, there is (according to the Braak staging 
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system, see section 3.2.3) evidence that early spread of Lewy bodies, before involvement of the 
basal ganglia and central nervous system (stages 1-2), may be involved. Conducting large, 
prospective studies in the future assessing potential premotor manifestations can help define the 
non-motor stage of PD. 
NMS can be potential sensitive, clinical biomarkers, leading to an earlier focus on a 
parkinsonian phenotype, but a major challenge is the present low specificity.  
 
3.3.5  Treatment of motor symptoms 
Since the genetic and molecular basis of PD is largely unknown, all therapeutic strategies are at 
present purely symptomatic. 
The mainstay of treatment of motor symptoms in PD has since the 1960's been dopamine 
replacement therapy, with L-Dopa being the gold standard. However, chronic L-Dopa use is 
associated with problematic side-effects including debilitating dyskinesias, and alternative 
medical treatments strategies are being researched (Stayte and Vissel, 2014). These include 
drugs targeting adenosine, serotonin, glutamate and adrenergic receptors and also calcium 
channel blockers, anti-inflammatory drugs and gene therapies.   
For patients experiencing serious side-effects or diminishing effects of dopamine replacement 
therapy, Deep Brain Stimulation (DBS), may be an alternative. In DBS, an electrode is 
surgically implanted in the subthalamic nucleus, globus thalamus or ventral intermediate 
nucleus, providing continuous high frequency electrical stimulation. 
For general treatment of non-motor symptoms in DLB and PDD, see section 3.4. 
 
3.3.6  Cognitive impairment 
 
3.3.6.1  The prevalence and incidence of Parkinson's disease dementia (PDD) 
One common complication in PD is PDD, and the Movement Disorder Society Task Force has 
proposed diagnostic criteria to be used in clinical practice (Dubois et al., 2007a) (Text box 8). 
 
The prevalence of PDD is estimated to be about 5% of all cases of dementia (Aarsland et al., 
2008). Several cross-sectional epidemiological studies have reported that the proportion of PD 
patients who have dementia is approximately 30% (Aarsland et al., 2005;Riedel et al., 2010). 
Cross-sectional studies, however, underestimate the proportion of people with PDD, since 
mortality in PD is influenced by dementia. 
Longitudinal studies have reported a six times higher risk of developing dementia in PD 
compared to people without PD of the same age. The incidence of dementia in cross-sectional 
PD cohorts is 100 per 100.000 patient-years. Consequently, a very high cumulative proportion 
of up to 80% with dementia has been reported among PD patients (Aarsland et al., 2003;Hely 
et al., 2008). A lower incidence has been reported for the first years after diagnosis. In a 
longitudinal study based on an incidence PD-cohort, a dementia incidence of 30 per 100,000 
person-years was reported (Evans et al., 2011) and slightly less than 50% of the cohort had 
developed dementia eight years after the diagnosis. The mean time-period to diagnosis with 
dementia was 6.2 years. 
 
3.3.6.2  Mild cognitive impairment in PD 
The term MCI is now well established as a precursor of dementia in AD, but remains an area of 
research in DLB and PD. 
About 20-25% of PD patients without dementia have mild cognitive impairment (PD-MCI) 
(Aarsland et al., 2010), and even at the time of diagnosis MCI is observed in 15-20%,   
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including non-treated patients (Aarsland et al., 2009a). Recently the Movement Disorders 
Society commissioned a task force which proposed the first clinical consensus criteria for MCI 
in PD (Litvan et al., 2012). The cognitive profile in PD is heterogeneous, and it has recently 
been demonstrated that impairments of visuospatial functions and memory occur in addition to 
the well-known attentional and executive deficits (Bronnick et al., 2011). More importantly, the 
early cognitive changes in PD seem to predict subsequent development of dementia. To date, 
three studies have published longitudinal data on PD-MCI patients (Janvin et al., 
2006;Pedersen et al., 2013;Williams-Gray et al., 2009a). 
 
 
 
 
 
Text box 8 
 
Diagnostic procedures for Parkinson’s Disease Dementia (PDD) - Recommendations 
from the Movement Disorder Society Task Force (Dubois et al., 2007) : 
 
 
-  A diagnosis of Parkinson’s disease (PD) 
-  PD developed prior to the onset of dementia 
-  Decreased global cognitive efficiency - Mini Mental Status Examination (MMSE) below   
   26 (level 1 testing *) 
-  Cognitive deficits severe enough to impact daily living 
-  Impairment in at least two of the following domains and proposed screening tests (level 1): 
 
a)     Attention - Serial 7's of the MMSE, months reversed within 90 seconds 
b)     Executive function – Lexical fluency within 60 seconds (words beginning with S),   
         Clock drawing test 
c)     Visuo-constructive ability -  MMSE pentagons 
d)     Memory impairment  - 3-word recall of the MMSE  
 
Supportive features: 
Apathy, depressed or anxious mood, hallucinations, excessive daytime sleepiness 
 
Diagnosis of probable PDD uncertain: 
Comorbidities including depression delirium or any other abnormality that can cause 
significant cognitive impairment make the diagnosis uncertain. Furthermore, if the time 
interval between motor and cognitive symptoms is uncertain, differentiation between 
dementia with Lewy bodies and PDD can be difficult.   
 
 
*Level 1 equals screening tests as opposed to a more detailed neuropsychological assessment 
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Janvin et al. concluded that non-amnestic MCI was strongly associated with development of 
dementia 4 years later (odds ratio 8.3%), and Pedersen et al. found that a diagnosis of MCI 
versus non-MCI had a relative risk of dementia of 39.2 at 3 years. 
A 5 year follow up of the CamPaIGN study incident cohort (Williams-Gray et al., 2009a), 
including 126 PD patients, IRXQGWKDWDJH\HDUVsemantic fluency and inability to copy an 
intersecting pentagons figure (a task in the Mini Mental Status Examination (MMSE)) were 
significant predictors of dementia risk. Furthermore, a polymorphism in the catechol-O-
methyltransferase (COMT) gene, involved in dopamine metabolism in the pre-frontal cortex, 
was associated with executive dysfunction, but not conversion to dementia. In contrast, patients 
with a genetic variant in the gene containing the microtubule-associated protein tau gene 
(MAPT, H1 haplotype) were strongly associated with an increased dementia risk. One 
interpretation of these findings is that frontal-type deficits are more related to dopaminergic 
lesions (causing executive, but more mild cognitive deficits), whereas the more posterior 
cognitive deficits may be associated with structural pathologies such as temporo-parietal Lewy 
bodies and plaque pathology (associated with semantic memory and visuospatial dysfunction,  
leading to a more rapid decline and dementia). Further studies are needed to test this “dual 
syndrome hypothesis”, and although conclusions cannot be drawn due to a cross-sectional 
design, recent data published from the ICICLE-PD study support these main findings (Nombela 
et al., 2014) (see also section 8.3).     
 
3.3.6.3  Variations in the course of cognitive impairment in PD 
There is a wide variation in the time from onset of PD to dementia. Whereas some patients 
develop dementia within a few years of the diagnosis, others do not show signs of dementia for 
more than 20 years (Aarsland et al., 2007b). Similarly, there is a variation in the rate of 
cognitive decline in PD. The mean rate of cognitive decline in PD is approximately 1 point per 
annum on the MMSE (Aarsland et al., 2004), but for unknown reasons there is large inter- and 
intra-individual variation in the rate of decline. As reported above, a slower rate of decline 
occurs in the early stages of the disease. Typically, in an individual PD patient, a period of no 
or very little decline is followed by an inflexion point after which a much more rapid decline 
occurs, with large inter-individual variation in the time-period to this inflexion point (Aarsland 
et al., 2011a;Johnson and Galvin, 2011). After the onset of PDD, the progression to the 
terminal stage of the illness is less variable, and there is an average of 3 years with increasing 
disability leading to death, whatever the age of onset (Kempster et al., 2010). Identifying 
predictors of time to diagnosis of dementia and of the rate of cognitive decline is thus a key 
clinical and research priority. 
 
3.3.6.4  Clinical risk factors for early cognitive decline in PD 
A shorter time to dementia is associated with older age at diagnosis of PD, non-tremor 
dominant motor subtypes with significant postural instability and gait disturbances (PIGD-
subtype) (Evans et al., 2011;Halliday and McCann, 2010;Williams-Gray et al., 2009a). In 
addition, visual hallucinations, RBD (Boot et al., 2012;Postuma et al., 2009;Williams-Gray et 
al., 2009a) and olfactory dysfunction (Baba et al., 2012) are associated with a shorter time to 
the development of dementia. MCI as a predictor of cognitive decline in PD is reviewed in 
section 3.3.6.2. 
 
3.3.6.5  Genetic contributions to cognitive impairment in PD 
Several studies have reported a familial association between dementia and PD, suggesting that 
genetic factors influence the emergence of cognitive impairment and dementia in PD (Kurz et 
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al., 2006). Despite the progress in identifying genes that cause or increase the risk of PD the 
specific genetic contribution to cognitive impairment in PD is not known (Singleton et al., 
2013). 
 
The H1 and H1p haplotypes of the tau-associated microtubule associated protein tau (MAPT) 
have been found to be significantly associated with PDD with significant odds ratios ranging 
from 1.35 to 3.7 (Goris et al., 2007;Nombela et al., 2014;Seto-Salvia et al., 2011), although not 
consistently. Furthermore, combining genomewide association studies (GWAS) from both AD 
and PD have recently provided insights into genetic pleiotropy (defined as a single gene or 
variant being associated with more than one distinct phenotype, i.e. shared pathobiology). In a 
recent large GWAS involving almost 90.000 subjects, single nucleotide polymorphisms (SNPs) 
were identified and it was concluded that the MAPT  locus was a site of genetic overlap 
associated with both AD and PD (Desikan et al., 2015).  
 
Alfa-synuclein gene mutations and duplications may lead to cognitive impairments and 
dementia (Chartier-Harlin et al., 2004;Polymeropoulos et al., 1997), but remains a rare cause of 
familial PD. 
 
PD patients with GBA mutations have more frequent and severe cognitive impairments when 
compared to sporadic cases of PD (Neumann et al., 2009), and GBA mutation status may be an 
independent risk factor for cognitive impairment in patients with PD (Alcalay et al., 
2012;Sidransky et al., 2009) These findings have recently been confirmed in a prospective 
study of newly diagnosed PD patients where the increased risk of progression to dementia was 
5 times greater in those with a GBA mutation compared to those without (Winder-Rhodes et al., 
2013).  
 
Other typical PD mutations such as LRRK2 and Parkin-mutations do not seem to be associated 
with the development of cognitive impairment (Alcalay et al., 2010). However, 
neuropathologic features of LRRK2-associated PD have been linked to cortical LB formation, 
and it is possible that cognitive impairment in Parkin-carriers only becomes apparent after a 
long disease duration (Alcalay et al., 2014;Poulopoulos et al., 2012).    
Furthermore, mutations of the COMT gene are associated with dopamine related cognitive 
deficits, such as reduced attention, but do not seem be associated with increased risk of 
dementia (Hoogland et al., 2010;Williams-Gray et al., 2009a) (see also section 3.3.6.2).  
 
Finally, inconsistent results have been found regarding the associations between APOE 
genotype and butyrylcholinesterase-K genotypes and the risk of dementia (Kurz et al., 
2009;Lane et al., 2009;Nombela et al., 2014;Williams-Gray et al., 2009b).  
 
3.3.6.6  Biomarkers of cognitive impairment in PD 
For a general introduction to different biomarkers, see section 3.2.8. 
Several different biomarkers, including genetics, EEG, CSF, MRI, SPECT, PET and even 
serum, have been associated with cognitive impairment in PD, and  several longitudinal studies 
have been reported (Bohnen et al., 2011;Chen-Plotkin et al., 2011;Dujardin et al., 
2004;Klassen et al., 2011;Siderowf et al., 2010). However, larger multicenter studies with 
robust and a priori defined cut-off points are necessary before these markers can be 
implemented in clinical practice. 
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3.3.6.6.1  MRI including computer-based analyzes 
MRI has been proposed as a tool for predicting cognitive impairment and dementia in PD, 
similar to its common use in AD. 
Most studies have used structural MRI and shown that atrophy of the temporoparietal lobe, 
entorhinal cortex, hippocampus, prefrontal cortex and posterior cingulate cortex (Burton et al., 
2004;Kenny et al., 2008;Lyoo et al., 2010;Song et al., 2011;Weintraub et al., 2011) are 
associated with PDD. Similar, but less marked, changes have also been identified in PD-MCI 
(Beyer et al., 2007;Song et al., 2011). In a large multicenter study it was recently found that 
PD-MCI was associated with widespread cortical atrophy and both anterior (superior frontal) 
and posterior (temporoparietal) cognitive deficits. There was even some atrophy in the right 
inferior temporal lobe of cognitively normal patients suggesting that cortical thinning can be an 
early biomarker of cognitive decline in non-demented PD (Pereira et al., 2014b). Moreover, an 
AD-like pattern of atrophy (hippocampus, temporoparietal cortex) was recently found to be 
related to cognitive performance in PD, and it was suggested that these changes might be used 
to predict a global cognitive decline in non-demented patients over a 2-year follow-up period 
(Weintraub et al., 2012). 
However, in a recent review of the literature it was concluded that MRI, although there were 
MRI detectable grey (and white) matter atrophy across all stages of PD, could not serve as a 
valid biomarker and that more longitudinal studies are necessary (Duncan et al., 2013). 
Other promising MR techniques are also emerging, including functional MRI, MR perfusion 
imaging with arterial spin labeling and MR spectroscopy, but more confirmatory studies with 
longitudinal design are needed (Duncan et al., 2013). 
 
WML  
White matter hyperintensities or lesions (WML), also termed leukoaraiosis, are small lesions of 
high intensity within periventricular and deep subcortical WM, normally seen on T2-weighted 
MRI or fluid-attenuated inverted recovery (FLAIR) sequences, and are thought to result from 
small vessel disease. Small vessel disease comprises different pathological processes, the most 
common being arteriolosclerosis which affect deep white matter (WM) arterioles. In the 
general population the prevalence of WML ranges from 11-21% in adults aged around 64 to 
94% at age 82 (Garde et al., 2000;Ylikoski et al., 1995) and predict an increased risk of 
cerebrovascular disease, including stroke (hazard ratio 3.3, 95% confidence interval 2.6 - 4.4), 
dementia (1.9, 1.3 -2.8), and death (2.0, 1.6 -2.7) (Debette and Markus, 2010).  
Despite an increased risk of dementia in the general population, the role of WML in cognitive 
impairment and progression to dementia in LBD is unclear and studies have been inconclusive.  
Importantly, methodological problems including heterogeneity of study populations, 
concomitant cerebrovascular burden and different MRI protocols (i.e. visual rating scales 
versus automated protocols) have made comparisons across studies challenging. 
WML comparisons (including periventricular hyperintensities) in AD, vascular dementia, DLB 
and normal aging have shown more extensive lesions in all dementia subtypes (Barber et al., 
1999), and in imaging studies of patients with established PD, WML were seen across all 
stages of disease (Beyer et al., 2006;Burton et al., 2006). In a longitudinal study comparing 
patients with AD, PDD, DLB and normal controls, WML burden at baseline was greater in AD, 
but cognitive decline was similar between groups (Burton et al., 2006). More severe WML load 
in advanced disease (PDD), typically associated with deep WM and periventricular 
involvement,  correlated to cognitive parameters including the MMSE and impairments in 
attention, visuospatial, memory and executive functions (Beyer et al., 2006;Lee et al., 
2010;Santangelo et al., 2010). 
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Of note, in early PD including PD-MCI, no significant WML load differences compared to 
normal controls and no association between WML load and cognitive impairment (attention-
executive functions) were seen (Dalaker et al., 2009).  
Taken together, the role of WML in neurodegeneration is unclear. These findings suggest an 
interaction between the effects of age and WML in PD or merely that cognitive effects of 
comorbid WMLs are more easily detectable in advanced disease (PDD). Underlying 
mechanisms are unknown, but possibly direct damage to neuronal networks or an interaction 
between WMLs and other regional structures are involved. Since WML load seems to increase 
the risk of cognitive impairment only in the general population, one can speculate that the 
effect of WMLs is less important once cognitive deterioration has begun. A more sensitive 
measure of WM integrity is diffusion tensor imaging, see below. 
 
Diffusion tensor imaging   
A special variant of MRI is Diffusion Tensor Imaging (DTI). DTI measures the diffusion of 
water in biological tissue and is a technique where the integrity and orientation of WM and 
WM tracts (tractography) can be visualized and evaluated (Le, 2007). Anisotropy reflects the 
directionality of diffusion (i.e. diffusion along axons and fiber bundles), as opposed to isotropy, 
which implies identical properties in all directions. Fractional anisotropy (FA), a measure of  
how strongly directional the local tract structure is, typically measures high in intact WM tracts 
because water tends to move parallel rather than perpendicular to fiber bundles. A measure of 
diffusivity in the perpendicular plane is the radial diffusivity (DR), and increased DR is 
characteristic of WM damage. Tractography essentially follows the primary eigenvector of 
diffusion from one voxel to the next. 
Still, there has not been a satisfactory solution to alignment of FA images from multiple 
subjects in a way that allows for valid conclusions in the subsequent voxelwise analysis.  
Tract Based Spatial Statistics (TBSS) is a new technique that aims to improve the sensitivity, 
objectivity and interpretability of analysis of multi-subject diffusion imaging studies by 
aligning all mages creating a “mean FA skeleton” which represents the centers of all tracts 
common to the group (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/TBSS).  
 
Over the last few years we have seen a proliferation of DTI studies in a wide range of 
neurodegenerative disorders including AD and Lewy body disease (LBD). When this thesis 
was planned, however, very few studies using DTI in PD, none that had focused on DTI and 
early cognitive impairment in LBD and no studies directly comparing PD and AD had been 
published.  
In a recent meta-analysis focusing on parkinsonian syndromes it was concluded that DTI shows 
promise as a candidate biomarker (including differentiating PD from atypical parkinsonian 
syndromes and detecting early WM changes), but that these preliminary findings need 
confirmation in larger cohorts (Cochrane and Ebmeier, 2013). Furthermore, most studies were 
small and based on a region of interest approach, no studies presented correlations between PD 
severity and cognition and no longitudinal results were presented. Focusing on PD, 4 studies 
found reduced FA in frontal WM compared to normal controls, and preliminary findings  in 
PDD and DLB were somewhat mixed, but primarily with FA reductions in WM in temporo-
occipital and posterior cingular areas. (Cingulum is known as a collection of WM fibers 
projecting from the cingulate gyrus to the entorhinal cortex. The posterior cingulum is typically 
related to cognitive functions, the anterior part probably more to emotion, including apathy and 
depression).  
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More recently, Kamagata et al. found that FA was significantly lower in patients with PDD 
(n=15) than in normal controls (n=15) in both the anterior and posterior cingulate WM fiber 
tracts and similarly in the anterior cingulate for PD (n=15) (Kamagata et al., 2012). MMSE and 
FA values of the anterior cingulate fiber tracts correlated (r= 0.633, p< .05) in patients with 
PDD. Hattori et al. enrolled patients with PD cognitively normal (n = 32), PD-MCI (n = 28), 
PDD (n = 25), DLB (n = 29) and normal controls (n =40) finding reduced FA in several major 
tracts in PD-MCI, PDD, DLB, but not PD cognitively normal. Grey matter and cerebral 
perfusion was also assessed, and results suggested a common disease progression with 
functional alteration (hypoperfusion) followed by structural alterations in which WM alteration 
preceded gray matter atrophy (Hattori et al., 2012).  
Conversely, a study by Meltzer et al. showed that WM integrity was compromised also in PD 
cognitively normal (n=63) and that these alterations increase with disease progression (Melzer 
et al., 2013). Importantly, these microstructural changes were associated with executive 
function, attention and memory. Similar findings have recently been reproduced in two other 
studies (Theilmann et al., 2013;Zheng et al., 2014). 
 
In the first study comparing AD (n=35) and DLB (n=36) using TBSS, it was concluded that 
DLB patients had a specific pattern of reduced FA in parieto-occipital tracts, and that changes 
were more diffuse in AD (Watson et al., 2012). 
There have also been attempts to detect early WM changes using TBSS analysis in 64 
asymptomatic first degree relatives of patients with PD (30 mutation carriers), who carry the 
G2019S mutation in the LRRK2 gene, but with negative result (Thaler et al., 2014).  
 
In conclusion, using DTI subcortical WM tract degeneration is detectable early in LBD and 
may precede changes observed on conventional structural MRI (Duncan et al., 2013). 
 
See further discussion in section 8.4 (paper 2). 
 
3.3.6.6.2 Electroencephalography (EEG) 
Quantitative electroencephalography (QEEG) studies suggest that low-frequency background 
rhythm is associated with cognitive impairment in PD, and that QEEG measures can predict 
future risk of developing dementia (Klassen et al., 2011). 
On the other hand, in a previous study EEG could discriminate between AD and DLB based 
primarily on posterior leads, but patients with PDD exhibited the same abnormalities in less 
than half of the DLB cases (Bonanni et al., 2008), suggesting low specificity in separating the 
different LBDs.  
 
3.3.6.6.3  PET-based imaging 
Reduced glucose metabolism in both frontal and parietal cortex measured by FDG-PET has 
been found to be associated with cognitive decline in PD-MCI (Huang et al., 2008). More 
specifically, hypometabolism in the temporal cortex has been associated with verbal memory, 
frontal cortex with executive dysfunction and parietal cortex with visuospatial dysfunction 
(Jokinen et al., 2010). A recent longitudinal study suggested that early metabolic changes in 
visual association and posterior cingulate cortices could predict incident dementia in PD 
(Bohnen et al., 2011). 
 
For amyloid-based PET, see section 3.2.8.7. 
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3.3.6.6.5 Perfusion SPECT 
Cross-sectional studies using SPECT have reported hypoperfusion in lateral parietal and frontal 
cortices in PD patients without dementia, which correlated with cognitive impairment (Firbank 
et al., 2003). Bilateral hypoperfusion in posterior parietal lobes and in the right occipital lobe 
were seen in PD-MCI, which differed from the pattern seen in non-PD-MCI (Nobili et al., 
2009). Perfusion has also been shown to aid in the prediction of cognitive decline in PD 
(Dujardin et al., 2004).  
 
3.3.6.6.6  Cerebrospinal fluid (CSF) and plasma 
It has been reported that Aȕ42 levels were lower and total-tau and p-tau were higher or normal 
in PDD patients compared to PD patients without dementia and controls (Montine et al., 2010). 
Likewise, a prospective study indicated that lower baseline Aȕ42, but not total-tau and 
phospho-tau (181p), was associated with a more rapid cognitive decline (Siderowf et al., 2010). 
Detailed analyses of several splice variants of Aȕ showed that early PD patients displayed 
significant reductions not only of CSF Aȕ42, but also Aȕ40 and Aȕ38. These reductions were 
associated with memory impairment (i.e. PD-MCI), but not with executive-attentional or 
visuospatial dysfunction (Alves et al., 2010). Similar findings in PDD and DLB suggest that 
amyloid pathology contributes to cognitive impairment in LBD, and that there is an interaction 
and overlap with typical pathology seen in AD (Brunnstrom et al., 2013;Mollenhauer et al., 
2006). 
Of great interest is the association between LBD and alfa-synuclein. Patients with PD and DLB 
have shown lower monomeric CSF alfa-synuclein levels than patients with AD and controls 
(Mollenhauer et al., 2011), but in a recent meta-analysis involving 2728 patients, lower CSF 
alfa-synuclein could only separate DLB from AD. No significant difference was found between 
DLB and PD or other neurodegenerative conditions (Lim et al., 2013). Moreover, correlations 
between cognitive status and lower CSF alfa-synuclein have been reported in DLB (Ballard et 
al., 2010), but at present not in PD. Conversely, alpha-synuclein oligomers or phospho-alfa-
synuclein (129p) in CSF have been reported to be higher in patients with PD compared to 
patients with AD or controls (Tokuda et al., 2010). Of note, in the DATATOP study with up to 
8 years follow-up of more than 300 unmedicated PD patients, CSF alfa-synuclein predicted 
better preservation of cognitive functions (Stewart et al., 2014).  
 
In a recent systematic review it was concluded that neither CSF nor plasma alfa-synuclein was 
a reliable biomarker in diagnosing PD, with CSF alfa-synuclein in the 71-94 % and 25-53 % 
range with regard to sensitivity and specificity respectively (Malek et al., 2014). Conversely, 
meausurements in peripheral solid tissues were more promising and in case of colonic mucosa, 
submandibular salivary glands and skin biopsies showed moderate sensitivity and high 
specificity (80-100%) in detecting alfa-synuclein. Furthermore, epidermal growth factor has 
been shown to predict cognitive decline in PD (Chen-Plotkin et al., 2011). 
 
In conclusion, findings from CSF studies confirms the heterogenous biology involved in PD 
including overlapping features with typical AD pathology. Currently CSF biomarkers cannot be 
used in clinical practice. 
     
Biomarkers in Lewy body dementia are summarized in table 5. 
 
 
 
50 
 
Table 5: Biomarkers in Lewy body dementia 
Modality DLB PDD Comment 
 
SPECT 
Dopamine 
Transporter 
(FP-CIT 
SPECT) 
DLB patients 
without clinically 
detectable 
parkinsonism can be 
identified (Walker et 
al., 2007). 
Pathological scan 
can predict DLB 
(O'Brien et al., 2009) 
 
Significantly 
reduced uptake in 
striatum (nucleus 
caudatus and 
putamen) relative to 
NC and AD  
(never clinically 
indicated) 
Diagnostically 
useful for 
distinguishing 
DLB from AD/NC 
and essential 
tremor and 
neuroleptic 
induced 
parkinsonism from 
DLB, PDD, MSA, 
PSP and CBD. 
Perfusion 
 
Global cortical 
hypoperfusion 
relative to NC. Some 
evidence for reduced 
occipital lobe 
perfusion relative to 
AD (horse shoe sign) 
(Lobotesis et al., 
2001). 
Similar findings for 
DLB and PDD with 
more parieto-
occipital affection 
compared to NC 
(Rossi et al., 2009). 
Perfusion has been 
shown to aid in the 
prediction of 
cognitive decline in 
PD (Dujardin et al., 
2004). 
Occipital 
hypoperfusion is 
indicative of DLB 
or PDD (but  
specificity is low) 
 
MRI 
Atrophy Diffuse pattern of 
global GM atrophy 
compared to NC. 
Generally less GM 
atrophy including 
MTL than AD (Mak 
et al., 2014)  
Detectable GM 
atrophy across all 
stages of PD, but 
less MTL atrophy 
than AD (Duncan et 
al., 2013) 
AD-like pattern of 
atrophy (including 
MTL) can possibly 
predict cognitive 
decline in PD 
(Weintraub et al., 
2012)  
MTL preserved 
supports diagnosis 
of DLB. No MTL 
atrophy or just 
general atrophy is 
not diagnostically 
helpful. 
Diffusion 
Tensor  
Imaging 
DLB patients show a 
specific pattern of 
reduced FA (WM 
damage) in parieto-
occipital tracts with 
more diffuse 
changes in AD 
(Watson et al., 
2012). 
A recent meta-
analysis concludes 
that DTI is a 
promising biomarker 
in PD and PDD 
(evaluation of WM 
integrity).  
(Cochrane and 
Ebmeier, 2013) 
 A possible future 
biomarker in early 
LBD and may 
precede changes 
observed on 
conventional 
structural MRI 
(Duncan et al., 
2013) 
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CSF 
Amyloid 
and tau 
 
Typical AD changes 
(lower Aȕ42 and 
higher total-tau and 
p-tau than NC) are 
also seen in DLB 
(Brunnstrom et al., 
2013) 
Typical AD changes 
(lower Aȕ42 and 
higher total-tau and 
p-tau than NC) are 
also seen in PDD 
(Mollenhauer et al., 
2006). 
Lower Aȕ42 has 
been shown to 
predict PDD 
(Siderowf et al., 
2010) 
 
Similar findings in 
PDD and DLB 
suggest that 
amyloid pathology 
contributes to 
cognitive 
impairment in 
LBD. 
 
Alfa-
synuclein 
 
 
Patients with DLB 
have shown lower 
monomeric CSF 
alfa-synuclein levels 
than patients with 
AD and NC (Lim et 
al., 
2013;Mollenhauer et 
al., 2011) 
Patients with PD and 
DLB have shown 
lower monomeric 
CSF alfa-synuclein 
levels than patients 
with AD and NC 
(Mollenhauer et al., 
2011), and may 
predict preservation 
of cognitive function 
(Stewart et al., 2014)  
Alfa-synuclein is a 
promising 
biomarker for 
LBD, but 
sensitivity and 
specificity is 
currently too low 
to be used in the 
clinical routine. 
 
 
 
 
EEG 
 
 A longitudinal study 
including DLB, AD 
and PDD patients 
with early dementia 
RQWKH
MMSE), concluded 
that EEG could 
discriminate between 
AD and DLB 
(Bonanni et al., 
2008) 
 
Low-frequency 
background rhythm 
is associated with 
cognitive 
impairment in PD, 
and can predict 
future risk of 
dementia (Klassen et 
al., 2011). 
At present more 
confirmatory 
studies are needed 
before EEG can 
serve as a reliable 
biomarker for 
LBD. 
 
Myocard 
scinti- 
graphy 
(MIBG) 
 A recent meta-
analysis involving 
46 studies and 2680 
patients concluded 
that AD, DLB and 
PD could be 
discriminated with a 
high level of 
accuracy (King et 
al., 2011).   
A recent meta-
analysis involving 46 
studies and 2680 
patients concluded 
that AD, DLB and 
PD could be 
discriminated with a 
high level of 
accuracy (King et 
al., 2011).   
A pathological 
scintigraphy is 
listed as a 
supportive feature 
in the 2005 DLB 
consensus criteria. 
Pathology is also 
seen in the elderly 
with comorbid 
heart disease and 
diabetes. 
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PET 
Glucose 
metabolism 
Generalized low 
uptake, but typical 
pattern of occipital 
hypometabolism 
with relative 
preservation of the 
posterior cingulate 
(as opposed to AD) 
(Kemp and Holmes, 
2007) 
Generalized 
hypometabolism, but 
typically more 
occipital 
involvement 
(Jokinen et al., 
2010).  
Early metabolic 
changes in visual 
association and 
posterior cingulate 
cortices could 
predict incident 
dementia in PD 
(Bohnen et al., 
2011). 
 
Supportive 
diagnostic feature 
for DLB.  Could 
distinguish FTD 
with reduced 
dopamine 
transporter uptake 
from LBD. 
Amyloid Amyloid retention 
seems to be less than 
in AD, but overall 
higher than in PDD 
and NC (Donaghy et 
al., 2013. 
 
No difference in 
deposition between 
PDD, PD, and NC 
(Donaghy et al., 
2013. 
At present the 
diagnostic use of 
amyloid PET in 
LBD is not 
established.  
May help identify 
patients for 
treatment with 
anti-amyloid 
agents in the 
future. 
 
 
Genetics 
 
 
 
 
 
Most DLB cases 
occur sporadically, 
but genetic alterations 
overlap with AD and 
PD. GWAS-studies 
have not yet been 
published. 
 
Alfa-synuclein, 
LRRK2, PINK1, 
PARK2 and PARK7 
are causal disease 
genes found in 
familial PD 
(Nuytemans et al., 
2010).   
The specific genetic 
contribution to 
cognitive 
impairment in PDD 
and DLB is not 
known. 
 
DLB = dementia with Lewy bodies. PDD = Parkinson's disease dementia. SPECT = Single 
photon emission computed tomography. FP-CIT SPECT = 123I-ȕ-carbomethoxy-ȕ-(4-
iodophenyl)-N-(3-fluoropropyl) nortropane SPECT. NC = Normal control. AD = Alzheimer’s 
disease. MSA = Multiple system atrophy. CBD = Corticobasal degeneration. PSP = Progressive 
supranuclear palsy. MRI=magnetic resonance imaging. CSF = Cerebrospinal fluid.  EEG = 
Electroencephalography.  PET=positron emission tomography.  GM = grey matter. 
MTL=Medial temporal lobe. LBD=Lewy body disease. MIBG= (123) I-
metaiodobenzylguanidine. FTD=frontotemporal dementia 
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3.4 Treatment/management of DLB and PDD 
 
3.4.1  Introduction 
Focusing on cognitive impairment, treatment is challenging for several reasons. First, there 
exists no curative treatment and thus per definition all interventions are directed against 
alleviating symptoms. Second, symptoms in DLB and PDD are often heterogeneous, involving 
a multitude of transmitter systems and organs and the patients are often frail. Thus, side effects 
are common and symptomatic targeting of one symptom will often affect and worsen others. 
This will present the physician with difficult priorities and tradeoffs in which one problem 
solved may create another. Third, there exist few randomized controlled trials and validated 
guidelines.    
Adequate treatment of concomitant somatic disease should always have first priority as it can 
cause delirium and add to Neuropsychiatric symptoms (see also section 3.3.4.2), and non-
pharmacological interventions are generally the treatment of choice. For details see (Ballard et 
al., 2013). 
 
3.4.2 Cognitive impairment 
A recent Cochrane review concluded that acetylcholinesterase inhibitors are beneficial in PDD 
(Rolinski et al., 2012), but most often with modest effects on cognition, neuropsychiatric 
symptoms and ADL. Similar evidence exists for DLB (McKeith et al., 2000;Mori et al., 2012). 
Despite mixed results (including no effect on motor and cognitive scores, but possible effect on 
global scores), a recent meta-analysis concluded that Memantine may be of benefit in Lewy 
body disorders (Matsunaga et al., 2015).   
 
3.4.3 Motor symptoms 
Dopamine replacement therapy is well established and effective in PD (see section 3.3.5). No 
studies focusing on PDD exist, but some evidence from uncontrolled studies suggests benefit in 
DLB (Ballard et al., 2011b;Mori et al., 2012). However, these medications are typically not as 
effective as in PD and the propensity to exacerbate neuropsychiatric symptoms such as 
hallucinations must be taken into consideration.  
 
3.4.4  Neuropsychiatric symptoms 
Non-pharmacological interventions, including support, cognitive therapy and education to staff 
and caregiver should always be the cornerstone in treating neuropsychiatric symptoms (see also 
section 3.4.7). 
Antipsychotic medication should ideally be avoided given the neuroleptic hypersensitivity 
about 50 % of these patients experience. Visual halluciantions and psychosis can be treated by 
screening and treating co-morbid somatic disease, reducing dopamine-based therapies or 
starting the patient on an acetylcholinesterase inhibitor. In severe cases of psychosis an atypical 
antipsychotic should be considered, the most convincing evidence exist for clozapine (Rongve 
et al., 2012). 
Depression is common in both PDD and DLB but evidence for the efficacy of antidepressants 
is scarce as patients with dementia most often are excluded from trials (Ballard et al., 2013). 
There is, however some evidence that antidepressants in PD is useful (Richard et al., 2012). 
 
3.4.5  Sleep problems 
Educating the patient, caregiver and staff on sleep hygiene is important as sleep disruption is 
common. RBD can be treated with melatonin, clonazepam or low dose quetiapine (Aurora et 
54 
 
al., 2010), and safety for the patient (and bed partner) must be secured for instance by padding 
the bed or floor and removing potential dangerous objects. 
 
3.4.6  Autonomic dysfunction 
Orthostatic hypotension can be alleviated using compression stockings and/or salt tablets or 
reducing antihypertensive or other medication affecting blood pressure. Anticholinergic 
medication should be avoided as they can induce a diversity of side effects including delirium. 
Stool softeners can be used for obstipation, and pain killers such as paracetamole with rather 
few side effects may be tried in first line treatment of pain. 
 
3.4.7  Non-pharmacological treatment 
There exists no systematic evidence for the use of non-pharmacological treatment in LBD, but 
information and regular support, appropriate activities including social interaction and follow-
up of patient and caregiver is important. There is some evidence that coping strategies for 
visual hallucinations (Diederich et al., 2003) and cognitive behavioral therapy for depression 
(Dobkin et al., 2011) in PD are effective. 
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4.0  Alzheimer's disease 
 
 
4.1 Introduction 
 
In 1907 Alois Alzheimer described the case of Auguste Deter, a 51 year old woman who a few 
years earlier presented with rapid deteriorating memory and progressive behavioral symptoms. 
During the course of her illness her husband was eventually unable to care for her at home and 
brought her in 1901 to the Institution for the mentally ill and for epileptics in Frankfurt, 
Germany. There she was examined by Dr. Alzheimer, and after her death in 1906 he performed 
an autopsy and noticed that the patient's cerebral cortex looked atrophied, with widening of the 
sulci. He also found histopathological changes including neurofibrillary deposits and amyloid 
plaques which are now the hallmarks of Alzheimer's disease (AD). The pathological findings 
and the early age of onset made Auguste Deter's condition unique, and she became the first 
patient diagnosed with what was later called AD dementia in recognition of Alzheimer's 
pioneering work. Recently it was discovered that she had a mutation in the gene encoding 
Presenilin 1, a well known cause of early onset AD (Muller et al., 2013). 
AD is typically characterized by early impairment of memory and later by additional affection 
of other cognitive domains and a gradual decline in ADL-functions ultimately leading to death. 
Since dementia is common and will increase (see below), and is a highly debilitating syndrome, 
the overall negative impact on the individual patient and the caregiver, as well as the health-
related costs for society, is already very high  and will increase dramatically. Current AD 
therapies are limited to symptomatic drugs and offer a moderate, but temporary improvement 
or stabilization of cognitive decline in selected patients. The underlying disease, however, is 
not targeted. Due to the expected increase in AD patients, there is an urgent need for 
continuous search for better understanding of the underlying disease mechanisms and for 
curative or disease-modifying treatment. 
 
4.2  Prevalence and incidence of Alzheimer's disease 
 
AD is the most common neurodegenerative disease and accounts for the majority (about 70 %) 
of about 70.000 people in Norway and 35-40 million worldwide that are currently estimated to 
suffer from dementia, a number expected to more than double towards 2050 due to the aging of 
the population (Hjort and Waaler, 2010;Prince et al., 2013). About 60 % of people with 
dementia live in developed countries with middle or low income, and this proportion is 
expected to rise to around 70 % in 2040 (Ferri et al., 2005). However, there are some 
indications that the incidence is decreasing slightly in high income countries, probably partly 
due to better treatment of cardiovascular risk factors and rising education, and thus the increase 
in number of people with dementia might be slightly lower (Langa KM, 2015). 
The prevalence increases exponentially with age, doubling with every 5 years increase above 
the age of 65, rising from 3% among those 65-74 years of age to almost 50% among those 85 
or older (Mayeux and Stern, 2012;Zhu and Sano, 2006). In 2005 it was estimated that the one-
year incidence of dementia worldwide was 4.6 million (one new case every 7 seconds) (Ferri et 
al., 2005).  Similarly, in a study involving more than 2300 people initially free of AD, it was 
found that 95 out of 642 persons further examined, had developed AD during a mean 4 years 
follow-up. Calculated incidence rates were substantial and about 14 times higher among 
participant above 85 years of age compared to those between 65-69 (Hebert et al., 1995).  
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4.3  Diagnostic criteria 
 
In 1984 the National Institute of Neurological and Communicative Disorders and Stroke and 
the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) published 
diagnostic criteria for AD which has been widely used since and still is the current definition 
according to ICD-10 (McKhann et al., 1984). These criteria are accurate with an average 
sensitivity and specificity of 81 % and 70 % respectively (Knopman et al., 2001). As reflected 
in the 1984 criteria, AD has traditionally been considered a pure clinical diagnosis which could 
only be confirmed by autopsy (“dual clinicopathological classification”), but the last decades 
research advances and development of reliable biomarkers in AD have modified this view. AD 
is still considered a clinical diagnosis, but it is now recognized that AD has a long, 
symptomatic pre-dementia phase (and even preclinical, biomarker-positive) and that in vivo 
biomarkers can help in diagnosis even before patients are demented. This has led to a revision 
of the original criteria for dementia due to AD (McKhann et al., 2011) (table 5) and 
incorporation of the term MCI due to AD (Aarsland et al., 2011b;Albert et al., 2011). The new 
criteria include clinical criteria for AD dementia and MCI to be used by all healthcare providers 
without access to relevant biomarkers and criteria encorporating the use of biomarkers for 
research purposes. Although pathologic evaluation for the presence of amyloid-beta ($ȕ) 
plaques and tau protein still is required for a definitive diagnosis, recent diagnostic criteria 
identify biomarkers that can increase sensitivity and specificity in the diagnosis of underlying 
AD. Main AD biomarkers LQFOXGHEUDLQDP\ORLG$ȕUHSUHVHQWHGE\low &6)$ȕDQGDP\ORLG
retention on PET and biomarkers of neuronal degeneration or injury represented by CSF tau 
(total-tau and phoshorylated tau), decreased fluorodeoxyglucose (FDG) uptake on PET in 
temporoparietal cortex and atrophy of the medial, basal and lateral temporal lobe and medial 
parietal lobe on structural magnetic resonance imaging (table 6). At present these biomarkers 
are not recommended in the clinical routine because of their limited access and standardization, 
the current high sensitivity and specificity of the clinical criteria and lack of validation of the 
new criteria.   
Of note, all patients who met criteria for probable AD by the old (1984-) criteria, would meet 
the current criteria for probable AD dementia shown in table 7. 
(See also sections 1.6 and 4.6). 
 
4.4  Pathogenesis 
 
The two core pathological hallmarks of AD are amyloid plaques and neurofibrillary tangles, but  
what causes AD and the exact mechanisms involved are unknown. The pathological changes 
typically begin in the entorhinal cortex and Hippocampus and then proceed to other cortical 
areas, resulting in increasing neuron damage and death (Braak and Braak, 1996). The amyloid 
cascade hypothesis, although challenged and revised, still offers a main framework for the 
understanding of AD progression (Karran et al., 2011). The hypothesis postulates that 
abnormal cleavage of the Amyloid Precursor Protein (APP) (ȕ-secretase [BACE1] pathway) 
leads to abnormal fibrillation and DJJUHJDWLRQRI$ȕLQFRQWUDVWWRWKHQRUPDO non-
amyloidogenic (Į-secretase) pathway in which Aȕ is not formed. After extracellular cleavage 
by the ȕ-secretase, the Ȗ- secretase cleaves within the transmembrane region of APP to generate 
a number of isoforms of 36-43 amino acid residues in length. The two most common isoforms 
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are $ȕ-DQG$ȕ-42, the former being the most common, but the latter most fibrillogenic 
and associated with disease.   
 
 
Table 6: Biomarkers for examination of AD-MCI and AD dementia* 
 
 
  %LRPDUNHUVRI$ȕGHSRVLWLRQ 
- &6)$ȕ 
- PET amyloid imaging 
 
 
  Biomarkers of neuronal injury: 
- Elevated CSF total/phosphorylated tau 
- Hippocampal volume or medial temporal atrophy on magnetic resonance imaging (volume or  
  visual rating) 
- Rate of brain atrophy  
- FDG-PET (including temporoparietal changes) 
- SPECT (similar, but poorer accuracy than FDG-PET)(Herholz, 2011)  
 
 
* McKhann et al., 2011, Albert et al. 2011. AD-MCI = Alzheimer's disease – Mild Cognitive 
Impairment, Aȕ = Amyloid beta, CSF = Cerebrospinal fluid, PET = Positron Emission 
Tomography, FDG = Fluorodeoxyglucose, SPECT = Single Photon Emission Tomography  
 
 
 
Amyloid is thought to be deposited in the extracellular brain tissue either causing AD or 
contributing to toxic effects on the surrounding neurons. The hypothesis also postulates that the 
microtubule-associated protein tau, the main constituent of neurofibrillary tangles, aggregates 
due to toxic effects from amyloid deposits (Ballard et al., 2011a). The protein tau is located 
principally in axons, and  hyperphosphorylation leads to detachment of tau from microtubules, 
degradation of microtubules and consequently neuronal death. 
Since studies of disease modifying treatment targeting amyloid has been unsuccessful have 
been unsuccessful, the original hypothesis has been challenged (Lee et al., 2004). A competing 
hypothesis postulates that amyloid deposits aggregate merely as a consequence of other causal 
events (i.e. neuronal stress) and as such can be seen as a possible side effect and down-stream 
marker (with possible protective properties) in AD pathogenesis.  
In clinical practice and in research settings, measuring proteins related to amyloid and tau 
metabolism is incorporated in the diagnostic criteria (see section 4.6) and remains an important 
diagnostic tool.  
 
It is estimated that around 70 % of the risk of developing AD can be attributed to genetics, but 
causal genes are rare, especially in late onset AD (after 65 years) (Ballard et al., 2011a). Early 
onset AD affects about 1-5 % of all AD cases and is usually linked to familial aggregation and 
autosomal dominant mutations in the genes coding for Presenilin 1, Presenilin 2 and  
APP (Bekris et al., 2010). A number of risk genes have also been identified, most consistently 
associated with late onset AD is ApoE (Bekris et al., 2010) (see section 4.6.1). 
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Table 7: General criteria for dementia and core clinical criteria for  
               probable AD dementia*: 
 
 
1.   General criteria for dementia are fulfilled when there are cognitive or neuropsychiatric    
      symptoms that  
 
      - interfere with the ability to function at work or at usual activities and 
      - represent a decline from previous levels of functioning and performing and 
      - are not explained by delirium or major psychiatric disorder 
      - Cognitive impairment is detected and diagnosed through a combination of (1) history-  
        taking from the patient and a knowledgeable informant and (2) an objective cognitive      
        assessment, either a “bedside” mental status examination or neuropsychological 
        testing. 
      - The cognitive or behavioral impairment involves a minimum of two of the following    
        domains: 
 
        a) Impaired ability to acquire and remember new information 
        b) Impaired reasoning and handling of complex tasks and poor judgment 
        c) Impaired visuospatial abilities 
        d) Impaired language functions (speaking, reading, writing) 
        e) Changes in personality, behavior or comportment 
 
2.   Probable AD dementia is diagnosed when the patient meets criteria for dementia described   
      above and the following characteristics: 
      a) Insidious onset. Symptoms have a gradual onset over months to years 
      b) Clear-cut history of worsening of cognition by report or observation and 
      c) The initial and most prominent cognitive deficits are evident on history and examination   
          in one of the following categories: 
       
          - Amnestic presentation: It is the most common syndromic presentation of AD dementia.  
            The deficits should include impairment in learning and recall of recently learned  
            information. There should also be evidence of cognitive dysfunction in at least one  
            other cognitive domain 
          - Non-amnestic presentations including: 
                  - Language presentation 
                  - Visuospatial presentation 
                  -  Executive dysfunction       
 
3. The diagnosis of probable AD dementia should not be applied when there is evidence of 
substantial concomitant cerebrovascular disease, core features of Dementia with Lewy bodies 
other than dementia itself, prominent features of behavioral variant of frontotemporal 
dementia, prominent features of semantic variant primary progressive aphasia or nonfluent/ 
agrammatic variant primary progressive aphasia or evidence for another concurrent, active 
neurological disease, or a non-neurological medical comorbidity or use of medication that 
could have a substantial effect on cognition. 
 
* McKhann et al., 2011 
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4.5  Clinical features 
 
AD progression can (broadly) be divided in the following stages: pre-dementia (further 
subdivided in an asymptomatic and a prodromal phase), mild, moderate and severe dementia 
stages (end stage). Each stage has typical clinical features, but there is a gradual decline with no 
distinct boundaries between the different stages as the disease progresses. There are also large 
inter-individual differences in the clinical presentation, and neuropsychiatric symptoms such as 
anxiety and depression may be prodromal symptoms of disease (McKhann et al., 2011;Sperling 
et al., 2011). 
 
4.5.1  Cognitive impairment 
Early memory loss is frequently the first clinical sign in AD, often seen years before a definite 
diagnosis of dementia can be made. AD-MCI can be defined as a state of subjective and/or 
informant based cognitive impairment, objective signs of impairment in any domain and 
relatively intact activities of daily living not fulfilling criteria for dementia (Petersen et al., 
2009) (see also section 1.3). AD-MCI is typically characterized by early memory complaints 
(amnestic MCI), and language, executive and visuospatial functions are relatively spared. Non-
amnestic MCI is characterized by a subtle decline in functions not related to memory 
(executive function, language, attention and visuospatial ability), and may be a forerunner to 
other dementias than AD, including DLB (Molano et al., 2010). 
As the disease progresses and cortical involvement increases, memory is typically worsened 
and impairment of other cognitive abilities becomes evident (mild AD dementia, roughly 
MMSE > 20). Symptoms in this phase include confusion and difficulties in orientation, poor 
judgment often leading to bad decisions, loss of initiative and spontaneity, mood and 
personality changes and overall increasing difficulties in maintaining ADL-functions.  
In moderate stage AD (roughly MMSE between 10-20) typical symptoms seen are language, 
reading and writing problems, shortened attention span, difficulties in recognizing friends and 
family members, inability in learning new things, reduced mental flexibility and difficulties in 
handling unexpected events.  
In end stage AD, the patients are generally incapacitated with severe or total loss of verbal 
skills, ability to remember or process information. Patients at this stage are often confused 
about past and present, frequent falls often render patients to the bed and they are in need of 
full time care in nursing homes.   
 
4.5.2  Neuropsychiatric symptoms 
Neuropsychiatric symptoms, also known as Behavioral and Psychiatric Symptoms of Dementia 
(BPSD), are the result of complex brain processes involving multiple transmitter systems. As 
many as 80-97 % of demented patients may have BPSD during the course of the disease, and it 
can exacerbate cognitive and functional impairment (Gauthier et al., 2010) (table 8).    
The spectrum of BPSD includes depression, anxiety, aggression, restlessness, agitation, 
psychosis including delusions and hallucinations, wandering and screaming. (see sections 5.5 
and 8.4), Depression is common in both MCI and AD dementia with prevalence rates as high as 
50 % (Lee and Lyketsos, 2003;Lee et al., 2007) and is described in more detail in section 5.5. 
Of note, the relationship between depression and cognitive impairment is complex. Depression 
has been shown to be a risk factor for dementia (Barnes and Yaffe, 2011), but depression 
occurring temporally close to cognitive impairment and dementia may also represent prodromal 
signs of the dementing process itself or a psychological reaction to being ill. In a diagnostic 
perspective, late life depression (LLD) is often underreported, partly because of the different 
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clinical presentation compared to depression in the young (including more prominent agitation, 
less sadness and more somatic complaints such as gastrointestinal distress, fatigue or insomnia 
in LLD) and lack of consensus criteria for LLD. Furthermore, the diagnostic precision is even 
lower when assessing comorbid depression and cognitive impairment. For further discussion of 
these matters, see section 8.4 (paper 3). 
Taken together, BPSD can be present early in the disease process and even be a risk factor of 
dementia, but typically BPSD are more frequent and severe as the disease progresses. 
 
4.5.3  Somatic symptoms 
As the disease reaches moderate and severe stages, gradually involving the entire cortex, there 
are also considerable somatic complications. These include perceptual-motor problems (trouble 
seeing and moving in three dimensional space, arising from chair, setting the table, etc.), 
reduced appetite and weight loss, seizures, visual impairment, delirium, autonomic dysfunction 
including bowel or urinary incontinence, dizziness, orthostatic hypotension and sleep problems.   
 
 
 
 
Table 8: Types of behavioral and psychological symptoms of dementia (BPSD) * 
 
 
Psychological or psychiatric symptoms 
 
 
Behavioral symptoms 
 
Delusions 
 
Aggression (physical or verbal) 
 
Hallucinations 
 
Agitation (hoarding, pacing, screaming)  
 
Anxiety (worrying, shadowing the caretaker) 
 
Apathy or indifference 
 
Depression or dysphoria 
 
Disinhibition (socially and sexual 
inappropriate behavior) 
 
 
 
Repetitive motor acitivities (wandering, 
rummaging) 
 
 
 
Waking and getting up at night 
 
*Based on modified neuropsychiatric inventory-Q categories 
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4.6  Biomarkers in Alzheimer's disease 
 
At present, only symptomatic treatments for AD exist, and much effort has therefore been made 
to develop drugs which slow or halt the disease process, so far without much success. A major 
challenge is to separate symptomatic effects from true disease-modifying effects, and surrogate 
biomarkers that can objectively measure the characteristic features of AD, and hence act as 
indicators of underlying disease and disease progression, are urgently needed. The existing 
diagnostic tests of AD are mostly based on neuropsychological assessment (see also table 7), 
but it remains inadequate for early detection and differentiation of AD from other types of 
dementia. 
A multitude of different candidate biomarkers of disease progression in AD have therefore 
been investigated, and there have been major advances in developing CSF markers and imaging 
techniques that can diagnose AD (and other dementia subtypes) at the MCI (and even SCI) and 
early dementia stage. The most valid biomarkers have been incorporated in the new AD 
dementia and AD MCI criteria (Albert et al., 2011;McKhann et al., 2011) (table 6). 
At present there are two main categories of biomarkers used in the investigation of AD based 
on the biology that is measured: ELRPDUNHUVRI$ȕaccumulation UHSUHVHQWHGE\ORZ&6)$ȕ
metabolites and amyloid retention on PET and what is believed to be more “downstream” 
markers including elevated CSF tau, decreased fluorodeoxyglucose (FDG) uptake on PET and 
atrophy of the medial temporal lobe (Hippocampus) and parietal cortex on structural MRI.   
Based on these findings, Jack et al. have proposed a hypothetical dynamic model of AD 
progression (adapted in the recent revised diagnostic criteria for AD) that relates disease stage 
to biomarker abnormalities (Jack, Jr. et al., 2010a). In this model, amyloid biomarkers first 
become abnormal, before tau-mediated neuronal injury, brain injury and ultimately memory 
and other cognitive and clinical symptoms.  
In this section, an outline of the most important biomarkers will be reviewed. Basic biomarker 
characteristics are described in section 3.0. 
 
4.6.1  Genetics 
AD is broadly divided in early (before the age of 65) and late onset. Early onset AD is often a 
rare autosomal dominant, familial disease (so-called Mendelian families, i.e. a single-gene 
disease, due to an error or mutation in one of the 25 000 genes in the human genome). The 
known genes that cause mendelian forms of dementia are autosomal dominant with high 
penetrance accounting for 1-5 % of all AD cases, typically presenting in the late 40's or early 
50's, and is caused by mutations in the genes encoding Amyloid Precursor Protein (APP), 
Presenilin1 and Presenilin 2 (Loy et al., 2014;Rongve et al., 2013).  
The APP, Presenilin 1 and Presenilin 2 genes share the same biological pathways, i.e. causing 
LQFUHDVHGSURGXFWLRQRI$ȕ-42 DQGRWKHU$ȕPHWDEROLWHVZKLFKDUH the main constituent of 
amyloid plaques found in the AD brain.  
The more common late onset AD occurs after the age of 65 and is assumed to be a polygenic 
and multifactorial disease of unknown origin. In clinical practice the two major types of AD are 
indistinguishable, but early onset is typically more severe and has a more rapid course. 
Inadequate clearance of amyloid beta is believed to contribute also in late onset AD.  
 
Several potential genes have been linked to an increased risk of AD, i.e. in a genetically 
complex manner, but the only established susceptibility gene in late AD is APOE. Individuals 
with two ApoE İ4 alleles have a more than seven times increased risk of developing AD 
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compared to those with ApoE İ3/İ3 alleles (Corder et al., 1993). The İ2/ İ2 and İ3/ İ4 alleles 
represent intermediate risk for a later AD development. In a recent and large study involving 
more than 17.000 subjects, it was demonstrated that double APOE İ4 alleles increased risk of 
AD 35 times as compared to double ApoE İ3/İ3 alleles, making APOE the strongest 
susceptibility gene to date (Genin et al., 2011).  However, since only 50% of individuals with 
AD carry an APOE İ4 allele, other genetic factors must contribute to risk for disease. After 
APOE, the best-validated gene modulating late-onset AD risk is the sortilin-related receptor 1 
(SORL1) gene (Rogaeva et al., 2007). 
 
Additionally, since 2009 genome-wide association studies (GWAS) have identified several 
genetic variations associated with AD, among them CLU, PICALM 1 and TREM2 (Lambert et 
al., 2013;Rongve et al., 2013) . Only a small portion of these risk genes have been replicated in 
other studies, and these variants contribute only slightly to an increased risk of disease, with 
much lower effect sizes than APOE (odd ratio < 2). In GWAS studies large sample sizes are 
essential, and it is likely that as sample sizes continue to grow, additional risk loci will be 
revealed. Taking advantage of this method, a recent study combined several large GWASs 
involving 300.000 subjects to identify single nucleotide polymorphisms (SNPs) and 
associations between AD, C-reactive protein and plasma lipid levels (specifically triglycerides, 
high- (HDL) and low-density lipoproteins (LDL)). It was demonstrated a polygenetic overlap 
between AD, inflammation and plasma lipids in support of the hypothesis that the latter 
influence AD pathogenesis (Desikan RS et al., 2015). 
 
Taken together, there are only three known genes causing AD, and mutation in the Presenilin 1 
gene is the most common, accounting for about 60 % of cases (Janssen et al., 2003;Raux et al., 
2005). The second most common form of familial AD is mutations or duplication of the gene 
encoding APP which account for about 20-25 % of AD cases (about 15 % of cases caused by 
mutations) (Janssen et al., 2003;Raux et al., 2005;Rovelet-Lecrux et al., 2006). Since mutations 
in Presenilin 2 are rather rare, initial screening for APP and subsequently Presenilin1 is the 
most common approach when examining families at risk. In clinical practice, testing for other 
risk genes, possibly with the exception of APOE, is at present not recommended. 
 
4.6.2  Structural MRI 
See sections 3.2.8.1.and 3.3.6.6.1 for further details. 
The hallmark MRI biomarker for AD is medial temporal lobe atrophy particularly in the 
hippocampus. Atrophy in the hippocampus and entorhinal cortex is associated with  
progression of memory impairment and an increased risk of AD (Apostolova et al., 
2006;Mungas et al., 2005) and the average hippocampal volume reduction is 20 % – 25 % in 
AD and 10 % – 15 % in MCI (Shi et al., 2009). 
MRI is widely used in the examination of potential AD, but the lack of a standardized 
methodology for measurement of hippocampal volumes has limited the incorporation 
of this biomarker into clinical practice. However, scales such as the Scheltens scale (Scheltens 
et al., 1992) are increasingly used and accurate considering age and other confounders are 
taken into account (Pereira et al., 2014a), whereas computer-based approach, which are more 
accurate, are yet not feasible for use in clinical practice. 
 
Diffusion Tensor Imaging (DTI) is presented in more detail in section 2.3.6.6, and is a 
promising biomarker both in LBD and AD. DTI has become a leading method in identification 
of white matter integrity reductions in several brain regions of persons with AD and MCI 
63 
 
compared to normal controls suggesting that these changes occur early in the disease process 
(Medina et al., 2006;Selnes et al., 2013;Stebbins and Murphy, 2009;Zhang et al., 2007). 
Increased mean diffusivity and decreased fractional anisotrophy values have been reported in 
AD and MCI in parietal and temporal areas, including the hippocampal region, but also in 
frontal regions, specifically in cingulum posterior, corpus callosum, fasciculus longitudinalis 
superior and fasciculus uncinatus.  
Moreover, DTI as a marker of tissue microstructure, appears to be a more sensitive marker of 
hippocampal integrity than macrostructural measurements with MR volumetry (Clerx et al., 
2012). At present, DTI is not used in the clinical routine, but reserved for research purposes. 
 
4.6.3  Cerebrospinal fluid (CSF)   
&KDUDFWHULVWLFFKDQJHVLQWKH&6)RI$'SDWLHQWVDUHWKHUHGXFWLRQRI$ȕ-42 and the increase 
in total-tau and phospho-tau. 5HGXFHG&6)$ȕ-42 is one of the first detectable biomarkers in 
AD disease progression and can be observed years or even decades before evident symptoms of 
cognitive decline (Jack, Jr. et al., 2013). CSF Aȕ1-42 levels show high sensitivity (78%-100%) 
in detecting AD dementia, but since the same pattern can be seen in different disorders 
including LBD, vascular and frontotemporal dementia, there is insufficient specificity (47%-
81%) in differentiating AD patients from other dementias (Blennow and Hampel, 
2003;Blennow et al., 2010;Skogseth et al., 2011).  
Elevated total-tau is not specific for AD, but rather a marker of unspecific neuronal damage,  
and hence specificity is insufficient to separate AD, vascular dementia, frontotemporal 
dementia, stroke and traumatic brain injury (Skogseth et al., 2011). However, total-tau can 
separate AD patients from normal controls with high sensitivity (84 %) and specificity (91 %) 
(Blennow, 2004).   
Phospho-tau better reflects pathology in AD (i.e. the phosphorylation state of protein tau in the 
build up of neurofibrillary tangles) with high specificity (92 %) and sensitivity (80 %) in 
separating AD patients from normal controls (Blennow and Hampel, 2003).   
A better accuracy in differentiating between AD and controls can be obtained by combining the 
PDLQ&6)ELRPDUNHUV$ȕ38, $ȕ40, $ȕ42 , total-tau and phosphor-tau) (Duits et al., 
2014;Hampel et al., 2014;Tapiola et al., 2009), but at present it is not recommended using these 
markers alone in differentiating between AD and other subgroups of dementia (Hansson et al., 
2006;Skogseth et al., 2011). 
Furthermore, large longitudinal studies have shown that an AD biomarker profile ORZ$ȕ42, 
high total-tau and phospho-tau) can separate SCI and MCI patients who will progress to 
dementia (with high degree of accuracy for amnestic MCI with up to 95 % sensitivity) from 
normal controls and stable MCI (Hansson et al., 2006;Mattsson et al., 2009;Visser et al., 2009). 
 
4.6.4  PET based imaging 
Using 18F-FDG PET, typical patterns of hypometabolism have been described in AD dementia 
in the hippocampi and medial temporal lobes, posterior cingulate, precuneus and lateral 
temporoparietal cortex, sparing the sensorimotor and visual cortex. Similar, but milder changes 
are seen at the MCI stage. 18F-FDG-PET can discriminate with high sensitivity and specificity 
patients with AD dementia from normal controls, and the most reliable early changes are seen 
in the posterior cingulate cortex and precuneus, areas with high positive and negative predictive 
value also in predicting conversion from MCI to AD dementia (Drzezga et al., 2005;Herholz et 
al., 2002;Kadir et al., 2012;Minoshima et al., 1997;Mosconi et al., 2007). 
Using PET scanning with the 11C-labeled Pittsburg compound B (PiB-PET), a benzothiazole 
derivative of Thioflavin T, allows for the estimation of amyloid levels in the living brain. 
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Amyloid-PET has shown high sensitivity in detecting AD dementia in a series of pathology 
proven studies, and about 50 % of MCI patients have positive scans, especially those with 
multiple cognitive domain affection (Vandenberghe et al., 2013;Wolk et al., 2009).  
Brain amyloid can be detectable decades before onset of dementia (Jack, Jr. et al., 2010b) and 
may be a valuable future biomarker as it allows for the direct measure of the efficacy of anti-
amyloid therapies. 
 
4.6.5 Conclusion 
AD is still a clinical diagnosis, but biomarkers can increase sensitivity and specificity, 
especially if different biomarkers are used in combination.  
In separating AD from normal controls, there is now solid evidence for biomarkers such as 
MRI (typically Hippocampus atrophy), FDG-PET (typically reduced metabolism in 
temporoparietal regions) and amyloid-PET (high retention of ligand in frontal and 
temporoparietal cortices). MRI and FDG-PET measures can also be used to predict transition 
from MCI to AD dementia. Furthermore, there is VROLGHYLGHQFHWKDWORZHU$ȕDQGKLJKHU
phospho-tau in CSF can differentiate between AD and healthy subjects and that pathologic CSF 
can predict a future transition (from SCI/MCI) to AD dementia. In the rather few cases of 
autosomal dominant inherited AD, genetic testing is valid and the investigation of choice. 
Biomarker differences between AD and other dementias, however, are less clear cut and, with 
the exception of Dopamine transporter scan, cannot at present be used at an individual level 
(see also section 3.2.8.). The most common biomarkers currently used in AD are shown in 
table 9. 
 
4.7  Treatment 
 
At present there are only symptomatic therapies available for AD. The standard medical 
treatment for cognitive impairment include acetylcholinesterase inhibitors (Donepezil, 
Rivastigmine and Galamantine) and a partial N -methyl-D-aspartate (NMDA) antagonist 
(Memantine). The acetylcholinesterase inhibitors are licensed for mild to moderate AD (MMSE 
10-26) and have a modest effect on cognition (1.5-2 points on the MMSE over 12 months) 
including some effects on function and global outcome (Birks and Flicker, 2006;Birks et al., 
2009;Loy and Schneider, 2006). Memantine is licensed for moderate to severe AD and has 
significant benefits on cognition, function, global outcome and possibly neuropsychiatric 
symptoms (agitation, aggression) over 6 months (McShane et al., 2006). There is some 
evidence that combination therapy (acetylcholinesterase inhibitor and Memantine) may be of 
benefit (Lopez et al., 2009). 
 
In BPSD, after concomitant somatic disease has been treated or excluded, the first line 
treatment is non-pharmacological interventions including psychosocial/psychological 
counseling and interpersonal and environmental management (Ballard et al., 2013;Gauthier et 
al., 2010). Psychotropic medications, including neuroleptics, antidepressants, anxiolytics and 
anti-epileptic drugs are extensively being used in clinical practice, but most studies  have 
demonstrated no or limited efficacy (Ballard et al., 2013;Gauthier et al., 2010). There is some 
evidence that cognitive training in mild disease is beneficial (Yu et al., 2009) and also other 
non-pharmacological approaches are effective and also other non-pharmacological approaches 
are effective (Testad et al., 2014). 
65 
 
Finding disease-modifying drugs that can slow or reverse the progression of AD are important 
and intensive research efforts are being made. However, at present no drugs has demonstrated 
efficacy in phase three trails (Ballard et al., 2011a;Schneider et al., 2014). 
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Table 9: Biomarkers in Alzheimer's disease 
 
Modality 
 
SCI or MCI 
stages 
 
AD dementia 
 
Comment 
 
 
 
 
Genetics 
 
 
 
Familial genes  
(APP, 
PRESENILIN 
1 and 2) 
 
 
 
 
 
 
 
 
 
  
Early onset AD is 
a rare autosomal 
dominant, familial 
disease caused by 
mutation in APP, 
PRESENILIN 1 
and 2 (1-5 % of 
AD cases) 
 
 
 
Risk genes 
(i.e. APOE) 
  
 
 
Genes linked to an 
increased risk of 
late onset AD, 
which is assumed 
to be a polygenic 
and multifactorial 
disease of 
unknown origin. 
 
 
MRI 
 
 
 
Atrophy 
 
 
The average 
hippocampal 
volume reduction 
is 10 – 15 % in 
MCI compared to 
controls (Shi F. et 
al., 2009) 
The average 
hippocampal volume 
reduction is 20 – 
25 % in AD 
compared to controls 
(Shi F. et al., 2009) 
 
The hallmark MRI 
biomarker for AD 
is medial temporal 
lobe atrophy 
particularly in the 
hippocampus. 
 
 
Diffusion 
Tensor 
Imaging 
Changes in 
parietal and 
temporal areas,  
but also in frontal 
regions (Selnes et 
al., 2013) 
Changes in parietal 
and temporal areas,  
but also in frontal 
regions (Selnes et 
al., 2013) 
Can predict 
conversion from 
MCI to AD 
dementia. At 
present only 
recommended for 
research purposes. 
 
 
CSF 
 
 
 
 
 
 
Amyloid  
 
5HGXFHG$ȕ
can be seen 
decades before 
symptoms of AD 
(Jack CR. et al. 
2013)  
 
High sensitivity 
(78%-100%) in 
detecting AD 
dementia, but 
insufficient 
specificity (47%-
81%) (Blennow K. et 
al., 2003) 
No combination of 
the main AD CSF 
biomarkers are 
recommended in  
differentiating 
between AD and 
other subgroups of 
dementia 
(Skogseth RE et 
al., 2011). 
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CSF 
 
 
 
 
 
 
Tau 
(Phospho-tau, 
total-tau) 
 
An AD biomarker 
profile can 
separate SCI and 
MCI patients who 
will progress to 
dementia with 
high degree of 
accuracy from 
normal controls 
and stable MCI 
(Visser PJ, 2009, 
Matsson N. et al., 
2009). 
Phosphorylated tau 
shows high 
specificity (92 %) 
and sensitivity 
(80 %) in separating 
AD patients from 
normal controls 
(Blennow and 
Hampel, 2003) 
 
  
No combination of 
the main AD CSF 
biomarkers are 
recommended in  
differentiating 
between AD and 
other subgroups of 
dementia 
(Skogseth RE et 
al., 2011). 
 
 
PET 
 
 
 
Glucose 
metabolism 
Similar, but 
milder changes as 
compared to AD 
dementia are seen 
at the MCI stage  
(Kadir et al., 
2012,  
Mosconi et al., 
2007) 
Hypometabolism 
have been described  
in the hippocampi 
and medial temporal 
lobes, posterior 
cingulate, precuneus 
and lateral 
temporoparietal 
cortex (Kadir et al., 
2012, Herholz et al., 
2002) 
High positive and 
negative 
predictive value  
in separating AD 
dementia from 
controls and in 
predicting 
conversion from 
MCI to AD 
dementia (Kadir et 
al., 2012). 
 
 
 
 
 
Amyloid 
About 50 % of 
MCI patients 
have positive 
scans, especially 
those with 
multiple cognitive 
domain affection 
(Wolk et al., 
2009). 
High sensitivity in 
detecting AD 
dementia in a series 
of pathology proven 
studies 
(Vandenberghe et 
al., 2013;Wolk et al., 
2009). 
 
At present the 
diagnostic use of 
amyloid PET in 
LBD is not 
established.  
May help identify 
patients for 
treatment with 
anti-amyloid 
agents in the 
future. 
 
SCI – Subjective Cognitive Impairment, MCI – Mild Cognitive impairment, AD – Alzheimer's 
disease, APP – Amyloid Precursor Protein, MRI – Magnetic Resonance Imaging, $ȕ– 
Amyloid Beta 1-42, PET – Positron Emission Tomography 
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5.0  Depression in the elderly 
 
5.1  Introduction 
 
A feeling of sadness and low mood is something most people will experience during life, but 
symptoms are most often elusive, will usually not effect daily functioning and is thus not 
necessarily considered an illness. In contrast, clinical depression is defined according to core 
criteria including a persistent state of sadness, loss of interest and fatigue and accompanying 
symptoms such as sleep problems, indecisiveness and suicidal thoughts (see section 1.7).  
Depression is common in all age groups, but especially in the very old, and represents a 
considerable burden for the individual and society. The latest global burden of disease study 
from 2010 concluded that depressive disorders were among the leading causes of years lived 
with disability (YLDs), second only to cardiovascular disease (Ferrari et al., 2013). MDD 
contributed not only to suicide, but also to an increased risk of ischemic heart disease. In 2001 
WHO proclaimed that neuropsychiatric disorders accounted for 4 out of the 10 leading causes 
of disability worldwide with depression ranked 4th. It was estimated that depression would 
jump to second place by the year 2020, second only to ischemic heart disease. There is broad 
consensus that depression leads to disability and  reduced quality of life (Papakostas et al., 
2004). 
 
 
 
Table 10: Symptoms related to late life depression12 
 
Hypochondriasis 
More somatic complaints (often related to the gastro-intestinal tract) 
Agitation and irritability 
Less guilt 
Less sexual interest 
Cognitive complaints 
Psychomotoric retardation 
Sleep disturbances 
Less sadness 
Poor concentration 
Fatigue 
Anhedonia and social withdrawal 
Less likely to have a family history of depression 
 
               1 Based on Hegeman et al., 2012, Wilkins et al., 2009, Lavretsky et al. 2002  
            and Ellison et al., 2012. 
              2 As compared to depression in the young 
 
 
 
69 
 
5.2  Late life depression 
 
Late life depression (LLD) is often defined as a major depressive episode in an older adult 
above 65 years of age and encompasses both first lifetime episodes and known depression re-
occurring in older life. LLD is a heterogeneous disorder, and the symptomatology is often 
different compared to depression in the young (see table 10). In  a meta-analysis including 11 
studies and 2000 patients, it was found that older depressed people more often presented with 
hypochondriasis, somatic complaints (most often from the gastrointestinal tract) and agitation 
compared to younger patients (Hegeman et al., 2012). Furthermore, older people demonstrated  
less guilt and sexual interest. Older people  more often present with irritability, anhedonia and 
social withdrawal and somatic and cognitive complaints, sleep disturbances, fatigue, poor 
concentration and psychomotoric retardation are often prominent (Ellison et al., 2012;Hegeman 
et al., 2012;Lavretsky and Kumar, 2002;Wilkins et al., 2009). 
Because the elderly can have numerous distressing ailments, subsyndromal depression (minor 
depression not meeting established criteria for major depression) is more common, and 
symptoms of depression may be overlooked because of the assumption that symptoms are 
merely related to somatic disease or normal age related decline. However, physical discomforts 
or normal aging alone are not likely to be the only cause of depression, but often becomes 
clinically relevant when it coexistent with other stressful life events such as loss of spouce and 
loneliness, impairment of mobility and economic worries. Using age-related symptom scales 
taking into account the often unusual clinical presentation can therefore assist in the diagnosis 
of LLD and is relevant for screening purposes in addition to the established criteria (see 
sections 1.7 and 8.4). 
Although there is evidence that the efficacy in treating LLD is similar to depression in the 
young, LLD seems to have a more chronic course, a worse prognosis and a higher relapse rate 
(Kok et al., 2012;Mitchell and Subramaniam, 2005). Since LLD severely impacts both quality 
as well as length of life (Baldwin et al., 2006;Penninx et al., 1998), it should be taken seriously 
and treated promptly.  
 
5.3  Risk factors, prevalence and incidence of depression 
 
Major depression (MDD) is one of the world's most debilitating and frequent disorders with 12-
month prevalence numbers around 5-6 % and lifetime prevalence around 13 % in the general 
adult population (Barnes and Yaffe, 2011).  
Population studies focusing on unipolar depression have rather consistently shown that women 
are more affected than men regardless of race, socio-economic status and nationality 
(Alexopoulos, 2005;Kuehner, 2003). Other risk factors include a history of depression, genetic 
susceptibility, negative life events including poverty and bereavement, poor health status and 
sleep disturbances (Cole and Dendukuri, 2003;Foland-Ross et al., 2013) .  
 
The diagnostic criteria for major depression are applicable both for LLD and depression in the 
young, but as mentioned the clinical presentation often differs affecting prevalence numbers in 
the two broadly divided groups. In addition, a large body of literature exist on the prevalence of 
LLD, but less is known about incidence rates of depression above the age of 70.  
1-4 % of the elderly population suffers from MDD with incidence rates around 0.15 % 
(Alexopoulos, 2005). Both prevalence (Palsson et al., 2001) and incidence (Teresi et al., 2001) 
rates double after the age of 70-85, and the prevalence is higher in medical settings than in the 
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community. About 10-12 % of patients admitted to hospital and 6-9 % of primary-care patients 
suffered from MDD in addition to symptoms of subthreshold (minor) depression (see below) 
(Alexopoulos, 2005). Among nursing home residents, prevalence number for MDD are in the 
12-14 % range (Alexopoulos, 2005). 
 
When planning for long-term care of depressed patients, longitudinal incidence studies are the 
method of choice. Interestingly, two large cross-sectional studies from Norway, HUNT 2 and 
HUNT 3, involving all adult inhabitants above 45 years in the county of Nord-Trøndelag 
(n=16517) were examined with an 11 year interval from 1995-97 to 2006-08 (Solhaug et al., 
2012). HUNT 2 was considered baseline and HUNT 3 follow-up, and the population was 
subdivided in 5-year age cohorts and interviewed with the Hospital Anxiety and Depression 
scale (HADS-D). Overall, the participation rate was 69 % and 54 % in HUNT 2 and HUNT 3 
respectively. As shown in table 11, the authors concluded that there was an increase in 
depression rates in all cohorts above 76-years at follow-up, with the largest increase in the 
oldest cohort (9.6 % in the 86-90 year group). Additionally, incidence rates increased with age 
with the highest incidence in the oldest. Incidence rates in the 65-69 and 70-74 age groups were 
around 10 % and almost 15 % in the 75-79 age group compared to around 5 % below the age of 
60. The phenomenon that depression seems to increase with age in the oldest age group was 
also shown in another longitudinal study (Heikkinen and Kauppinen, 2004), but can also 
represent cohort effects (the oldest participants in HUNT was born in the early 1920s, during 
the interwar period). Of note, although symptom scale-based studies indicate higher prevalence 
rates of depression with age, epidemiological studies based on formalized diagnostic criteria 
(i.e. DSM and ICD) have shown a decrease in prevalence of major depressive disorder with age 
(Scott et al., 2008). This contrast can be explained by the different clinical presentation of 
depression in old age compared to the younger and that formalized criteria are less sensitive in 
detecting depression in the old (see section 5.2). A similar conclusion was drawn in a recent 
systematic review of incidence of late life depression (Buchtemann et al., 2012).    
 
Minor depression is a subthreshold state not meeting established criteria for major depression, 
and prevalence rates are estimated to 0-18 % depending on the definition of depression and 
population studied (Blazer, 2003;Polyakova et al., 2014) (table 12). Although not fulfilling 
established criteria for major depression, this condition is associated with an increased risk of 
not only major depression, but also suicide and substance abuse (Polyakova et al., 2014). As 
such, minor depression can be regarded as a prodromal state of a later conversion to a more 
serious and debilitating depressive disorder. Furthermore, minor depression is probably more 
prevalent among the elderly in a primary care setting than major depression, and clinically 
relevant symptoms up to 36 % are recorded (Heun et al., 2000;Luppa et al., 2012).  
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                  Table 12: Studies reporting the prevalence of minor depression  
                 without MCI in people 55 years and older 
 
 
Study 
 
 
Design, 
number in 
study 
 
Diagnostic 
criteria 
 
Prevalence of 
minor depression 
Vilalta-Franch et 
al. (2012) 
Community-
based,  
451 
DSM-IV Point prevalence 
16.8 % 
Grabovich et al. 
(2010) 
Primary care, 
745 
DSM-IV Point prevalence 
6.9 % 
 
Park et al. (2010) Community-
based,  
714 
DSM-IV 
research 
criteria 
Point prevalence  
5,5 % 
 
Steffens et al. 
(2009) 
Community-
based, 
851 
DSM-IV 
 
12-months 
prevalence  
13.5 % 
Mossaheb et al. 
(2009) 
Community-
based, 
331 
DSM-IV 
 
Point prevalence  
10.7 % 
 
Mechakra-Tahiri 
et al. (2009) 
Community-
based, 
2670 
DSM-IV 
 
Point prevalence  
9.5 % 
 
Kramer et al. 
2009 
Nursing home 
residents, 
97 
DSM-IV 
 
Point prevalence  
14.4 % 
Han et al. (2008) Medical 
inpatients, 
281 
DSM-IV 
 
Point prevalence  
18.1 % 
 
Preville et al. 
(2008) 
 
Community-
based, 
2798 
DSM-IV 
 
12-months 
prevalence  
5.7 % 
Norton et al. 
(2006) 
Community-
based, 
2877 
DSM-IV 
 
Point prevalence  
14.8 % 
Licht-Strunk et 
al. (2005) 
Primary care, 
5686 
DSM-IV 
 
Point prevalence  
10.2 %  
Heun et al. 
(2000) 
Community-
based,  
287 
DSM-III 
 
Point prevalence 
0 %, Life time 
prevalence 23 % 
                            
                  MCI: Mild Cognitive Impairment, DSM: Diagnostic and Statistical  
Manual of Mental Disorders 
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Cognitive impairment is a common symptom in LLD. Similarly, behavioral and psychological 
symptoms of dementia are common, and depression is especially prevalent among these 
symptoms (Lee and Lyketsos, 2003) (see also section 5.5). Prevalence rates differ according to 
the population and also by the definition of depression, but in MCI 20 % of patients have been 
found to have major depression and 17-27 % minor depression (Gabryelewicz et al., 
2004;Kumar et al., 2006). In a recent study examining the prevalence of depression among 
SCI, MCI and demented patients referred to a memory or outpatients clinic, it was found that 
37 % were depressed according to the Cornell score of depression in dementia (Knapskog et 
al., 2014). Depression in dementia is associated with negative outcomes such as earlier  
admission to nursing homes, higher morbidity and mortality rates, reduced quality of life and 
difficulties in performing ADL's (Dorenlot et al., 2005;Starkstein et al., 2005). 
 
 
 
Table 11: Prevalence of depression with age (Solhaug et al., 2012) 
 
 
Years at baseline 
 
 
Age at follow-up 
 
Depression baseline 
(HUNT 2) 
 
Depression follow-up 
(HUNT 3) 
 
45 - 49 
 
 
56 – 60 
 
9.7 % 
 
10.1 % 
 
50 -  54 
 
 
61 – 65 
 
11.1 % 
 
9.4 % 
 
55 - 59 
 
 
66 - 70 
 
12.1 % 
 
9.5 % 
 
60 - 64 
 
 
71 - 75 
 
11.9 % 
 
12.3 % 
 
65 - 69 
 
 
76 - 80 
 
11.6 % 
 
15.0 % 
 
70 - 74 
 
 
81 - 85  
 
11.9 % 
 
15.7 % 
 
74 - 79 
 
 
86 - 90 
 
11.3 % 
 
20.9 % 
 
HUNT: The Nord-Trøndelag Health Survey (Helseundersøkelsen i Nord-Trøndelag) 
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5.4 Biomarkers of depression in the elderly 
 
At present MDD remains a clinical diagnosis defined according to operationalized criteria (see 
section 1.7). However, over the last decades  a large body of evidence has accumulated and 
points to a diversity of contributing factors and pathways including the effects of pro-
inflammatory cytokines, oxidative stress, serotonergic dysfunction, endocrine and genetic 
factors and metabolic dysregulation (Felger and Lotrich, 2013;Lopresti et al., 2014;Schmidt et 
al., 2011;Schneider and Prvulovic, 2013).  
 
The roles of noradrenaline, dopamine and serotonin (5HT) have long been the basis for 
pharmacological intervention and are pivotal in the understanding of pathogenic mechanisms in 
depression (Baldessarini, 1975;Schildkraut, 1965). The serotonin hypothesis postulates lower 
levels of 5HT both in plasma and in the brain involving 5HT at multiple levels including 
abnormal serotonin transporter binding, abnormalities in the metabolism of the precursor 
tryptophan and effects at receptor and cell level. Similarly, the catecholamine hypothesis 
suggests that lower concentrations of noradrenaline and dopamine at different levels facilitate 
depression. There is also evidence that anxiety and depression share pathophysiology, the most 
consistent common abnormality has been found to be hyperactivity within the amygdala, and 
that also the transmitter GABA is involved in common pathways (Martin et al., 2009;Mohler, 
2012). Since underlying mechanisms are unclear, what ultimately strengthens the role of 
serotonin and other transmitters in the neurobiology of depression is the effect of serotonin 
reuptake inhibitors (SSRIs) and other antidepressants (Kok et al., 2012).   
 
There are no known causal genes in depression, but major depression is moderately inheritable 
and several known polymorphisms, mostly related to monoaminergic (i.e. noradrenaline, 
dopamine and serotonin) transmission, are known to increase the risk (Levinson, 2006). Among 
targets for genetic research include the serotonin transporter promoter region (5-HTTLPR), 
genes related to neurotoxicity (including effects involving the hypothalamic-pituitary (HPA-) 
axis) and neuroprotection (including brain-derived neurotrophic factor, BDNF). In the largest 
GWAS to date including 9240 subjects with MDD and 9519 controls, no significant 
associations to single-nucleotide polymorphisms (SNPs) were found due to low sample size 
(Ripke et al., 2013)  The high prevalence of MDD suggests that power issues are critical in the 
detection of genetic effects typical for complex traits. The role of personality (e.g., personality 
traits like neuroticism, extraversion, openness to experience and conscientiousness), which is 
also known to be important in the etiology of depression, complicates these matters further 
(Klein et al., 2011). 
 
Vascular depression has been suggested as a subtype of depression affecting people in late life. 
The vascular depression hypothesis originated from the findings that patients with late life 
depression (LLD) had higher WML load compared to early onset depression andthat high 
WML load was associated with neuropsychological deficits and poor treatment outcomes 
(Sneed and Culang-Reinlieb, 2011). Of, note, there seems to be a bidirectional relationship 
between cardiovascular disease and LLD, i.e. cardiovascular risk factors (represented by the 
surrogate marker WML) (see also section 3.3.6.6.1) is associated with depression, but also 
conversely, depression is associated with hypertension, diabetes, stroke etc. (Gothe et al., 
2012). The role of WML in the etiology of depression is, however, poorly understood, but 
potential mechanisms include inflammation (and possibly increased oxidative stress and higher 
levels of pro-inflammatory cytokines such as IL-6 and tumor necrosis factor), HPA-axis 
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hyperactivity, atherosclerosis and reduced brain perfusion, typically in subcortical areas (Gothe 
et al., 2012). 
  
In addition, there have been considerable efforts to find neuroanatomical markers of depression 
by means of imaging techniques. There seems to be consensus that the orbitofrontal cortex, 
anterior cingulate and Hippocampus are central structures often implicated in depression 
(Benjamin and Steffens, 2011;Enache et al., 2011;Gothe et al., 2012) (see also section 5.5).    
 
In conclusion, the clinical syndrome of depression is probably multicausal, and there is a clear 
need for development of biomarkers to make more accurate diagnosis, finding more reliable 
tools for evaluation of treatment and to better understand disease mechanisms. The 
heterogeneous nature of depressive symptoms is a major challenge in this regard, and there is 
probably no single biomarker, but more likely a panel of biomarkers that can contribute to a 
better understanding of the neurobiology involved.      
 
5.5  Depression and cognitive impairment  
 
The understanding of the neurobiology of depression in cognitive disorders is limited, but a 
number of proposed mechanisms appear to be similar in both depression and neurodegenerative 
disease, including LBD and AD (Benjamin and Steffens, 2011;Enache et al., 2011;Gothe et al., 
2012).  
 
Neuropsychological dysfunctions are often present in MDD and have been shown to contribute 
independently to poor functional outcome. But it has been less clear whether cognitive deficits 
in recurrent MDD are independent or a consequence of mood state. In a recent meta-analysis 
psychomotor speed, attention, visual learning and memory and executive functioning were 
significantly impaired in first-episode MDD compared to NC (Lee et al., 2012).  It was further 
concluded that attention and executive deficits were not associated with clinical variables of 
illness severity, in contrast to deficits in psychomotor speed and memory, suggesting that the 
former may function as important trait-markers. 
 
Importantly, studies have shown a high prevalence of depression in both MCI (Panza et al., 
2010) and dementia cohorts (Lyketsos and Olin, 2002), and it seems to be more common  in 
LBD (Fritze et al., 2011) and vascular dementia (Castilla-Puentes and Habeych, 2010) than 
AD. Depression is the most common comorbidity in AD and dementia in general and 
prevalence numbers are in the 30-50 % range including both minor and major depressive states 
(Lee and Lyketsos, 2003). Similarly the prevalence of post-stroke depression has ranged from 
30-50 %, typically peaking 3-6 months after the stroke (Robinson, 2003). Depression in AD 
present slightly different from in non-demented elderly, and diagnostic criteria for comorbid 
depression and AD dementia have been proposed (Olin et al., 2002). Loss of interest and 
dysphoria are the most common symptoms of depression in AD, but the severity of signs and 
symptoms may be less than in non-demented. Other criteria including apetite, pessimism, 
worthlessness and low self-esteem vary considerably depending on the study sample. 
 
In meta-analyses there is evidence that mid-life and late life depression increases (doubles) the 
risk for a later development of dementia, with an estimated 10-15 % of AD cases potentially 
attributed to depression (Byers and Yaffe, 2011;Ownby et al., 2006). A 25 % reduction in 
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depression prevalence could potentially result in 800.000 fewer AD cases worldwide. 
Furthermore, there is also evidence that LLD not only increases the risk but represents a 
prodrome of dementia (Byers and Yaffe, 2011), but studies are conflicting. Depression has also 
been shown to increase conversion to AD in subjects with MCI (Enache et al., 2011), but 
whether concomitant depressive symptoms in MCI and dementia accelerate neurodegeneration 
is unclear. Importantly, patients with PD have been found to have higher odds ratios for a prior 
history of depression preceding the onset of PD compared to control subjects (Leentjens et al., 
2003;Nilsson et al., 2001), but the role of depression in the underlying pathology of PD is 
uncertain. Depression is also reported as a supportive feature in DLB (McKeith et al., 2005), 
but as in PD, little is known about the predictive properties of depression and underlying 
mechanisms.   
 
Overall, there seems to be a bidirectional relationship between MDD and several common 
neurological disorders including PD, AD, cerebrovascular disease (stroke), multiple sclerosis 
and epilepsy. This does not imply that the one causes the other or vice versa, but that common 
mechanisms are operant in both cases and facilitate each other. These mechanisms are at 
present poorly understood. Of note, depressive disorders in neurological disorders often present 
with atypical signs and symptoms and can fail to meet established criteria.  
 
Among the most studied neuroanatomical structures involved in depression is the 
Hippocampus, and evidence strongly support an association between MDD and reduced 
Hippocampal volume (Benjamin and Steffens, 2011;McKinnon et al., 2009). Hippocampus is 
also central in neurocognitive disorders and may be a common link. 
 
The vascular depression hypothesis states an association between depression and WMLs as 
well as cerebrovascular risk factors (Sneed and Culang-Reinlieb, 2011). WMLs are believed to 
be caused by small vessel disease affecting subcortical brain perfusion. More important than 
WML load (count and size of lesions), is seemingly the localization, and the past decade has 
revealed a correlation between LLD and WMLs in mainly frontal subcortical regions 
(Greenwald et al., 1998;MacFall et al., 2001;O'Brien et al., 2006;Videbech et al., 2004). 
WMLs have also been associated with an increased risk of cognitive impairment and dementia 
(Debette and Markus, 2010). Interestingly, the LADIS study evaluated the longitudinal 
influence of depressive symptoms on cognition in independent older people (n=639), 
accounting for the severity of WMLs. Depression was shown to be a predictor of cognitive 
impairment (MCI and dementia) at follow-up, independent of the effect of the severity of 
WMLs and medial temporal lobe atrophy (Verdelho et al., 2013)  Thus, the role of WMLs in 
depression and cognitive impairment is not fully understood, but evidence suggest that 
cerebrovascular factors may initiate, but not necessarily be the driving force as 
neurodegeneration accelerates (See also sections 3.3.6.6.1 and 8.4). 
 
Neural deficits in frontal regions have also been shown for depressed patients with other 
imaging techniques including DTI (Sexton et al., 2009) and functional MRI (fMRI) (Ebmeier 
et al., 2006). Other areas are also implicated, and in a recent study it was found that depressive 
symptoms in AD patients were associated with cortical thinning in temporal and parietal 
regions (Lebedeva et al., 2014). It was also suggested that protein pathology (total-tau) in these 
areas may contribute to the development of depressive symptoms. Overall however, the 
association between CSF, depression and degree of AD-related pathology is unclear (Enache et 
al., 2011). Of note, in mild AD and LBD, depression was associated with cortical thinning in 
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prefrontal and temporal areas and antidepressant use was associated with parahippocampal 
thinning (Lebedev et al., 2014). The latter is in contrast to the finding that treatment with 
antidepressants can induce hippocampal cell proliferation and neurogenesis (Pilar-Cuellar et al., 
2013), and could explain the low efficacy of antidepressants in cognitively impaired elderly. 
Finally, studies have shown that a previous history of depression or coexistent depression and 
AD, increased the likelihood of an autopsy-proven diagnosis of AD (Rapp et al., 2006;Rapp et 
al., 2008). Similar findings have been shown using amyloid-PET (Butters et al., 2008). 
Interestingly, in a recent clinical-pathologic cohort study, 1764 older persons without cognitive  
impairment at baseline were followed for almost 8 years until autopsy (Wilson et al., 2014). 
Evaluation included assessment of depressive symptoms, and in 582 cases neuropathological 
H[DPLQDWLRQWRTXDQWLI\ȕ-amyloid plaques, tau tangle density, neocortical LBs, hippocampal 
sclerosis and cerebral infarcts were performed. Both MCI and dementia were associated with 
higher depressive scores, but only comorbid depression and dementia with a more rapid 
cognitive decline. Furthermore, there were no associations between depressive scores and 
biomarkers of neurodegeneration. An interpretation of these findings is that depression 
accelerates cognitive impairment, but traditional biomarkers of dementia are unrelated, 
suggesting alternative etiologies.   
 
To conclude, the neural mechanisms underlying both dementia and depressive disorders and 
the interaction between the two are complex. Clarification is important in order to improve 
future assessment and diagnosis, early intervention and treatment. 
LLD is often accompanied by cognitive impairment, making diagnosis and treatment 
challenging. The etiology of LLD is not known, but probably involves fronto-subcortical 
neuronal networks, cerebrovascular factors and inflammation. The low efficacy of 
antidepressants in demented patients, necessitates more targeted interventions.  
Cognitive impairment can be secondary to depression, but depression can also be a prodrome 
and risk factor of dementia. In general, there seems to be a bidirectional relationship between 
depression and neurological disorders including stroke, epilepsy, PD and AD. This 
interdependence means that depression imposes an increased risk of a later development of 
several common neurodegenerative disorders, but also vice versa. 
The determination of the temporal relationship between depression and cognitive impairment is 
important, but not always possible in a clinical setting. If depression pre-dates cognitive 
impairment ,although cognitive deficits improve, but do not completely resolve after remission 
of LLD, depression is the likely primary diagnosis (Alexopoulos, 2005). Conversely, cognitive 
impairment is the most likely diagnosis if it pre-dates depression and persists after successful 
treatment of depression.  
 
5.6  Treatment 
 
Both major and minor depression need to be treated as the latter also increases the risk of major 
depression, substance abuse and suicide (Polyakova et al., 2014). 
In all cases a thorough medical examination including blood tests and subsequent treatment of 
primary somatic causes of depression is essential before any specific measures are introduced.  
The main treatment options for depression are social interventions including physical activity, 
psychotherapy, antidepressant medication and Electroconvulsive Treatment (ECT). The 
indication and efficacy of treatment of LLD and depression in the young is basically similar 
(Kok et al., 2012;Mitchell and Subramaniam, 2005), but there is evidence of widespread 
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undertreatment of LLD probably because of doubts about the efficacy and fear of adverse 
effects. Medical treatment should never be the only intervention, but be combined with 
psychological modalities. 
Of note, probably the most serious risk of LLD is mortality. Depressed older people can die 
either from worsening of an accompanying medical illness or by suidide. The risk of suicide 
among elderly is high in most countries and especially high in older men (Mitty and Flores, 
2008).  Health care professionals and others therefore need to raise their awareness to the signs 
and symptoms of depression in the elderly as the consequences of ignorance can be high.     
 
Psychotherapy has proven effective in the treatment of LLD, and in a meta-analysis no 
differences were seen between individual or group format or between cognitive behavioral 
therapy (CBT) and other types of interventions (Cuijpers et al., 2006). The evidence for 
psychotherapy in demented patients with depression is weak, but some studies indicate effects 
in patients with mild cognitive impairment (Kurz et al., 2012;Wilkins et al., 2009).  
Physical activity can alleviate depressive symptoms in elderly depressed, but may not be 
appropriate for all groups, including the cognitively impaired and the severely somatic ill 
(Arean and Niu, 2014). In addition, further research need to be conducted on the long-term 
effects of physical exercise. 
 
Of note, most studies on antidepressants have been conducted in younger populations, but 
response rates in LLD seem comparable in elderly with or without comorbid medical illnesses 
(Gill and Hatcher, 2000;Kok et al., 2012). Before selecting an antidepressant it is particularly 
important to avoid worsening of medical conditions due to adverse events and/or dangerous 
interactions. Thus, the tricyclic antidepressant should best be avoided in the oldest (newer class 
antidepressants, including SSRIs, are in any case first choice). The evidence supporting 
antidepressants in the demented is in general weak (Banerjee et al., 2011;Gill and Hatcher, 
2000;Nelson and Devanand, 2011). 
 
In cases of severe, psychotic, or refractory depression, ECT is warranted. Most studies have 
been performed on elderly without cognitive impairment, but there is evidence that ECT is 
equally effective and well tolerated in depressed patients with MCI or dementia (Hausner et al., 
2011).      
 
Of note, depression is often a recurrent disorder. It is therefore essential that patients are 
followed up by health care professionals also in the vulnerable period succeeding the initial 
successful treatment of the acute episode. Systematic evidence for the optimal post-depression 
management is sparse. 
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6.0  Aims of the study 
 
 
The overall objective of this thesis was to investigate early, clinical features of dementia and to 
find potential biomarkers that could help explain underlying disease mechanisms. Our main 
focus has been on Lewy body disease since little is known about the early features of disease in 
this patient group. 
 
Specific objectives of this thesis include: 
 
            In patients with mild dementia (paper 1): 
1) to retrospectively explore presenting and early, clinical symptoms of DLB.  
 
In early, non-demented PD patients (paper 2): 
2) use DTI to test the hypothesis that there is decreased WM integrity compared to NC. 
3) use DTI to test the hypothesis that WM integrity is differentially reduced in PD and 
early AD.  
4) test the hypothesis that DTI changes are specifically associated with cognitive 
performance. 
 
In SCI and MCI patients (paper 3): 
5) test the hypothesis that depressive symptoms correlate with AD type changes in CSF. 
6) test the hypothesis that depressive symptoms correlate with AD type changes in 
structural imaging including hippocampus volume, cortical thickness, WML and DTI. 
7) test the hypothesis that depressive symptoms correlate with AD type changes in FDG-
PET. 
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7.0  Methods 
 
 
7.1  Design 
 
Both the Dementia study in Western Norway (DemVest) and the MCI-study at Akershus 
University Hospital (AHUS) are longitudinal cohort-studies, using a variety of biomarkers and 
diagnostic techniques. The projects include patients with early, pre-dementia (SCI and MCI) 
states (AHUS) and early dementia (DemVest). Participants are recruited from the referrals to 
clinical routine service in university-based hospitals. 
In all papers of this thesis, a cross-sectional design has been used, although the longitudinal 
design of the overall project is relevant for diagnostic and strengthens diagnostic accuracy. In 
addition, in paper 1 we used a retrospective technique asking caregivers if certain symptoms 
had ever occurred between onset of disease and the time of assessment (text box 9).  
 
7.2  The subjects 
 
7.2.1  DemVest study 
In the first paper, patients referred between 2005-2007 to 5 outpatient clinics of geriatric 
psychiatry and geriatric medicine in Rogaland and Hordaland counties were screened for a first 
time diagnosis of mild dementia according to the Diagnostic and Statistical Manual for Mental 
Disorders (DSM-IV, 4th edition). The neurology clinics in the area were asked to refer such 
patients to the study. From 2007 only early DLB and PDD patients were recruited. In paper 1 
only patients with a diagnosis of DLB (n=61) and AD dementia (n=109) were included. All 
patients underwent a clinical examination including standardized clinical rating scales (see 
section 7.3). “Mild dementia” was defined as a MMSE score > 19 or Clinical Dementia Rating 
(CDR) = 1. Patients with acute delirium or confusion, terminal illness, a recently diagnosed 
major somatic illness, previous bipolar disorder or a psychotic disorder were excluded. Patients 
were recruited for brain donation, and results for the first 36 cases coming to autopsy have 
shown that all patients with a clinical diagnosis of probable DLB had limbic and/or cortical 
Lewy bodies. 
 
7.2.2  MCI-study Ahus 
In the second and third paper, patients with SCI, MCI and recently diagnosed PD were 
recruited from referrals to a university-hospital based memory clinic and neurology outpatient 
clinic. These are the only memory and neurology clinics in the area, and general practitioners 
have for a long time been encouraged to refer people with early memory problems.  
Inclusion criteria for both groups were age 40-79, and for patients included from the memory 
clinic impaired cognition (SCI or MCI) for at least 6 months. Exclusion criteria for both groups 
were impaired activities of daily living (i.e. dementia), a previous diagnosis of a (major) 
psychiatric disorder, cancer, drug abuse, solvent exposure, anoxic brain damage or other severe 
physical disease which could influence cognition. Subjects underwent standardized clinical 
examination, blood tests, MRI including DTI, FDG-PET and lumbar puncture with CSF 
extraction. All PD patients had pathological Dopamine transporter scans ([123I]FP-CIT 
SPECT). The total number of inclusions is 22 SCI, 56 MCI, 18 PD and 19 NC. 
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Text box 9 
 
Eliciting presenting and early symptoms of dementia with Lewy bodies and Alzheimer's 
disease dementia according to the DemVest study protocol (paper 1)* : 
 
Presenting Symptoms 
Caregivers were interviewed by a trained research clinician 
regarding the presenting symptoms of dementia using a scripted 
list of symptoms (more than one answer was possible):  
 
-  Reduced memory  
-  Problem solving difficulties  
-  Depression  
-  Visual hallucinations 
-  Gait problems  
-  Tremor, stiffness  
-  Tendency to fall 
-  Language problems 
-  “Other” 
 
Symptoms during course of disease 
Caregivers were also asked whether symptoms had ever occurred between onset and time of 
assessment: 
 
-  Tremor or stiffness  
-  Gait problems/problems with balance or falling 
-  Visual hallucinations  
-  Delirium or fluctuations of consciousness. 
 
 
*The answers were further explored with detailed questioning by the clinician and recorded   
as present or absent. The final diagnosis was not known at the time of administering this    
questionnaire. 
 
 
 
 
In the second paper all 18 PD patients with available data were included. As a comparison 
group, 18 subjects with MCI and pathological CSF (low AB42and/or high p-tau) (i.e. AD-MCI 
according to research critera (Dubois et al., 2007b)), were individually matched for age, gender 
and level of education to the PD patients and included. In addition, 19 non.demented control 
subjects were recruited from spouses or relatives of the patients with AD-MCI on the basis of a 
clinical interview by a neurologist and neuropsychological tests administered by a trained 
neuropsychologist. Cognitive normality was ensured by T-scores  40 on tests of memory, 
executive functioning and visuospatial ability (see section 7.4.5 below). 
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In the third paper we included all available patients with SCI (n=22) and MCI (n=38) and used 
the Geriatric Depression Scale (see section 7.3.2 below) to divide the cohort into those with and 
without depressive symptoms. 
 
7.3 Diagnostic procedures and clinical assessment 
 
7.3.1 DemVest-study 
All included patients had a thorough somatic examination including a battery of blood tests. 
The diagnosis of dementia was made according to the Diagnostic and Statistical Manual for 
Mental Disorders 4th edition (DSM-4) based on interview with patient and caregiver in addition 
to the clinical and biomarker evaluation program. The diagnosis for AD dementia was made 
according to The National Institute of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria 
(McKhann, et al., 1984). DLB was diagnosed according to the revised consensus criteria 
(McKeith, et al., 2005) based on a number of clinical rating scales focusing on the core DLB 
features. PDD was diagnosed according to the recommendations from the Movement Disorder 
Society Task Force (Emre, et al., 2007) (text box 8). The clinician completed the Clinician 
Dementia Rating scale (CDR), range 0 – 3, 0 meaning no cognitive impairment, 0.5 mild 
cognitive impairment or very mild dementia, 1 mild dementia, 2 moderately severe dementia 
and 3 severe dementia (Morris, 1997). ADL were assessed using the Rapid Disability Rating 
Scale-2 (Linn & Linn, 1982). The clinical diagnosis was made by two of the researchers taking 
into account all available information and the diagnosis was revised annually. Study nurses 
administered a neuropsychological test battery including the Mini Mental Status Examination 
(MMSE) (Folstein et al., 1975) and met regularly to ensure consensus and harmonisation of the 
conduct of the study program.  
7.3.2 MCI-study Ahus  
All included patients underwent a thorough somatic examination including a battery of blood 
tests. All patients with PD (Paper 1) were examined by a neurologist with training in movement 
disorders and met the criteria of probable PD (3 of 4 features: asymmetric onset, bradykinesia, 
rigidity and resting tremor) (Gelb et al., 1999) (text box 7). To further support the PD diagnosis, 
all participants had a pathological single photon emission computer tomography using an 
ioflupane (123I) biomarker (DaTSCAN). Standardized rating scales of motor function (Unified 
Parkinson’s Disease Rating Scale (UPDRS) motor subscale) (Fahn and Elton, 1987) and Hoehn 
and Yahr staging were performed by trained research physicians (Hoehn and Yahr, 1967).  
 
The Stepwise comparative status analysis (STEP) combines psychiatric and neurologic status 
examination to identify common dementia symptoms by which regional brain symptom 
profiles can be determined (Wallin et al., 1996). Furthermore, the Clinical Dementia Rating 
Scale (CDR) is a six item questionnaire (including memory, orientation, judgment and 
problem-solving, community affairs, home and hobbies and personal care) and was used to 
exclude people with dementia (Berg, 1988).  
Cognitive staging (paper 2 and 3) in SCI and MCI was performed according to the Global 
Deterioration Scale (GDS) (Auer and Reisberg, 1997) after a clinical interview of patient and a 
relative and the use of the following screening tests: MMSE (Folstein et al., 1975), STEP 
parameters 13-20 (memory, abstract thinking, visuospatial ability, language, sensory aphasia, 
visual agnosia and apraxia) (Wallin et al., 1996), I-Flex (fluency, interference and numeral-
letter items) (Royall et al., 1992) and Cognistat (memory, including cued recall, and executive 
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functions) (Kiernan et al., 1987). Cognitively normal patients were classified as GDS 1. 
Patients reporting subjective cognitive impairment in addition to scoring above published 
cutoff on all screening tests (including 28 or higher on MMSE), were classified as GDS 2 
(Subjective Cognitive Impairment, SCI), whereas patients scoring below cutoff were classified 
as GDS 3 (MCI). Patients who scored GDS>3, CDR >0.5 or > 1 in sum of  STEP variables 13-
20 were classified as demented and excluded as previously described (Nordlund et al., 2005). 
 
In paper 3 (and 2) we used the 15-item Geriatric Depression Scale (Sheikh JI and Yesavage JA., 
1986; Brown, L. M. and J. A. Schinka, 2005) with 5/6 as cutoff for the evaluation of depressive 
symptoms. The questions are on a yes/no basis and is a valid and reliable measure of 
depression both in the elderly) and in populations with MCI (Marc LG et al., 2008) (Debruyne 
et al., 2009). Of the 15 items, 10 indicate the presence of depression when answered positively, 
while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. 
Scores of 0-4 are considered normal; 5-8 indicate mild depression; 9-11 indicate moderate 
depression and 12-15 indicate severe depression. 
 
7.4  Biomarkers for the Ahus cohort (papers 2 and 3) 
 
7.4.1 Cerebrospinal fluid 
CSF extraction by lumbar puncture in the L3/L4 or L4/L5 intervertebral space was performed 
and analyzed according to protocol at a standardized time and as previously described (Fjell et 
al., 2008). CSF p-tau was considered pathological if Ӌ80 ng/L, Aß42 if ӊ550 ng/L and t-tau if  
> 450 ng/L (age 50–69) or 500 ng/L (age Ӌ70) (Sjogren et al., 2001). 
 
7.4.2 FluroDeoxyGlucose – Positron Emission Tomography (FDG-PET) 
18F-FDG PET/CT imaging was performed with a Siemens Biograph 16 PET/CT scanner. 
Subjects fasted for at least 4 hours prior to imaging (water only), and plasma glucose had to be 
8 mmol/L for FDG to be injected. After 10 minutes rest with eyes closed, subjects had an 
intravenous bolus of 200 +/-10 MBq 18F-FDG injected and rested for 45-60 minutes before 
scanning. For each subject, FDG-PET frames were registered to the corresponding intensity-
normalized MRI volume. PET activity was averaged within each ROI defined on the MRI and 
normalized to activity within the brainstem. 
 
7.4.3 Dopamine Transporter Scan 
Dopamine transporter imaging was performed by intravenous injection of 185 MBq [123I] FP-
CIT (supplied by GE Healthcare), and SPECT images were acquired 3 h after injection. Images 
were acquired with 2-headed gamma camera (Infinia Hawkeye 4) in a procedure that lasted 
approximately 30 min. 10-30 minutes before 123I-FP-CIT administration, we gave every 
patient a thyroid-blocking preparation (200 mg i.v. sodium perchlorate) to stop local uptake of 
the ligand. The raw image data were reconstructed on a VISION workstation (Sopha 
medical/GE) using FBP (Filtered back projection) reconstruction, Butterworth filter, order 6, 
cut off 0.30 and no attenuation correction. Reconstructed images were initially analyzed 
visually by a nuclear medicine physician. In addition, volume-of-interest based semi-
quantification of regional DAT striatal binding was undertaken calculating the Total Striatal 
Binding Potential Index (BP) and the Asymmetry Index (AI) using Dr. Durval Costa's method 
(reference area for BP %: DQGIRU$,! %). The relationship between the uptake in 
striatum compared to the occipital cortex (ratio 1) and the relationship between the uptake in 
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putamen and nucleus caudatus (ratio 2) was calculated using the Dr. Freiberg Bispebjerg 
Hospital method (rHIHUHQFHDUHDIRUUDWLRDQGIRUUDWLR8). (European Association 
of Nuclear Medicine (EANM) procedure guidelines for Brain neurotransmission SPECT 
using 123I -labelled dopamine transporter ligands. www.eanm.org) (Booij et al., 1999).  
 
7.4.4 Magnetic resonance imaging  
MRI scans were obtained using a Siemens Espree 1.5 T system. For structural imaging (cortical 
thickness and volumetry) a T1-weighted (3D) magnetization prepared rapid gradient echo 
(MPRAGE) sequence was used. The protocol also included 2D axial fluid-attenuated inversion 
recovery (FLAIR) images. 
For post-processing of imaging data (cortical reconstruction and volumetric segmentation) 
Freesurfer version 4.5.0 was used. This labels cortical sulci and gyri, and thickness values are 
calculated in the ROIs. 
The Oxford Centre for Functional MRI of the Brain (FMRIB) Software Library (FSL) version 
4.1 was used for standard registration calculations and DTI analyzes. Tract-Based Spatial 
Statistics (TBSS) was used for voxel-wise statistical analysis of the DTI variables (FA, DR). 
WM ROIs based on the Freesurfer WM parcellations were extracted for FA and DR. 
The processing stream includes segmentation of the subcortical WM and deep gray matter 
volumetric structures and parcellation of the cortical surface.  
 
7.4.5  Neuropsychological assessment 
All neuropsychological tests were performed by a neuropsychologist within three months of 
baseline examination and consisted of a battery of tests covering all 5 cognitive domains 
(memory, attention, executive, language, and visuospatial domains). The following tests were 
applied in paper 2: 
 
Trail making test (TMT) 
TMT measures visual scanning, processing speed, mental flexibility and executive functions 
(Spreen and Strauss, 1998). The TMT consist of two parts, but only TMT-B was used. In TMT-
B the examinee is required to connect number and letters (1-A-2-B-3-C, etc.) on a piece of 
paper, and the time is recorded.  
 
Controlled Oral Word Association Test – FAS (COWAT-FAS) 
The COWAT-FAS is a measure of letter fluency (Reitan and Wolfson, 1985), and the 
participants are given one minute to say out loud as many words as possible within one minute 
starting with the letters “F”, “A” and finally “S”. The total number of words is recorded. 
 
Rey Complex Figure Test (RCFT)  
The RCFT consists of a copy trail, followed by a recall trial after 3 and 30 minutes (Meyers and 
Meyers, 1995). Only the copy trail was executed, which is a measure of visuospatial ability. 
 
Rey Auditory Verbal Learning Test (RAVLT) 
RAVLT is a measure of learning and episodic memory (Schmidt M, 1996). 15 different words 
are read to the examinee five times, and the number of correctly repeated words is recorded and 
summoned in a total score. Scores for both short (immediate) and delayed (30 minutes) recall 
are recorded.   
 
Color-Word Interference Test (CWIT)    
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The CWIT from Delis-Kaplan Executive Function System (D-KEFS) measures selective 
attention and ability to inhibit a dominant and automatic verbal response (Delis et al., 2001). 
The CWIT includes four subtests: 1) Color naming, 2) Word reading, 3) Inhibition (i.e. 
determining colours of the ink of inconsistently coloured names) and 4) Inhibition/switching 
(i.e. switching between naming colours of the ink of inconsistently coloured names and reading 
words).    
 
7.5  Statistics 
 
SPSS/PASW statistics versions 18 and 20 were used for all analyzes and p = 0.05 was 
considered statistically significant. Significance at trend-level was defined as 0.05< p< 0.10. 
For the comparisons of demographic and clinical data, Chi-square test, independent sample T-
test and Mann-Whitney U-test were used as appropriate. Kolmogorov-Smirnov test for 
normality was used to assess if variables were normally distributed. Demographic and clinical 
characteristics of patients were described as means and standard deviations (SD) or frequencies 
and percentages.  
In paper 2 we used one-way analysis of variance (ANOVA) to compare the pre-dementia PD 
group to AD-MCI and HC. The DTI WM ROI variables were normally distributed (after the 
effects of age and sex had been corrected by regression analysis), and hence one-way ANOVA 
(with a priori planned contrast AD vs. NC and PD vs. NC including polynomial linear trends) 
was used to compare the three groups. The Pearson's correlation method (for normally 
distributed data) was used to compare neurocognitive test data in three domains with DTI 
variables in a priori selected brain regions. The effects of sex and age on the DTI parameters 
were corrected by linear regression before correlations were determined. 
In paper 3 Hippocampus volume, cortical thickness, DTI and FDG-PET variables were 
adjusted for age and sex by a linear regression model before a multivariate analysis of variance 
(MANOVA) was performed for simultaneous comparison with cognitive impairment (SCI or 
MCI) as factors in the model together with depressed/non-depressed (independent variables). 
Post-hoc comparisons were done by ANOVA. Analyses stratified by CSF were defined as 
secondary and were performed by including CSF (pathological or not) in addition to cognitive 
classification (SCI or MCI) as factors into the MANOVA model together with depressed/non-
depressed (independent variables) and interaction between the two. Bonferroni adjustment for 
multiple tests was applied for primary analyses only. 
 
7.6  Ethical considerations 
 
In Norway the first committees for research ethics were established in 1977 (Lahlum and 
Ruyter, 2012). The precipitating cause was the 1975 revised World Medical Association’s 
declaration of Helsinki that stated that “any experiment involving human beings (...) must be 
submitted to an especially appointed, independent committee for review, comment and 
guidance”. Further laws and regulations were implemented in 2006 (Research Ethics Act) and 
2009 (Health Research Act). In all studies were people are involved there is a balance between 
disadvantages for the individual participant and the benefits for future patients and society.  
The DemVest-study and the MCI-study were approved in advance by the Data Inspectorate of 
Norway and the Regional Committee for Medical and Health Research Ethics (REK number 
DemVest 2010/0633, REK numbers MCI-project Ahus 2011/99 (PD) and 2013/150 ). All 
patients and healthy control subjects received detailed oral and written information and written 
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approval was obtained before inclusion. All participants could withdraw from the study at any 
time without explanation. Patient’s ability to make informed decisions on their own behalf were 
assumed and secured by involvement of caregivers. Having mild dementia was assumed not to 
significantly affect that ability.  
The projects did not raise any major ethical concerns, but some of the procedures were both 
time-consuming and strenuous for the participants. The neuropsychological evaluation often 
lasted half a day, and imaging, including MRI and PET, was obtained at neighboring hospitals 
which increased travelling distances. In addition, all patients were encouraged to perform a 
lumbar puncture and CSF extraction. This is not part of the clinical routine, but often preferable 
given the diagnostic sensitivity and specificity especially in AD-MCI cases. All patients were 
given detailed information about potential risks and complications in advance (which in general 
are regarded as minor), including post puncture headache, back pain and localized bleeding 
(Wright et al., 2012).      
Of note, all study-specific procedures were free of charge and travelling expenses (and to a 
certain extent work-related costs) were refunded. 
Many of the participants expressed gratitude and a sense of security that they could reach 
project assistants at convenience and that they benefitted from the regularly and thoroughly 
conducted examination. Other health issues not directly related to the project were diagnosed 
and dealt with at the appropriate health care level.  
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8.0 Discussion 
 
8.1 Main findings 
 
The main goal of this thesis has been to explore the earliest clinical and biological changes in 
LBD and AD with a special emphasis on LBD. More specifically, investigate presenting 
clinical features in early DLB, WM changes associated with cognition in early non-demented 
PD and find potential neurobiological substrates for depressive symptoms in patients with SCI 
and MCI. In articles 1 and 2, more established knowledge regarding AD has been used to 
contrast findings in LBD. 
Summarizing our main observations, we found that DLB patients most often present with 
memory problems and visual hallucinations, that WM changes can be seen early and are 
associated with cognitive impairment in PD and that minor depression in SCI and MCI patients 
attending a memory clinic are associated with cognitive impairment and may be the earliest 
features of neurodegenerative disease.  
 
8.2 Paper 1 
 
At the time of publishing this paper, very few studies had focused on pre-dementia DLB. 
  
We found that the most common presenting symptoms in DLB were memory impairment (57 
% of cases) and visual hallucinations (VH) (44 %). In contrast 99 % of AD patients presented 
with memory problems and almost none with VH (3%). It is well established that memory 
impairment is an early and central feature in AD. Conversely, memory impairment is less 
common and less pronounced in the early stages of DLB relative to impaired visuospatial and 
executive skills (Ferman et al., 2013;Yoshizawa et al., 2013).  
 
In a pivotal study, the first prospective study of the pre-dementia stage of DLB, Molano et al. 
followed 8 MCI patients until death with subsequent autopsy-proven LBD (Molano et al., 
2010). 7 patients developed DLB prior to death, one patient remained mildly cognitively 
impaired. All 8 patients also had parkinsonian symptoms, 7 had RBD and 6 had experienced 
VH and fluctuating cognition. A main finding was that REM sleep behavior disorder (RBD 
preceded cognitive symptom onset by a median of 10 years (2–47 years) and a MCI diagnosis 
by a median of 12 years (3–48 years). The cognitive domains most frequently affected were 
attention, visuo-construction and executive ability, but also memory problems were recorded.  
Conversely, memory was the most common presenting symptom in our study, although other 
domains were not specifically researched (other than problem solving ability as a substitute for 
executive functioning). The sensitivity of caregivers retrospectively detecting memory 
impairment (and other domains) is subject to recall bias and is probably variable (Noe et al., 
2004), but suggested to be good reporting early cognitive deficits (Naismith et al., 2011). 
Furthermore, reported impairment of memory does not necessarily reflect an isolated single-
domain amnestic deficit. Other domains, especially attention which is commonly affected in 
LBD, are also likely to affect memory thus raising the question of reduced specificity and over-
reporting of memory impairment.  Furthermore, memory does not only have to be linked to 
medial temporal lobe pathology (as typical seen in AD), but may also be secondary to 
executive dysfunction.  The observed high prevalence of early memory impairment in the 
present cohort, regardless of underlying pathology, is nevertheless an interesting finding and 
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relevant for clinicians, who should consider DLB as a differential diagnosis also when memory 
impairment is an early complaint.   
 
44 % of DLB patients presented with VH, a core symptom in the clinical consensus criteria 
(McKeith et al., 2005). It is likely that such a symptom would be more accurately reported than 
cognitive impairment because of the peculiar nature of its presentation. On the other hand, VH 
may be under-reported by the patients due to feelings of shame and guilt. 
In another pivotal study, Tiraboschi et al. wanted to determine the best clinical predictors 
(among VH, extrapyramidal signs (EPS) and visuospatial impairment) of a later autopsy-
proven diagnosis in 23 DLB and 95 AD cases (Tiraboschi et al., 2006). It was retrospectively 
found that DLB was best predicted by VH (seen only in 22 % of all DLB cases, positive 
predictive value 83 %).  In contrast, although not a core feature, visuospatial impairment was 
the best negative predictor of DLB at autopsy (negative predictive value 90 %). In conclusion, 
a recent history of VH was the most specific clinical sign of DLB (99 % specificity) and 
visuospatial impairment the most sensitive (74 %). Of note, only 26 % of DLB patients had a 
history of EPS and only 13 % had both EPS and VH. These findings are in accord with our 
finding that VHs are common and early features of DLB. Similarly, 25-30 % of the patients in 
our study reported that EPS (tremor, stiffness and gait problems) was the presenting symptom, 
suggesting that VH precede motor symptoms. Informant-based assessment tools such as the 
Neuropsychiatric Inventory (NPI) can be useful both for screening for VH and assessing their 
severity and frequency (Cummings et al., 1994). 
 
The biological substrate of VH is not established, but there is an association between Lewy 
body deposition in the temporal lobe and VH (Harding et al., 2002). Furthermore, evidence 
suggest an association between VH and deficits in cortical acetylcholine (Ballard et al., 2000), 
and VH may therefore respond well to acetyl cholinesterase inhibitors (McKeith et al., 2004). 
There is mounting evidence to suggest that VH in Lewy body disease can occur after lesions in 
all parts of the visual pathway, from the retina to the occipital cortex, and both increased and 
decreased metabolic activity have been documented (Archibald et al., 2009;Boecker et al., 
2007;Perneczky et al., 2008). In a recent study,  DLB patients and normal controls were 
presented with simple visual stimuli during functional MRI (fMRI) with subsequent arterial 
spin labelling. It was concluded that higher (V5), but not lower (V1, V2, V3), visual areas, 
particularly in occipito-parietal regions, appear abnormal in DLB (Taylor et al., 2012). 
Similarly, in another recent study using resting state FMRI, there were no differences in 
connectivity in the primary visual cortex (V1) between DLB, AD and normal controls (Kenny 
et al., 2012). These findings suggest that the underlying brain changes associated with VH are 
complex and involving higher order visual pathways.  
FMRI has also been used to explain impaired visual processing in PD patients with VH 
suggesting that these patients are creating their own false images (Meppelink et al., 2009). 
Clinically, the patients with VH often have more profound visuo-perceptual dysfunction 
compared to those without hallucinations (Mosimann et al., 2004), and also deficits in attention 
have been reported (Collerton et al., 2005). 
Finally, there is mounting evidence that DTI can reveal WM damage in DLB, and that  
common predilections sites include the visual pathways (Kantarci et al., 2012b;Watson et al., 
2012), but at present no DTI study has focused on early Lewy body disease and potential 
associations to VH. 
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Depression can precede AD dementia and PD by several years, i.e. be a prodromal symptom, 
and is also known to be a risk factor in development of cognitive impairment and dementia 
(See also sections 5.0 and 8.4). Conversely, the prevalence and role of depression in pre-
dementia DLB is not known, but recently a history of depression was shown to be more 
common in DLB than in normal controls (Boot et al., 2013).  
In this study depression was reported as the third most common presenting symptom (in 34 % 
of DLB cases), and similar prevalence rates were seen in AD (38 %). However, the method of 
eliciting depressive symptoms has weaknesses, and a diagnosis of depression according to 
ICD-10 cannot be made. Although answers were explored by detailed questioning by the 
clinician (see text box 9), all depressive symptoms were collected retrospectively, making 
validation according to established criteria difficult. Furthermore, included patients were mildly 
demented, and although caregivers added valuable information, depression in itself will often 
induce secondary cognitive impairment in the patient, adding to the symptoms of dementia, 
including memory loss. However, depression is a known prodrome in AD and it is reasonable 
to conclude that (minor) depressive symptoms probably are present also in the early stages of 
DLB. Of note, as discussed in more detail later, depressive symptoms may also represent 
psychological reactions to the experience of the earliest signs of neurodegeneration. It is thus 
not surprising that the different dementia subtypes share depression as an early reaction to 
disease. The neurobiology of depression in DLB needs further investigation, and one method is 
to evaluate depressive symptoms and biomarkers in SCI/MCI cohorts followed longitudinally 
(see also discussion of paper 3 in section 8.4).  
 
After publication of this paper, a few other studies have focused on early symptoms in DLB.  
In a retrospective study of prodromal symptoms it was concluded that patients with DLB 
(n=34) exhibited higher prevalence rates of RBD, olfactory dysfunction, constipation and 
increased salivation at onset compared to AD (n=32) and normal controlsd (n=30) (Chiba et al., 
2012).  
Toledo et al. examined biomarker correlates of 22 autopsies (from the Alzheimer's Disease 
Neuroimaging Initiative (ADNI)) including clinical data, imaging, neuropsychological profiles 
and CSF. It was found that VHs were a strong predictor of coincident DLB (100% specificity) 
and a more severe dysexecutive profile suggested coincident DLB (80 % sensitivity and 83 % 
specificity) (Toledo et al., 2013).  
Finally, in the second prospective study of pre-dementia DLB, Ferman et al. followed 337 
patients with MCI until a clinical diagnosis of DLB (n=49) or AD (n=162). Autopsy-
confirmation of the clinical diagnosis was available in a subgroup. Non-amnestic MCI 
progressed more often to probable DLB and amnestic MCI more often to probable AD, and 88 
% of DLB cases included attention and/or visuospatial deficits at baseline (Ferman et al., 
2013).   
To conclude, recent studies confirm our findings that the pre-dementia phase of DLB has 
multiple clinical starting points and that VH and MCI are common prodromes of the full DLB 
syndrome.   
 
Of note, our findings suggest that a top-down clinical progression rather than the bottom-up 
pathological progression as suggested by Braak et al. for PD may be a more common pattern in 
DLB. Despite differences in the relative timing of clinical features and neuropathology between 
PD and DLB,  there has recently been an initiative to redefine diagnostic criteria for PD, 
proposing to omit the “1-year rule” and incorporate DLB as a PD subtype (see section 3.2.3 and 
further discussion in section 8.3 (paper 2)). 
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8.3  Paper 2 
 
At the time of planning this thesis, few studies had focused on white matter (WM) integrity in 
Lewy body disease (LBD), and very few had focused on WM using diffusion tensor imaging 
(DTI). Furthermore, no DTI studies of early, non-demented PD including comparisons to AD 
and associations to neuropsychological tests had been published. In AD, some promising 
results regarding DTI and early WM affection suggested that DTI could be a potential sensitive 
biomarker (Selnes et al., 2013). Whether this was the case also in early LBD was uncertain. We 
therefore included newly diagnosed PD patients without dementia and compared them to pre-
dementia AD and normal controls. 
  
Main findings of this paper include WM affection in temporal, parietal and occipital cortices in 
early PD without dementia as compared to controls. Some of these WM changes also related to 
neuropsychological testing. Furthermore, differences between pre-dementia PD and AD could 
be detected using whole-brain analysis. The exact neurobiology of early cognitive impairment 
in PD is not known, but these findings offer some insight into pathological mechanisms.  
 
DTI is a rather new MRI technique that basically measures the movement of protons when 
biological tissue is introduced to a magnetic field (gradient). In most of its applications this 
movement of protons is most sensitive to the general mobility of water molecules depending on 
factors in the tissue including temperature, viscosity and larger molecules. This movement of 
water molecules will be hindered by biological/microstructural barriers such as cell 
membranes, myelin and cell organelles. See section 3.3.6.6.1 for more details.  
This brings forth an important and debatable question: what exactly is measured by DTI and 
can we use it as a biomarker of neurodegenerative disease?  
DTI has proven useful in examining tissue where diffusivity is anisotrophic (i.e. directionally 
unequal), and there is increasing evidence that DTI can function as a surrogate marker for 
various pathological processes including WM integrity (Jones et al., 2013). There is to some 
extent a correlation between WML and DTI parameters (Zhan et al., 2009), and DTI is also 
probably a more sensitive method of evaluating WM integrity than conventional MRI (Assaf 
and Pasternak, 2008;Cochrane and Ebmeier, 2013;Duncan et al., 2013). Thus, in the present 
study we regard DTI as surrogate marker of WM affection. 
However, despite the increasing use of DTI as a biomarker also in neurodegenerative disease it 
is important to be aware of the limitations and that such an “indirect” method of measuring 
potential pathophysiologic processes must be interpreted with caution.  
Furthermore, different artifacts including physiologic noise and image artifacts as well as the 
analytic method used, may complicate diffusion parameters and their biologic 
interpretation (Basser and Jones, 2002). 
 
Our findings suggest that DTI can differentiate between WM affection in early PD versus 
controls, but also potentially between early PD and AD. The latter is questionable since we did 
not find any significant changes in the pre-planned region of interest (ROI) based analyzes, but 
only in some regions using a whole brain approach.  Also, a main limitation in the present 
study is the rather low sample size and these findings must therefore be interpreted with 
caution. 
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Our main finding, that WM affection is present in early PD, however, is consistent with recent 
and larger studies (see also section 3.3.6.6.1 for a more detailed review). Indeed, we and others 
have found correlations between DTI abnormalities and cognitive measures including 
microstructural changes associated with executive function, attention and memory (Melzer et 
al., 2013;Theilmann et al., 2013;Zheng et al., 2014) supporting the role of DTI as a promising 
biomarker of early cognitive decline in PD.  
 
The past decade’s advances in neuropathology, genetics and epidemiology have increased our 
understanding of the neurobiology involved in LBD. Clinical risk factors for cognitive decline 
in PD include older age of onset of PD, non-tremor dominant motor subtypes, REM sleep 
behavior disorder, olfactory dysfunction and visual hallucinations (see section 3.3.6.4), and a 
variety of biomarkers are associated with cognitive decline in LBD (see sections 3.2.8 and 
3.3.6.6). Cortical Lewy bodies and Lewy neurites are the most significant correlates of 
dementia in PD (Irwin et al., 2012), but in contrast to AD there are no reliable biomarkers at 
present in use in the clinical routine to predict cognitive impairment and dementia in LBD. A 
multimodal biomarker approach combining different techniques is probably needed to 
disentangle the different aspects of cognitive decline in PD including visual hallucinations.   
There are, however, some areas of research that are encouraging, and worth discussing. 
 
Like in AD, a prodromal MCI stage predicts a later conversion from PD to PDD, affecting 
several domains, especially attention, executive and visuo-constructive abilities (see section 
3.3.6.2). Neuropsychological deficits including impaired semantic fluency and pentagon 
copying, have been shown to predict PDD (Williams-Gray et al., 2009a), and this pattern may 
offer some insight into the underlying pathology as impairments in semantic fluency (memory) 
and pentagon copying (visuospatial ability) are thought to represent temporal and parietal lobe 
dysfunction respectively. This “posterior cortical LB pathology” is believed to predict a more 
rapid progression to dementia in PD and is possibly related to cholinergic loss. In contrast, 
defects in dopaminergic transmission affect fronto-striatal pathways resulting in working 
memory and executive impairment, but seem to less often progress to dementia. This is also 
known as the “the dual syndrome hypothesis” (Kehagia et al., 2013), and it signifies an 
important, but controversial, hypothesis in the understanding of cognitive impairment in PD.  
Posterior cortical defects in PD/PDD can to some extent be assessed using different imaging 
techniques including structural MRI, DTI, FDG-PET and amyloid-PET, but diagnostic 
sensitivity and specificity is at present too low to be used in the clinical routine for the 
diagnosis of LBD (see section 3.3.6.6). Our results indicate that early WM affection in PD is 
not related to memory, but possibly to executive and visuospatial deficits and prefrontal 
involvement. However, the study sample is too small to draw definite conclusions and follow-
up studies to confirm the importance of these findings are needed. 
Of note, the MMSE is commonly used around the world as a screening instrument for cognitive 
dysfunction and it is a sensitive tool for separating moderate and severe dementia from persons 
without dementia. However, the MMSE is less sensitive in the differentiation between MCI and 
mild dementia and for detection of cognitive impairment in LBD (Hoops et al., 2009). The use 
of more advanced neuropsychological tests in the differentiation between SCI, MCI and 
dementia in this cohort could have increased the validity of our findings.      
 
The CamPaIGN study (Williams-Grey et al., 2009) further postulates an association between 
these “posterior” neuropsychological deficits and gene alterations in the MAPT H1/H1 
haplotype which is implicated in the buildup of isoforms of tau. The exact role of tau in LBD is 
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unknown, but a recent study strengthens the hypothesis that an interaction between tau and 
alfa-synuclein can occur through cross-seeding (i.e. direct interaction between misfolded 
proteins) of tau to promote alfa-synuclein aggregation (Guo et al., 2013). Other possible 
genetic associations to dementia in PD include GBA mutations and possibly APOE, but not 
COMT genotypes (which are associated with “anterior deficits” related to dopamine-dependent 
fronto-striatal pathways) (see also section 3.3.6.5).  
“The dual syndrome hypothesis” was further supported by recent findings in the ICICLE-PD 
study (Nombela et al., 2014) were 168 participants with early PD and 85 normal controls 
underwent clinical, neuropsychological and fMRI assessments and  genotyping for three 
polymorphisms commonly related to cognitive impairment in PD (COMT, MAPT and APOE). 
It was concluded that task-specific regional activations in PD (assessed with fMRI) were linked 
to genetic variation, i.e. COMT to executive functions, MAPT to visuospatial and APOE to  
memory tasks respectively. 
Up to 50 % of PDD cases have concomitant amyloid and tau pathology sufficient for a 
secondary AD diagnosis (Irwin et al., 2013), and decreased levels of AȕKDYHEHHQVKRZQWR
predict future PDD (Siderowf et al., 2010). This confirms the heterogeneous nature of PD 
including overlapping features with AD and possibly synergistic effects between the two.  
A recent prospective study over 18 months involving 27 non-demented PD patients combined 
&6)$ȕQHXURSV\FKRORJLFDOWHVWV³SRVWerior cortical based” including verbal learning, 
semantic fluency and visuo-perception) and structural MRI. At follow-up all participants 
without baseline biomarker abnormalities remained non-demented whereas all with 
abnormalities in all three biomarkers progressed to dementia, with intermediate risk for those 
showing abnormalities in on or two biomarker types (Compta et al., 2013). Abnormal MRI-
findings included limbic- and posterior cortical thinning.  
Despite the central role of Lewy bodies in the pathogenesis of LBD and promising preliminary 
results, so far the sensitivity and specificity of CSF (and plasma) alfa-synuclein have been too 
low to reliably diagnose PD and predict disease progression. 
 
WM was long thought to be passive tissue, but is now known to consist of myelin producing 
glia cells that actively modulate neural signaling including support and protection of neurons 
and maintaining of homeostasis.  
A surrogate marker for WM disintegrity is white matter lesions (WMLs) which can be defined 
as areas of high intensity in WM observed on T2-weighted MRI. WMLs, especially those in the 
deep WM, are believed to be caused by small vessel disease and have been shown to increase 
the future risk of stroke, dementia and death in the general population (Debette and Markus, 
2010). There is also increasing evidence that small vessel disease is linked to incipient AD 
(Snowdon et al., 1997;Stenset et al., 2006), but the role in LBD is unclear.  
Although WMLs can be seen in all stages of PD, including PDD, and are associated with 
cognitive impairment, there exists no evidence to conclude that WMLs accelerate 
neurodegeneration. Similarly, the role of cardiovascular risk factors and PD is poorly 
understood. Our results, however, suggest that cardiovascular risk factors, including 
hypertension, diabetes, hypercholesterolemia and WMLs cannot aid in the differentiation 
between early AD, PD and controls. It is of major interest to investigate the role of 
cardiovascular risk factors and WM affection in PD (and AD) since these are potential 
preventable and/or reversible factors available for treatment. 
Of note, WMLs represented as smooth periventricular lining probably have another etiology 
than those clearly separated from the ventricles, so-called deep WMLs. The former are 
associated with loss of ependymal lining of the ventricles, gliosis and lack of hypoxia-induced 
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inflammatory tissue damage and is probably unrelated to small vessel disease in contrast to the 
latter (especially when they present as punctuate lesions and not beginning confluent or 
confluent abnormalities)) which are associated with a low progression rate (O'Brien, 2014). 
Deep WMLs are associated with chronic hypoxia or episodic hypoperfusion, and can as such 
be regarded as “incomplete” infarcts. Indeed, there can be a number of other etiological factors 
to WMLs affecting cognition other than vascular including toxic and metabolic 
leukoencephalopathies, neoplasms, infections, mitochondriopathies and immune related disease 
(Weidauer et al., 2014). Further studies on the different representation of WMLs types are 
needed in order to understand the possible pathogenic role of different WM involvement in 
neurodegeneration. 
 
Interestingly, no previous DTI study has focused on early Lewy body disease and potential 
associations to visual hallucinations. We found early signs of occipital WM affection that could 
signify the earliest signs of visual pathway affection, but larger cohorts followed longitudinally 
are required to elucidate the neurobiology of visual hallucinations in PD. 
Future research will also be facilitated by higher field strength MRI (7-11 Tesla) and greater 
congruity in MRI protocols which will enable multicenter studies.  
To our knowledge no DTI study focusing on early PD with a longitudinal design has yet been 
published, which is needed before conclusions regarding DTI as a biomarker in PD can be 
drawn.   
 
Finally, recent recognition of non-motor symptoms (both early and late) has raised awareness 
of PD as a neuropsychiatric disorder, and the present understanding and classification of LBD 
has thus been debated. An area of controversy is the distinction between DLB and PDD, in 
practice to distinct disorders separated by the “one year rule” (McKeith et al., 2005). In 
addition, there are currently two classification systems in use for the assessment of Lewy body 
pathology, i.e. Braak's staging system for PD and McKeith's staging system for DLB including 
criteria for mixed LB and AD pathology (Braak et al., 2003, McKeith et al., 2005) (see also 
section 3.2.3). Furthermore, the present criteria for PD focus on motor symptoms and non-
motor symptoms, including pre-motor symptoms, cognitive impairment and dementia, are 
largely neglected (except that early dementia is an exclusion criterion for PD). A recently 
convened task force has therefore proposed to redefine current criteria for PD (Berg et al., 
2014). Among proposals are that early pre-motor features should be termed “prodromal” or “ 
pre-clinical”, suggestion of omitting the “1-year rule” (i.e. dementia is no longer an exclusion 
criterion in PD) and that core clinic-pathologic criteria of the motor syndrome accompanied by 
neurodegeneration in substantia nigra and alfa-synuclein deposition remain the gold standard of 
PD diagnosis. The current staging systems for LBD have not been proposed to be revised at 
present awaiting further understanding of the underlying disease mechanisms and disease 
progression.  
 
To summarize, no single marker is presently able to predict progression of cognitive decline in 
PD with good reliability and validity. We and others have shown that DTI changes characterize 
early stages of cognitive affection in both AD and Lewy body disease (Cochrane and Ebmeier, 
2013;Selnes et al., 2013), but the best approach in predicting dementia in PD is at present by 
using a combination of biomarkers rather than a single biomarker. 
Furthermore, there is reason to believe that DTI abnormalities reflect axonal integrity and that 
diffusivity changes in AD may be directly related to AD neuropathology (Selnes et al., 2013). 
Whether this is the case in LBD remains an important research question.  
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The considerable overlap between neuropathological changes and clinical presentation in DLB 
and AD has so far made it difficult to find biomarkers able to distinguish between the disorders. 
Like in AD, affected cognition in Lewy body disease may be characterized by amyloid 
dysmetabolism, but also by a multitude of other pathological factors including alfa-synuclein, 
suggesting a generalized neuronal disease (Ferrer et al., 2012).  
In the present study, we have shown that DTI can potentially differentiate between normal 
controls, pre-dementia AD and PD and that WM affection is an early event in PD pathogenesis. 
DTI is thus a promising biomarker in predicting conversion to dementia in PD and also in the 
differentiation between AD and LBD in general. It remains to be seen whether this rather new 
technique will offer sufficient sensitivity and specificity to be a valid tool in diagnosing Lewy 
body disease and prediction of disease progression in the future. Hopefully more specific 
changes can be found with larger groups followed longitudinally.   
 
8.4  Paper 3 
 
Due to the high prevalence rates of concomitant depression in cognitive disorders and the 
future growth of the elderly population, there is a need for a better understanding of the 
neurobiology involved with the ultimate goal of modifying or preventing disease.  
 
As described in more detail in section 5.0, the relationship between major depression and AD is 
complex. Depression can be a prodrome of AD, increase the risk of dementia and is a common 
neuropsychiatric symptom in all stages of AD. Moreover, the concomitant prevalence of 
depression and dementia is probable even higher in Lewy body dementia and vascular 
dementia than in AD (Castilla-Puentes and Habeych, 2010;Enache et al., 2011). Depression is 
also a common pre-motor symptom in PD (Postuma et al., 2012), but little is known about the 
prevalence of depression in the pre-dementia phase of DLB despite the fact that depression is 
included as a supportive feature in the DLB consensus criteria (McKeith et al., 2005). Despite 
some evidence to support an increased risk of AD dementia in subjects with concomitant MCI 
and depression (Enache et al., 2011), little is known about the underlying mechanisms.   
 
We hypothesized that minor depressive symptoms, a sub-threshold depressive state not 
fulfilling formalized criteria for major depression, in SCI and MCI would correlate with typical 
AD-type changes in CSF and imaging parameters. On the contrary, our main finding was that 
depression correlated with less changes associated with neurodegeneration. An explanation for 
this, and in contrast to the above mentioned association between major depression and 
established AD, may be that minor depressive states are elusive and have no or only subtle 
impact on the neurodegenerative process. It seems that minor depressive symptoms can explain 
cognitive impairment in this group of patients attending a memory clinic.  
 
Several challenges have been described using self-report scales for depression in  the elderly 
(Yesavage et al., 1982). A main explanation is probably that the symptomatic phenomenology 
may differ between depression in the young and in the elderly. Potential sources of error 
previously reported are among others a too strong focus on somatic symptoms which are 
common in the elderly for other reasons than depression, complex response formats which 
exclude the cognitively impaired and questions about the future. In addition there are several 
significant comorbidities in late life depression, including sleep disturbances, grief, frailty and 
drug interactions affecting symptomatology.    
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In the present study we used the short version of the Geriatric Depression Scale (GDS15), 
which is an established test for depression in the elderly living in different environments (Marc 
LG et al., 2008) including patients with MCI (Debruyne et al., 2009)(Marc LG et al., 2008). 
Although adapted to elderly populations, it is not diagnostic and cannot replace clinical 
judgment and use of established criteria for depression, but rather help the clinician in deciding 
whether further comprehensive investigation is necessary.  
In the original study by Scheik et al. (Sheikh JI and Yesavage JA, 1986), the GDS15 was found 
to have a rather high sensitivity (92 %) and specificity (89 %).  In a later systematic review of 
21 studies, cutoff values of 5/6 (six studies) or 6/7 (seven studies) and a diagnosis of major 
depression according to DSM-IV or ICD-10 were most often used as “gold standard”. Mean 
sensitivity (80.5 %) and specificity (75.0 %) were found to be considerably lower than in the 
original study (Wancata et al., 2006).  
Since no validation study of the Norwegian version of the GDS15 has been conducted, 
sensitivity and specificity are unknown, but probably comparable to the other European 
countries included in the review. The rather low specificity of the GDS15 increases the 
probability of including patients having symptoms not related to depression, which partly could 
explain the negative result in the present study. Specificity could have been raised by using a 
higher cutoff value, but the present level is well established for screening purposes. Similarly, a 
lower cutoff would increase sensitivity, but lower specificity. This was demonstrated in a study 
by Friedman et al. involving 960 functionally impaired, but cognitively intact community-
dwelling primary care elderly. It was shown that sensitivity increased from 81 % to 89 % using 
5/6 as cutoff compared to 6/7. Similarly, specificity varied from 75 % with a cutoff of 6/7 to 
65 % with a cutoff of 5/6 (Friedman et al., 2005).    
In the present study, patients were screened for depression using the GDS15 followed by a 
clinical examination to see if diagnostic criteria for major depression according to ICD-10 were 
fulfilled. The latter patients were excluded, but some misdiagnosis (i.e. inclusion of presumed 
minor depression when in fact major depression) contaminating the analyses cannot be 
excluded. 
 
Minor depression is common in the elderly with prevalence numbers in the 0-18 % range 
(Polyakova et al., 2014). Several of the included studies have only used one single diagnostic 
instrument and a single clinical examination which could explain the wide variety in prevalence 
rates. 
Risk factors for minor depression are similar to those in major depression (see section 5.3), 
except that data on age and gender are inconclusive (Polyakova et al., 2014). There is also 
evidence that patients with minor depression are at increased risk of developing major 
depression (MDD), substance abuse and even suicidal behavior (Polyakova et al., 2014), 
complications that suggest that this “minor” condition also deserves attention. However, studies 
on the co-existence of minor depression and MCI are rare, as depressive patients most often are 
excluded from MCI studies and vice versa. Available studies suggest that almost half of MCI 
patients in hospital-based settings exhibit depressive symptoms, but prevalence rates vary due 
to methodological differences (Panza et al., 2010). Studies on comorbid MCI and minor 
depression are rare, and only two studies were found using established criteria. Gabryelewicz et 
al. (hospital-based) and Kumar et al. (community-based) found prevalence rates for comorbid 
minor depression and MCI of 26.5 % and 17.2 % respectively (Gabryelewicz et al., 
2004;Kumar et al., 2006). In the hospital-based sample about 46 % of MCI patients had minor 
and major depression combined which is comparable to our findings of 40 % minor depression 
in SCI and MCI (and exclusion of major depression). Of note, we only used the GDS15 as 
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screening instrument and conducted only one clinical examination which could have resulted in 
a lower estimate of prevalence. Another weakness in our study is the fact that ICD-10 does not 
contain a diagnostic category for minor depression in contrast to DSM-IV.  
 
Inclusion of patients with major depression in this study might have shown more pronounced 
changes, but was an exclusion criterion since core criteria for MCI dictates ruling out 
comorbidities including depressive, vascular, traumatic, neurologic or medical comorbidities 
that could imitate cognitive impairment (Albert et al., 2011). As mentioned in section 1.3, MCI 
has an annual dementia conversion rate of about 10-15 % (Petersen et al., 2009), but it may not 
harbor early signs of neurodegeneration, and the concept of SCI is even more heterogeneous 
with annual conversion rates in the 6-7 % range (Reisberg and Gauthier, 2008). Since 
international consensus criteria for SCI until recently have been lacking (see below), similar 
exclusion criteria as for MCI were used.  
Recently Jessen et al. proposed multiple points that should be described in studies on SCI 
patients in order to select patients with increased risk of dementia and to facilitate multi-center 
comparisons (Jessen et al., 2014). Risk factors raising the likelihood of a pre-clinical AD state 
in SCI are among others onset of SCI the last 5 years, affection of memory, concerns (worries) 
associated with SCI, age at onset > 60 years, confirmation of cognitive decline by an informant 
in addition to APOE genotype and biomarker evidence for AD. Our SCI patients fulfilled the 
first three points and the average age was 60 years, but other biomarkers typically seen in AD 
were only randomly present. The SCI inclusion criteria used in this paper would thus probably 
lower the probability that the SCI patients represent pre-dementia states compared to the 
proposed criteria.  
Similarly, one can argue that the 40 year age cut is too low and that it is unlikely that 40-50 
year olds have SCI (or MCI) due to AD or other dementias. This is an additional source of 
insignificant findings in this paper. On the other hand, all MCI classifications were based on 
established criteria, and despite sub-optimal sensitivity and specificity in predicting dementia, it 
is at present a pertinent approach for defining at risk populations. 
 
Pooling SCI and MCI patients together can be seen as a limitation in this study as the two 
conditions constitute different likelihoods of a future conversion to dementia and often reflect 
different etiologies. On the other hand, both conditions are dementia risk states and finding 
relevant associations to biomarker pathology as soon as possible is a priority. Since SCI can be 
seen as a pre-MCI state, AD biomarker pathology in the combined group, or even in an isolated 
SCI group, would be an important finding and worth examining. Analyzing SCI and MCI 
separately did not, however, reveal any significant correlations, but the number of patients 
included in these analyses was limited. Of note (and as mentioned in section 8.3), the MMSE is 
less sensitive in the differentiation between MCI and mild dementia than between normal 
cognition and moderate/severe dementia. A more thorough examination with a battery of 
neuropsychological test would better discriminate between dementia and risk groups such as 
SCI and MCI. However, since the demarcation between SCI, MCI and dementia is not sharp it 
makes pooling of SCI and MCI relevant, but the number of patients included should ideally be 
higher in order to increase the probability of significant findings.  
 
In an effort to increase the likelihood that the underlying disease (in SCI and MCI) indeed 
reflect a neurodegenerative disorder, we included a subgroup with concomitant depression and 
pathological CSF biomarkers, but also in this cohort depressed had less pathology. Secondary 
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depression duo to psychosocial stress (not necessarily related to neurodegeneration) may also 
be a plausible explanation for our findings.  
 
One major obstacle in finding underlying pathology in concomitant depression and cognitive 
impairment is the present classification of depression and especially the classification of 
depression in dementia. This is not unexpected since both disorders are heterogeneous in 
nature. Although there has been progress in the development of biomarkers in dementia, 
including CSF and imaging parameters, very few biomarkers can be used in a clinical setting, 
and with regard to depressive states even less is available. Thus, despite progress in developing 
biomarkers in dementia and depression, the diagnostic precision is still low, and biomarkers are 
at present mostly reserved for research purposes. In, addition, depression has different, age-
dependent clinical phenotypes not reflected in the current criteria. Late life depression (LLD) is 
characterized by sub-syndromal symptoms and atypical presentation such as vegetative signs 
(including weight loss and anorexia, insomnia, inattention and fatigue), somatization and 
cognitive impairment, which can lead to underreporting of depression in the elderly 
(Alexopoulos, 2005). Focusing on cognitive impairment, an unresolved question is whether 
these atypical symptoms in LLD constitute a different type of depression with another etiology 
than in younger people. If that is the case, the atypical and sub-syndromal presentation in a 
(large) subgroup of elderly depressed could possibly be secondary to neurodegeneration and 
have other underlying mechanisms than “classic” symptomatology. Indeed, the concept of 
apathy in this regard is relevant as there are overlapping presentation in depressive states and 
dementia. Apathy can be defined as a state of indifference, or the suppression of emotions such 
as concern, excitement, motivation and/or passion and is the most prevalent neuropsychiatric 
syndrome in dementia affecting 19-76 % of patients (Tagariello et al., 2009). Furthermore, 
evidence suggests that apathy increases the risk of dementia in MCI (Robert et al., 2006).  
Could it be that atypical presentation and sub-threshold depression in the elderly are mistakenly 
interpreted as somatic complications or even “normal” aging, and that some of these symptoms 
(i.e. apathy and/or depression) in reality reflect prodromes and neuropsychiatric symptoms of 
neurodegeneration? Developing diagnostic consensus criteria that encompass both “traditional” 
depression, depression in the elderly, atypical presentation including apathy and criteria for 
depression in dementia are thus needed. At present, provisional diagnostic criteria for 
depression in AD and diagnostic criteria for apathy have been proposed, but are currently only 
used for research purposes (Olin et al., 2002;Robert et al., 2009).  
 
To conclude, our results suggest that minor depression is common and the driving force 
responsible for the cognitive impairment in this SCI/MCI cohort and not caused by 
neurodegenerative changes. Despite the negative association between minor depression and 
imaging and CSF parameters, it is possible that the subgroup with pathologic CSF and 
depressive symptoms are at increased risk of a faster progression to dementia. One can 
speculate that minor depression in these cases represents a prodrome of dementia and as such 
an important symptom that may bring these patients earlier to the memory clinic. Follow-up 
studies are needed to determine the significance of these findings. 
Statistically, most of the cases of SCI and MCI converting to dementia will be cases of AD, but 
since MCI probably is a pre-dementia stage also in Lewy body disease, some will also convert 
to Lewy body dementia. This can shed light on depression as a potential biomarker also in non-
AD cases. 
 
97 
 
8.5  Methodological issues and limitations 
 
A cross-sectional approach was used in all 3 papers and thus conclusions regarding causality 
cannot be drawn. In paper 1, a retrospective technique was used which introduces a prevalence-
incidence bias (Neyman bias) (Grimes and Schulz, 2002). Even if standardized questionnaires 
are used it is impossible to answer questions from the past with total accuracy. This fact will  
likely affect the results.  
 
It is important to critically evaluate the sensitivity and specificity of the clinical criteria for 
DLB and AD. The 1996 consensus criteria for DLB (McKeith et al. 1996) had high specificity 
(80-100 %), but low sensitivity (20-60 %) and thus the 2005 criteria incorporated Dopamine 
transporter scan, RBD and neuroleptic sensitivity as suggestive features to improve sensitivity. 
Although no systematic evaluation of the new criteria has been conducted, the specificity using 
the new criteria is believed to be generally good when a diagnosis of probable DLB can be 
made. Similarly, the 1984 criteria for probable AD are reliable with more than a dozen clinical-
pathological studies showing an average sensitivity of 81% and specificity of 70% (McKhann 
et al., 2011). In paper 1, only probable DLB (2005 DLB criteria) and probable AD (1984 AD 
criteria) were included, and the high specificity was confirmed in the 36 cases at present 
submitted to autopsy (of 10 with a clinical diagnosis of DLB, 8 had pathological verification, 
and 11 of 13 with a clinical diagnosis of probable AD were confirmed at autopsy (T. 
Hortobabyi, personal communication)). In paper 2 all AD diagnoses were strengthened by CSF 
biomarkers. Furthermore, the PD diagnosis was determined according to established criteria 
(Gelb) and all patients had been followed in the clinic for some time and had a pathological 
Dopamine transporter scan ([123I]FP-CIT SPECT) strengthening the diagnosis. With these 
procedures the diagnostic accuracy of PD is expected to be high, although some misdiagnosis 
may occur.  
 
Selection bias may occur in referral based cohorts since it is likely that SCI and MCI patients 
recruited from a hospital based memory clinic are not completely representative of the general 
SCI and MCI population. For instance, there is a chance that patients and caregivers coming to 
the memory clinic are more resourceful  (e.g. higher educated with more insight into disease 
processes and on average with better performance on cognitive tests) and that depressive and 
cognitive symptoms in this group are differently expressed compared to other social groups 
who may not seek medical assistance at an early stage. For instance, depression scores may be 
less than the average in the general population because of better coping strategies (including 
better socio-economic resources) or conversely more pronounced because they are usually 
highly functioning and may be more sensitive to change and the suffering caused by illness. 
What impact these matters may have had on the present results is difficult to conclude, but a 
potential limitation to be aware of. In addition, it is possible that MCI and also PD and 
dementia patients who are referred may differ clinically from similar groups in the general 
population, for example by being more atypical, having more co-morbidity or more personality 
disorders.   
 
The heterogeneous nature of SCI and MCI has been discussed in more detail under section 8.4 
and could explain why we could not find any associations between minor depression and AD-
related pathology in these groups. 
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As mentioned (in section 1.8), an ideal biomarker should have sensitivity and specificity above 
80 %. These criteria are currently not fulfilled by the biomarkers used in this thesis. For 
instance, DTI indices are thought to reflect axonal bundle microstructure, but their relationship 
to pathophysiology is debatable (Assaf, 2008). A continuous effort to improve biomarker 
sensitivity and specificity through technical innovation, replication of findings and autopsy-
proven diagnosis is essential and may improve sensitivity and specificity and thereby their 
diagnostic accuracy. 
  
Another issue worth mentioning is the relative small sample sizes employed in the current 
thesis. It has been claimed that many conclusions drawn from biomedical research are false due 
to small sample sizes (Button et al., 2013;Ioannidis, 2005). The lower the statistical power of a 
study (due to either low sample size, small effect size or both), the lower the probability that 
significant findings are actually true. The obvious solution is ideally to participate in 
multicenter studies to raise the number of participants. Another issue is that true effect sizes are 
seldom (never) known in neuroscience. Metaanalyzes, which can provide an optimal starting 
point for estimates of effect size, power calculations and study design are not always available 
in experimental research.      
 
8.6  Conclusions and future directions for research 
 
In this thesis we have found that DLB patients present with memory impairment and Visual 
hallucinations before parkinsonism. This is important as early memory problems not always 
indicate AD. Similar to AD and PD, DLB patients probably also have depressive symptoms 
prior to diagnosis. Furthermore, we found that white matter damage is an early event in PD 
without dementia and that DTI could potentially serve as a biomarker to differentiate between 
LBD and AD. Larger, confirmatory studies are however needed before DTI can serve as a 
reliable biomarker in clinical practice. Finally, we found that depressive symptoms are common 
in SCI and MCI patients seeking help at the memory clinic, but minor depression was not 
associated with AD-related pathology. Cognitive impairment in SCI and MCI could be related 
to depression, or depression could potentially signal early and subtle neurodegenerative 
changes motivating these patients for a prompt clinical investigation. Our findings are a 
reminder that depressive symptoms should always be considered when cognitive impairment 
and neurodegenerative disease is suspected.     
 
The ultimate goal of all neurodegenerative research is to develop (curative) neuroprotective or 
disease-modifying therapies. Predicting future cognitive impairment in at risk populations as 
early as possible is an important research priority and finding valid biomarkers including 
clinical features, genetics, neuropathology, CSF and imaging parameters for better 
understanding of disease mechanisms with subsequent refinement of clinical diagnostic criteria 
and development of new treatment targets are important priorities. Given the complexity of the 
various disease manifestations in cognitive disorders, a multimodal approach is most likely to 
yield success.  
 
The vast majority of biomarker studies (including neuroimaging) in LBD (and AD) are cross-
sectional, small and focusing on established disease. In the future, larger, longitudinal studies 
focusing on known risk factors, including SCI/MCI, autonomic symptoms, RBD and visual 
hallucinations are needed. Similarly, to disentangle the role of depression, elderly patients with 
depressive disorders should be monitored with selected biomarkers (neuroimaging, markers of 
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cerebrovascular disease, genetics and immunology in addition to measuring depressive 
symptoms) and monitored to detect cognitive impairment. Furthermore, there is a need for a 
better understanding of the differences and similarities between late life depression, comorbid 
depression and dementia and the role of apathy in neurodegeneration. As most depressive 
patients will not develop dementia, a better characterization of the clinical and biological 
features which represent risk factors for dementia development is a key clinical challenge. Such 
knowledge can only be achieved by conducting longitudinal studies using careful, 
comprehensive and standardized clinical and biomarker measurements. 
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